

0001628280-24-03386610-Q Vanda Pharmaceuticals Inc. 2024080120240801070135070136070136 0 0001628280-24-033866 10-Q 81 20240630 20240801 20240801 Vanda Pharmaceuticals Inc. 0001347178 2834 030491827 DE 1231 10-Q 34 001-34186 241164160 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 10-1 Q vnda 20240630.htm 10-Q vnda 202406300001347178December

312024Q0FALSE.001xbrli:sharesiso4217:USDiso4217:USDXbrli:sharesvnda:segmentvnda:productcxbrli:purevnda:installment00013471782024-01-012024-06-300001347178us-gaap:CommonStockMember2024-01-012024-06-300001347178vnda:SeriesAJuniorParticipatingPreferredStockPurchaseRightMember2024-01-012024-06-3000013471782024-07-2500013471782024-06-3000013471782023-12-3100013471782024-04-012024-06-3000013471782023-04-012023-06-3000013471782023-01-012023-06-300001347178us-gaap:CommonStockMember2023-12-310001347178us-gaap:AdditionalPaidInCapitalMember2023-12-310001347178us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001347178us-gaap:RetainedEarningsMember2023-12-310001347178us-gaap:CommonStockMember2024-01-012024-03-310001347178us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001347178us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001347178us-gaap:RetainedEarningsMember2024-01-012024-03-310001347178us-gaap:CommonStockMember2024-01-012024-06-300001347178vnda:SeriesAJuniorParticipatingPreferredStockPurchaseRightMember2024-01-012024-06-3000013471782024-07-2500013471782024-06-3000013471782023-12-3100013471782023-04-012023-06-3000013471782023-01-012023-06-300001347178us-gaap:CommonStockMember2023-12-310001347178us-gaap:AdditionalPaidInCapitalMember2023-12-310001347178us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001347178us-gaap:RetainedEarningsMember2023-12-310001347178us-gaap:CommonStockMember2024-01-012024-03-310001347178us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001347178us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001347178us-gaap:RetainedEarningsMember2024-03-3100013471782024-03-310001347178us-gaap:CommonStockMember2024-04-012024-06-300001347178us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001347178us-gaap:RetainedEarningsMember2024-04-012024-06-300001347178us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001347178us-gaap:CommonStockMember2024-06-300001347178us-gaap:AdditionalPaidInCapitalMember2024-06-300001347178us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001347178us-gaap:RetainedEarningsMember2024-06-300001347178us-gaap:CommonStockMember2022-12-310001347178us-gaap:AdditionalPaidInCapitalMember2022-12-310001347178us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001347178us-gaap:RetainedEarningsMember2022-12-3100013471782022-12-310001347178us-gaap:CommonStockMember2023-01-012023-03-310001347178us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100013471782023-01-012023-03-310001347178us-gaap:RetainedEarningsMember2023-01-012023-03-310001347178us-gaap:CommonStockMember2023-03-310001347178us-gaap:AdditionalPaidInCapitalMember2023-03-310001347178us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001347178us-gaap:RetainedEarningsMember2023-03-3100013471782023-03-310001347178us-gaap:CommonStockMember2023-04-012023-06-300001347178us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001347178us-gaap:RetainedEarningsMember2023-04-012023-06-300001347178us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001347178us-gaap:CommonStockMember2023-06-300001347178us-gaap:AdditionalPaidInCapitalMember2023-06-300001347178us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001347178us-gaap:RetainedEarningsMember2023-06-3000013471782023-06-300001347178vnda:FanaptMember2024-04-012024-06-300001347178vnda:FanaptMember2023-04-012023-06-300001347178vnda:FanaptMember2024-01-012024-06-300001347178vnda:FanaptMember2023-01-012023-06-300001347178vnda:HetliozMember2024-04-012024-06-300001347178vnda:HetliozMember2023-04-012023-06-300001347178vnda:HetliozMember2024-01-012024-06-300001347178vnda:HetliozMember2023-01-012023-06-300001347178vnda:PONVORYMember2024-04-012024-06-300001347178vnda:PONVORYMember2023-04-012023-06-300001347178vnda:PONVORYMember2024-01-012024-06-300001347178vnda:PONVORYMember2023-01-012023-06-300001347178us-gaap:SalesRevenueNetMembersus-gaap:CustomerConcentrationRiskMembersvnda:FiveMajorCustomersMember2024-01-012024-06-300001347178us-gaap:CreditConcentrationRiskMembersus-gaap:AccountsReivableMembersvnda:FiveMajorCustomersMember2024-01-012024-06-300001347178vnda:PONVORYAcquisitionMember2023-12-072023-12-070001347178us-gaap:USTreasuryAndGovernmentMember2024-06-300001347178us-gaap:CorporateDebtSecuritiesMember2024-06-300001347178us-gaap:USTreasuryAndGovernmentMember2023-12-310001347178us-gaap:CorporateDebtSecuritiesMember2023-12-310001347178us-gaap:USTreasuryAndGovernmentMembersus-gaap:FairValueInputsLevel1Member2024-06-300001347178us-gaap:FairValueInputsLevel2Membersus-gaap:USTreasuryAndGovernmentMember2024-06-300001347178us-gaap:FairValueInputsLevel3Membersus-gaap:USTreasuryAndGovernmentMember2024-06-300001347178us-gaap:CorporateDebtSecuritiesMembersus-gaap:FairValueInputsLevel1Member2024-06-300001347178us-gaap:CorporateDebtSecuritiesMembersus-gaap:FairValueInputsLevel2Member2024-06-300001347178us-gaap:CorporateDebtSecuritiesMembersus-gaap:FairValueInputsLevel3Member2024-06-300001347178us-gaap:USTreasuryAndGovernmentMembersus-gaap:FairValueInputsLevel1Member2023-12-310001347178us-gaap:USTreasuryAndGovernmentMembersus-gaap:FairValueInputsLevel2Membersus-gaap:USTreasuryAndGovernmentMembersus-gaap:FairValueInputsLevel3Member2023-12-310001347178us-gaap:CorporateDebtSecuritiesMembersus-gaap:FairValueInputsLevel1Member2023-12-310001347178us-gaap:CorporateDebtSecuritiesMembersus-gaap:FairValueInputsLevel2Member2023-12-310001347178us-gaap:CorporateDebtSecuritiesMembersus-gaap:FairValueInputsLevel3Member2023-12-310001347178us-gaap:CashEquivalentsMember2024-06-300001347178us-gaap:CashEquivalentsMember2023-12-310001347178vnda:FanaptMember2024-06-300001347178vnda:FanaptMember2023-12-310001347178vnda:HetliozMember2024-06-300001347178vnda:HetliozMember2023-12-310001347178vnda:HetliozMember2024-01-012024-01-310001347178vnda:HetliozMember2018-04-012018-04-300001347178vnda:HetliozMember2018-01-012018-12-310001347178vnda:PONVORYMember2024-06-300001347178vnda:PONVORYMember2023-12-310001347178vnda:FanaptMember2024-12-312019-12-310001347178vnda:FanaptMember2014-12-312014-12-310001347178vnda:HetliozMember2004-02-012024-06-300001347178us-gaap:NonUsMembersvnda:HetliozMember2024-01-012024-06-300001347178vnda:HetliozMembercountry:US2022-01-012022-11-3

[illegible]

prior to the closing, and the Company has agreed to indemnify Janssen against losses arising from the Company's activities pertaining to PONVORYA after the closing. Simultaneously and in connection with the Purchase Agreement, the parties also entered into certain supporting agreements, including a customary transition agreement, pursuant to which, during a transition period, Janssen will continue PONVORYA operations. The Company announced in May 2024 that ownership of the U.S. New Drug Application (NDA) and Investigational New Drug applications for PONVORYA had been transferred to Vanda from a Johnson & Johnson Company, fully allowing the Company to commercialize PONVORYA in the U.S. The acquisition of PONVORYA has been accounted for as an asset acquisition in accordance with ASC 805-50 because substantially all of the fair value of the assets acquired is concentrated in a single asset, the PONVORYA product rights. The PONVORYA products rights consist of certain patents and trademarks, regulatory approvals, marketing assets, and other records, and are considered a single asset as they are inextricably linked. The total consideration of \$104.9 million was fully allocated to the acquired intangible asset for the U.S. and Canadian rights to PONVORYA. The straight-line method is used to amortize the intangible asset, as disclosed in Note 7, Intangible Assets. Table of Contents 4. Marketable Securities The following is a summary of the Company's available-for-sale marketable securities as of June 30, 2024, which all have contractual maturities of less than two years: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value (in thousands) U.S. Treasury and government agencies \$144,155 \$474 \$(384) \$143,818 Corporate debt \$141,004 \$4 (99) \$140,905 Total marketable securities \$285,159 \$478 \$(483) \$284,723 The following is a summary of the Company's available-for-sale marketable securities as of December 31, 2023, which all have contractual maturities of less than two years: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value (in thousands) U.S. Treasury and government agencies \$185,168 \$227.4 \$(280) \$185,115.4 Corporate debt \$67,352.4 \$(26) \$67,328.4 Total marketable securities \$252,520.4 \$229.4 \$(306) \$252,443.5 Fair Value Measurements Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1 defined as observable inputs such as quoted prices in active markets; Level 2 defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; Level 3 defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company's assets classified in Level 1 and Level 2 as of June 30, 2024 and December 31, 2023 consist of cash equivalents and available-for-sale marketable securities. The valuation of Level 1 instruments is determined using a market approach and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of Level 2 instruments is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level 2 securities include certificates of deposit, commercial paper and corporate notes that use as their basis readily observable market parameters. The Company held certain assets that are required to be measured at fair value on a recurring basis as of June 30, 2024, as follows: A Fair Value Measurement as of June 30, 2024 Using Total Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) U.S. Treasury and government agencies \$143,818 \$143,818 \$4 (99) \$143,818 Corporate debt \$153,773 \$4 (153) \$153,773 A Total assets measured at fair value \$297,591 \$143,818 \$153,773 A Table of Contents The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2023, as follows: Fair Value Measurement as of December 31, 2023 Using Total Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) U.S. Treasury and government agencies \$209,103 \$209,103 \$4 (107) \$209,103 Corporate debt \$107,108 \$4 (107) \$107,108 A Total assets measured at fair value \$316,211 \$209,103 \$107,108 A Total assets measured at fair value as of June 30, 2024 and December 31, 2023 include \$12.9 million and \$63.8 million cash equivalents, respectively. The Company also has financial assets and liabilities not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities, and product revenue allowances, the carrying values of which materially approximate their fair values. 6. Inventory Inventory consisted of the following as of June 30, 2024 and December 31, 2023: (in thousands) June 30, 2024 December 31, 2023 Current assets Work-in-process \$27.4 Finished goods 1,469.4 1,330.4 Total inventory, current \$1,469.4 \$1,357.4 Non-current assets Raw materials \$934.4 Work-in-process \$6,928.4 7,177.4 Finished goods 190.4 737.4 Total inventory, non-current \$8,052.4 8,848.4 Total inventory \$9,521.4 \$10,205.4 Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. The Company evaluates the risk of excess inventory and product expiry by evaluating current and future product demand relative to product shelf life, taking into account all possible alternative uses for the inventory available in the ordinary course of business. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, patient usage, and generic competition. The Company's inventory balance included \$2.2 million and \$3.0 million of Fanapt product as of June 30, 2024 and December 31, 2023, respectively, and \$7.2 million of HETLIOZA product as of June 30, 2024 and December 31, 2023. 7. Intangible Assets HETLIOZA. In January 2014, the Company announced that the FDA had approved the NDA for HETLIOZA. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of \$8.0 million to BMS. In April 2018, the Company met its final milestone under its license agreement with BMS when cumulative worldwide sales of HETLIOZA reached \$250.0 million. As a result of the achievement of this milestone, the Company made a payment to BMS of \$25.0 million in 2018. These milestone payments were determined to be additional consideration for the acquisition of HETLIOZA and capitalized as an intangible asset and are being amortized on a straight-line basis over the estimated economic useful life of the related product patents. PONVORYA. On December 7, 2023, the Company acquired the U.S. and Canadian rights to PONVORYA from Janssen. The total purchase price was allocated to the acquired intangible for the U.S. and Canadian rights to PONVORYA. See Note 3, PONVORYA Acquisition, for additional details. The PONVORYA intangible asset is being amortized on a straight-line basis. Table of Contents over the estimated economic useful life of the related product rights. During the first quarter of 2024, the estimated useful life for the PONVORYA intangible asset was changed from 2035 to 2042 based on a change in the estimated economic useful life of the related product rights. The following is a summary of the Company's amortizing intangible assets as of June 30, 2024, 2024 A June 30, 2024 (in thousands) Estimated Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount HETLIOZA 2035 \$33,000 \$16,668 \$16,332 PONVORYA 2041 \$104,894 \$3,627.4 101,267.4 Total amortizing intangible assets \$137,894 \$20,295.4 \$117,599.4 The following is a summary of the Company's amortizing intangible assets as of December 31, 2023: A December 31, 2023 (in thousands) Estimated Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount HETLIOZA 2035 \$33,000 \$15,937.4 \$17,062.6 PONVORYA 2035 \$104,894 \$588.4 104,306.4 Total amortizing intangible assets \$137,894 \$16,525.4 \$121,369.4 As of June 30, 2024 and December 31, 2023, the Company also had \$27.9 million of fully amortized intangible assets related to Fanapt. Intangible assets are amortized over their estimated useful economic life using the straight-line method. Amortization expense was \$1.8 million and \$0.4 million for the three months ended June 30, 2024 and 2023, respectively. Amortization expense was \$3.8 million and \$0.8 million for the six months ended June 30, 2024 and 2023, respectively. The following is a summary of the future intangible asset amortization schedule as of June 30, 2024: (in thousands) Total 2024 2025 2026 2027 2028 Thereafter HETLIOZA \$16,332.4 \$731.4 \$1,463.4 \$1,463.4 \$1,463.4 \$9,749.4 PONVORYA \$101,267.4 \$2,772.4 \$5,444.4 \$5,444.4 \$5,444.4 \$76,317.4 Total amortizing intangible assets \$117,599.4 \$3,503.4 \$7,007.4 \$7,007.4 \$7,007.4 \$86,068.8 8. Accounts Payable and Accrued Liabilities The following is a summary of the Company's accounts payable and accrued liabilities as of June 30, 2024 and December 31, 2023: (in thousands) June 30, 2024 December 31, 2023 Research and development expenses \$15,290.4 \$15,691.4 Consulting and other professional fees \$13,561.4 \$4,404.4 Compensation and employee benefits \$4,545.6 \$4,134.4 Operating lease liabilities \$2,426.4 \$2,398.4 Royalties payable \$1,510.4 \$2,409.4 Accounts payable and other accrued liabilities \$2,266.4 \$7,145.4 Total accounts payable and accrued liabilities \$39,598.4 \$38,460.4 9. Commitments and Contingencies Guarantees and Indemnifications The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company's business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with 15 Table of Contents respect to the Company's products. The term of these indemnification agreements is generally perpetual from the date of execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions. License Agreements The Company's rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies. Fanapt. Pursuant to the terms of a settlement agreement with Novartis Pharma AG (Novartis), Novartis transferred all U.S. and Canadian rights in the Fanapt franchise to the Company on December 31, 2014. The Company paid directly to Sanofi S.A. (Sanofi) a fixed royalty of 3% of net sales through December 2019 related to manufacturing. Know-how. The Company is also obligated to pay Sanofi a fixed royalty on Fanapt net sales equal to 6% on Sanofi know-how not related to manufacturing under certain conditions for a period of up to 10 years in markets where the new chemical entity (NCE) patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026. HETLIOZA. In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZA. As of June 30, 2024, the Company has paid BMS \$37.5 million in upfront fees and milestone obligations, including \$33.0 million of regulatory approval and commercial milestones capitalized as intangible assets (see Note 7, Intangible Assets). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZA net sales to BMS. The royalty period in each territory where the Company commercializes HETLIOZA is 10 years following the first commercial sale in the territory. In territories outside the U.S., the royalty is 5% on net sales. In the U.S., the royalty on net sales in the U.S. decreased from 10% to 5% in December 2022. This U.S. royalty ended in April 2024. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the mid-twenties. The Company is obligated to use its commercially reasonable efforts to develop and commercialize HETLIOZA. Tradipitant. In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an NK-1 receptor antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. As of June 30, 2024, the Company has paid Lilly \$5.0 million in upfront fees and development milestones. These payments for upfront fees and development milestones include a \$2.0 million milestone paid to Lilly during the year ended December 31, 2023 for the filing of the first application for marketing authorization for tradipitant in either the U.S. or European Union (E.U.). As of June 30, 2024, remaining milestone obligations include \$10.0 million and \$5.0 million milestones for the first approval of an application for marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to \$80.0 million for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant. Portfolio of CFTR activators and inhibitors. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as single-digit royalties on net sales. As of June 30, 2024, the Company has paid UCSF \$1.6 million in upfront fees and development milestones. As of June 30, 2024, remaining milestone obligations include \$11.9 million for development milestones and \$33.0 million for future regulatory approval and sales milestones. Included in the \$11.9 million of development milestones are \$1.1 million of milestone obligations due upon the conclusion of clinical studies for each licensed product but not to exceed \$3.2 million in total for the CFTR portfolio. VQW-765. In connection with a settlement agreement with Novartis relating to Fanapt, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765, a Phase IIA alpha-7A nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize VQW-765 and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the mid-teens. Other Agreements. Olipass. In September 2022, the Company entered into an agreement with Olipass Corporation (Olipass) to jointly develop a set of ASO molecules based on Olipass proprietary modified peptide nucleic acids. As consideration for entering into the arrangement, the Company paid Olipass an upfront fee of \$3.0A million, which was recorded as research and development expense in 2022. The Company is funding the research and development activities and has the option to license jointly developed intellectual property upon successful development. Shareholder Rights Plan. On April 17, 2024, the Company's board of directors authorized and declared a dividend distribution of one right (each, a Right) for each outstanding share of common stock of the Company to stockholders of record as of the close of business on April 29, 2024 (the Record Date). Each Right entitles the registered holder to purchase from the Company, subject to certain conditions which have not yet occurred, one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value \$0.001 per share (the Preferred Stock), of the Company at an exercise price of \$25.00 (the Exercise Price), subject to adjustment. The complete terms of the Rights are set forth in a Rights Agreement, dated as of April 17, 2024, between the Company and Equiniti Trust Company, LLC, as rights agent (the Rights Agent), as amended by that certain Amendment No. 1 to the Rights Agreement, by and between the Company and the Rights Agent (as amended, the Rights Agreement). In general terms, subject to certain enumerated exceptions, the Rights Agreement works by imposing a significant penalty upon any person or group that acquires beneficial ownership of 10% or more of the shares of common stock without the prior approval of the board of directors. In general, any person will be deemed to beneficially own any securities (a) as to which such person has any agreement, arrangement or understanding with another person for the purpose of acquiring, holding, voting or disposing of any shares of Common Stock or (b) that are the subject of a derivative transaction or constitute a derivative security. As a result, the overall effect of the Rights Agreement and the issuance of the Rights may be to render more difficult or discourage a merger, tender or exchange offer or other business combination involving the Company that is not approved by the board of directors. However, neither the Rights Agreement nor the Rights should interfere with any merger, tender or exchange offer or other business combination approved by the board of directors. Purchase Commitments In the course of its business, the Company regularly enters into agreements with third-party vendors under fee service arrangements, which generally may be terminated on 90 days' notice without incurring additional charges, other than charges for work completed or materials procured but not paid for through the effective date of termination and other costs incurred by the Company's contractors in closing out work in progress as of the effective date of termination. The Company's non-cancellable purchase commitments for agreements longer than one year primarily relate to commitments for data services. Various other long-term agreements entered into for services with other third-party vendors, such as inventory purchase commitments, are cancellable in nature or contain variable commitment terms within the agreement. 10. Accumulated Other Comprehensive Loss The accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows as of June 30, 2024 and December 31, 2023: (in thousands) June 30, 2024 December 31, 2023 Foreign currency translation \$(1) \$21.4 Unrealized loss on marketable securities (329) \$(51) Accumulated other comprehensive loss \$(330) \$(30) 11. Stock-Based Compensation As of June 30, 2024, there were 7,677,419 shares subject to outstanding options and restricted stock units (RSUs) under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms in April 2016, and the Company adopted the 2016 Plan. Outstanding options under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company's stockholders approved the 2016 Plan. The 2016 Plan has been amended a number of times since to increase the number of shares reserved for issuance, among other administrative changes. Each of the amendments to the 2016 Plan was approved by the Company's stockholders. There is a total of 15,690,000 shares of common stock

authorized for issuance under the 2016 Plan, 4,673,878 shares of which remained available for future grant as of June 30, 2024. Stock Options The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have 10-year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over four years, with the first 25% of the shares subject to service option awards vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the service option awards in 36 equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Service option awards granted to executive officers and certain other employees provide for partial acceleration of vesting if the executive officer or employee is subject to an involuntary termination, and full acceleration of vesting if the executive officer or employee is subject to an involuntary termination within 24 months after a change in control of the Company. Service option awards granted to directors provide for accelerated vesting if there is a change in control of the Company or if the director's service terminates as a result of the director's death or total and permanent disability. As of June 30, 2024, \$4.6 million of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of 1.0 years. No option awards are classified as a liability as of June 30, 2024. A summary of option activity under the Plans for the six months ended June 30, 2024 follows: (in thousands, except for share and per share amounts)

Number of Shares	Weighted Average Exercise Price at Grant Date	Weighted Average Remaining Term (Years)	Aggregate Intrinsic Value Outstanding at December 31, 2023	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	1616	1615	1614	1613	1612	1611	1610	1609	1608	1607	1606	1605	1604	1603	1602	1601	1600	1599	1598	1597	1596	1595	1594	1593	1592	1591	1590	1589	1588	1587	1586	1585	1584	1583	1582	1581	1580	1579	1578	1577	1576	1575	1574	1573	1572	1571	1570	1569	1568	1567	1566	1565	1564	1563	1562	1561	1560	1559	1558	1557	1556	1555	1554	1553	1552	1551	1550	1549	1548	1547	1546	1545	1544	1543	1542	1541	1540	1539	1538	1537	1536	1535	1534	1533	1532	1531	1530	1529	1528	1527	1526	1525	1524	1523	1522	1521	1520	1519	1518	1517	1516	1515	1514	1513	1512	1511	1510	1509	1508	1507	1506	1505	1504	1503	1502	1501	1500	1499	1498	1497	1496	1495	1494	1493	1492	1491	1490	1489	1488	1487	1486	1485	1484	1483	1482	1481	1480	1479	1478	1477	1476	1475	1474	1473	1472	1471	1470	1469	1468	1467	1466	1465	1464	1463	1462	1461	1460	1459	1458	1457	1456	1455	1454	1453	1452	1451	1450	1449	1448	1447	1446	1445	1444	1443	1442	1441	1440	1439	1438	1437	1436	1435	1434	1433	1432	1431	1430	1429	1428	1427	1426	1425	1424	1423	1422	1421	1420	1419	1418	1417	1416	1415	1414	1413	1412	1411	1410	1409	1408	1407	1406	1405	1404	1403	1402	1401	1400	1399	1398	1397	1396	1395	1394	1393	1392	1391	1390	1389	1388	1387	1386	1385	1384	1383	1382	1381	1380	1379	1378	1377	1376	1375	1374	1373	1372	1371	1370	1369	1368	1367	1366	1365	1364	1363	1362	1361	1360	1359	1358	1357	1356	1355	1354	1353	1352	1351	1350	1349	1348	1347	1346	1345	1344	1343	1342	1341	1340	1339	1338	1337	1336	1335	1334	1333	1332	1331	1330	1329	1328	1327	1326	1325	1324	1323	1322	1321	1320	1319	1318	1317	1316	1315	1314	1313	1312	1311	1310	1309	1308	1307	1306	1305	1304	1303	1302	1301	1300	1299	1298	1297	1296	1295	1294	1293	1292	1291	1290	1289	1288	1287	1286	1285	1284	1283	1282	1281	1280	1279	1278	1277	1276	1275	1274	1273	1272	1271	1270	1269	1268	1267	1266	1265	1264	1263	1262	1261	1260	1259	1258	1257	1256	1255	1254	1253	1252	1251	1250	1249	1248	1247	1246	1245	1244	1243	1242	1241	1240	1239	1238	1237	1236	1235	1234	1233	1232	1231	1230	1229	1228	1227	1226	1225	1224	1223	1222	1221	1220	1219	1218	1217	1216	1215	1214	1213	1212	1211	1210	1209	1208	1207	1206	1205	1204	1203	1202	1201	1200	1199	1198	1197	1196	1195	1194	1193	1192	1191	1190	1189	1188	1187	1186	1185	1184	1183	1182	1181	1180	1179	1178	1177	1176	1175	1174	1173	1172	1171	1170	1169	1168	1167	1166	1165	1164	1163	1162	1161	1160	1159	1158	1157	1156	1155	1154	1153	1152	1151	1150	1149	1148	1147	1146	1145	1144	1143	1142	1141	1140	1139	1138	1137	1136	1135	1134	1133	1132	1131	1130	1129	1128	1127	1126	1125	1124	1123	1122	1121	1120	1119	1118	1117	1116	1115	1114	1113	1112	1111	1110	1109	1108	1107	1106	1105	1104	1103	1102	1101	1100	1099	1098	1097	1096	1095	1094	1093	1092	1091	1090	1089	1088	1087	1086	1085	1084	1083	1082	1081	1080	1079	1078	1077	1076	1075	1074	1073	1072	1071	1070	1069	1068	1067	1066	1065	1064	1063	1062	1061	1060	1059	1058	1057	1056	1055	1054	1053	1052	1051	1050	1049	1048	1047	1046	1045	1044	1043	1042	1041	1040	1039	1038	1037	1036	1035	1034	1033	1032	1031	1030	1029	1028	1027	1026	1025	1024	1023	1022	1021	1020	1019	1018	1017	1016	1015	1014	1013	1012	1011	1010	1009	1008	1007	1006	1005	1004	1003	1002	1001	1000	999	998	997	996	995	994	993	992	991	990	989	988	987	986	985	984	983	982	981	980	979	978	977	976	975	974	973	972	971	970	969	968	967	966	965	964	963	962	961	960	959	958	957	956	955	954	953	952	951	950	949	948	947	946	945	944	943	942	941	940	939	938	937	936	935	934	933	932	931	930	929	928	927	926	925	924	923	922	921	920	919	918	917	916	915	914	913	912	911	910	909	908	907	906	905	904	903	902	901	900	899	898	897	896	895	894	893	892	891	890	889	888	887	886	885	884	883	882	881	880	879	878	877	876	875	874	873	872	871	870	869	868	867	866	865	864	863	862	861	860	859	858	857	856	855	854	853	852	851	850	849	848	847	846	845	844	843	842	841	840	839	838	837	836	835	834	833	832	831	830	829	828	827	826	825	824	823	822	821	820	819	818	817	816	815	814	813	812	811	810	809	808	807	806	805	804	803	802	801	800	799	798	797	796	795	794	793	792	791	790	789	788	787	786	785	784	783	782	781	780	779	778	777	776	775	774	773	772	771	770	769	768	767	766	765	764	763	762	761	760	759	758	757	756	755	754	753	752	751	750	749	748	747	746	745	744	743	742	741	740	739	738	737	736	735	734	733	732	731	730	729	728	727	726	725	724	723	722	721	720	719	718	717	716	715	714	713	712	711	710	709	708	707	706	705	704	703	702	701	700	699	698	697	696	695	694	693	692	691	690	689	688	687	686	685	684	683	682	681	680	679	678	677	676	675	674	673	672	671	670	669	668	667	666</
------------------	---	---	--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-------

the FDA based its decision on the relevant criteria. Therefore, among other reasons, the Company maintains that the FDA’s denial is unlawful. The Company has asked the DC District Court to, among other things, set aside and vacate the FDA’s denial. An oral argument was held in January 2023. In August 2023, the DC District Court ruled against the Company. In September 2023, the Company appealed the ruling to the U.S. Court of Appeals for the District of Columbia Circuit. The Court of Appeals has scheduled an oral argument for September 25, 2024. In September 2022, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with two separate non-discretionary obligations under the FDCA and its implementing regulations: an obligation to publish a notice of an opportunity for a hearing on the Company’s sNDA for HETLIOZA in the treatment of jet lag disorder in the Federal Register within 180 days of the filing of the sNDA, and a separate obligation to publish the same notice within 60 days of the request for a hearing. The FDA published the notice of an opportunity for a hearing on October 11, 2022. The Company has asked the DC District Court to, among other things, compel the FDA to comply with its obligations and declare that its lack of compliance violates the FDCA and the FDA regulations. In January 2024, the DC District Court held an oral argument on dispositive cross-motions, following which the DC District Court granted in part the Company’s motion for summary judgment. The DC District Court ruled that the FDA violated the statute and ordered the FDA to either finally resolve the Company’s application or commence a hearing on or before March 5, 2024. In March 2024, the Company and the FDA filed a consent motion for entry of final judgment in the Company’s favor on its Administrative Procedure Act claim for the FDA’s unreasonable delay in resolving the hearing request. In May 2023, the Company filed a lawsuit in the U.S. Court of Federal Claims (Federal Claims Court) against the federal government for the uncompensated taking and misuse of the Company’s trade secrets and confidential information. The Company believes that the FDA violated the Fifth Amendment’s due process clause by improperly providing confidential details from the Company’s drug master files for HETLIOZA and Fanapt to generic drug manufacturers during the FDA’s 22Table of Contentsreview of the manufacturers’ ANDAs. The Company has asked the Federal Claims Court to, among other things, declare that the FDA’s disclosure of the Company’s confidential commercial information constitutes a taking for purposes of the Fifth Amendment and award just compensation. The federal government filed a motion to dismiss the complaint, which the Company opposed. In January 2024, the Federal Claims Court held an oral argument on the motion to dismiss, following which the Federal Claims Court issued a decision denying in part the government’s motion, allowing the Company’s takings claim to proceed. The Company’s lawsuit remains pending. In February 2024, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with its statutory obligations under the FDCA and its implementing regulations, and to challenge the FDA’s complete response letter and 60-day filing regulations, which the Company believes do not absolve the FDA of its statutory responsibilities. Under the FDCA, the FDA has an obligation to either approve the Company’s sNDA for HETLIOZA in the treatment of insomnia characterized by difficulties with sleep initiation within 180 days of the filing of the sNDA or give the Company a notice of an opportunity for a hearing. The Company submitted the sNDA on May 4, 2023. The Company has asked the DC District Court to, among other things, compel the FDA to comply with its obligations, declare that its lack of compliance violates the FDCA and the FDA regulations and declare the FDA’s complete response letter and 60-day filing regulations unlawful. In June 2024, the Company filed a motion for summary judgment and the FDA published a notice of opportunity for a hearing. In July 2024, the FDA opposed the Company’s motion for summary judgment. The DC District Court has scheduled an oral argument for September 17, 2024. In March 2024, the Company filed a petition for review in the U.S. Court of Appeals for the District of Columbia Circuit seeking review of the FDA’s final order refusing to hold a hearing or to approve the Company’s sNDA for HETLIOZA in the treatment of jet lag disorder. Under the FDCA, the FDA has an obligation to either approve an sNDA or to hold a hearing on the application’s approvability. The Company’s petition asks the DC Circuit to set aside the FDA’s order refusing to hold a hearing and refusing approval. The Company’s petition remains pending. On April 22, 2024, a purported stockholder of the Company filed a lawsuit in the Court of Chancery of the State of Delaware against the members of the Company’s board of directors and the Rights Agent, along with the Company as nominal defendant (collectively, the Defendants), captioned Steamfitters Local 449 Pension Fund v. Mihael H. Polymeropoulos, et al., CA No. 2024-0416-KSJM. The lawsuit contends, among other things, that the members of the Company’s board of directors breached their fiduciary duties in adopting the Rights Agreement. The lawsuit seeks relief declaring, in part, that provisions of the Rights Agreement be deemed unenforceable and seeks to enjoin the use of such provisions as well as damages, costs, and other remedies, and also sought to enjoin for 30 days the Company’s 2024 Annual Meeting of Stockholders (the Annual Meeting) that was held on May 17, 2024. At a hearing on May 7, 2024, the Delaware Chancery Court denied the plaintiff’s request to enjoin the Annual Meeting. A three-day trial in the case is scheduled to begin on November 4, 2024. The Defendants believe the claims are without merit and intend to vigorously defend the lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient. 23Table of ContentsITEM 2Management’s Discussion and Analysis of Financial Condition and Results of OperationsOverviewVanda Pharmaceuticals Inc. (we, our, us or Vanda) is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. We strive to advance novel approaches to bring important new medicines to market through responsible innovation. We are committed to the use of technologies that support sound science, including genetics and genomics, in drug discovery, clinical trials and the commercial positioning of our products. Our commercial portfolio is currently comprised of three products, Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZA for the treatment of Non-24-Hour Sleep-Phase Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), and PONVORYA for the treatment of relapsing forms of multiple sclerosis (MS) to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, in adults. HETLIOZA is the first product approved by the United States Food and Drug Administration (FDA) for patients with Non-24 and for patients with SMS. In addition, we have a number of drugs in development, including: Milsaperidone (VHX-896), the active metabolite of Fanapt (loperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia; Fanapt (loperidone) long acting injectable (LAI) formulation for the treatment of schizophrenia; Tasimelteon (N-24) (tasimelteon) for the treatment of jet lag disorder, insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24; PONVORYA (ponesimod) for the treatment of psoriasis and ulcerative colitis; Tradipitant (VLY-686), a small molecule neurokinin-1 (NK-1) receptor antagonist, for the treatment of gastroparesis, motion sickness and atopic dermatitis; Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and VPO-227 for the treatment of secretory diarrhea disorders, including cholera; VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of onychomycosis and hematologic malignancies and with potential use as a treatment for several oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, for the treatment of social/performance anxiety and psychiatric disorders; and Antisense oligonucleotide (ASO) molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease, Type 2S (CMT2S), caused by cryptic splice site variants within the IGHMBP2 gene. Operational Highlights Psychiatry Portfolio Fanapt: We initiated the commercial launch of Fanapt for the treatment of bipolar I disorder in adults in the third quarter of 2024, including the expansion of its existing sales force and the introduction of prescriber awareness and comprehensive marketing programs. Milsaperidone: We expect to submit a New Drug Application (NDA) for milsaperidone (also known as VHX-896 and P-88), the active metabolite of Fanapt, for the treatment of schizophrenia and acute bipolar I disorder to the FDA in early 2025. Loperidone LAI: We expect to initiate a Phase III program for the LAI formulation of Fanapt by the end of 2024. HETLIOZA We have initiated a HETLIOZ LAQ program in pediatric insomnia. Although the prevalence of insomnia in children is difficult to determine, it is estimated that 20-40% of children experience significant sleep problems. There are currently no approved treatments for pediatric insomnia. 24Table of Contents We continue to pursue FDA approval for HETLIOZA for the treatment of jet lag disorder and insomnia. We are challenging the FDA’s rejection of our supplemental New Drug Application (sNDA) for the treatment of jet lag disorder in the U.S. Court of Appeals for the D.C. Circuit. We have accepted the opportunity for a hearing with the FDA on the approvability of the insomnia sNDA. Our lawsuit asserting that U.S. Patent No. 11,285,129 will be infringed by generic versions of HETLIOZA marketed by Teva Pharmaceuticals USA, Inc. (Teva) and Apotex Inc. and Apotex Corp. (Apotex) is currently pending in the U.S. District Court for the District of Delaware. We announced in July 2024 that the District Court ordered that our HETLIOZA lawsuit may proceed. We submitted a Marketing Authorization Application for HETLIOZA and a Line Extension Application for HETLIOZ LAQ to the European Medicines Agency for the treatment of nighttime sleep disturbances in SMS. PONVORYA We announced in May 2024 that ownership of the United States (U.S.) NDA and Investigational New Drug (IND) applications for PONVORYA had been transferred to us from a Johnson & Johnson Company. We initiated the commercial launch of PONVORYA for the treatment of relapsing forms of multiple sclerosis in the third quarter of 2024 including the deployment of a specialty sales force. We expect to file IND applications with the FDA for PONVORYA in the treatment of psoriasis and ulcerative colitis, in 2024. Tradipitant The NDA for tradipitant for the treatment of symptoms of gastroparesis is under review by the FDA with a PDUFA target action date of September 18, 2024. Although the review is ongoing, the FDA provided a preliminary notice that deficiencies preclude discussion of labeling. Gastroparesis is a significant unmet medical need with the last treatment option approved over 40 years ago and an estimated prevalence in the U.S. of over 6 million individuals. In May 2024, we announced positive results from the second Phase III study of tradipitant for the treatment of motion sickness. We expect to submit an NDA for the treatment of motion sickness to the FDA in the fourth quarter of 2024. An eventual NDA approval of tradipitant for the treatment of motion sickness would significantly expand the addressable patient population, with approximately 30% of the U.S. population reported to suffer from motion sickness under ordinary travel conditions that include travel by sea, air and land. Early-Stage Programs VPO-227, a CFTR inhibitor for the treatment of cholera, has received approval to proceed in a Phase I study in Bangladesh, a country where treatment of cholera remains a significant and unmet need. We plan to initiate this study by the end of 2024. The Phase I clinical study for VCA-894A for the treatment of a patient with Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), an inherited peripheral neuropathy for which there is no available treatment, expects to enroll the patient in mid-2024. The Phase I clinical study of VTR-297 for the treatment of onychomycosis, a fungal infection of the nail, was initiated in April 2024. The study is over 75% enrolled and is expected to be completed in the third quarter of 2024. VQW-765, an alpha-7 nicotinic acetylcholine receptor partial agonist, is currently in clinical development for the treatment of acute performance anxiety in social situations. Since we began operations, we have devoted substantially all of our resources to the in-licensing, clinical development and commercialization of our products. Our ability to generate meaningful product sales and achieve profitability largely depends on our level of success in commercializing Fanapt and HETLIOZA in the U.S. and Europe and PONVORYA in the U.S. and Canada, on our ability, alone or with others, to complete the development of our products, and to obtain the regulatory approvals for and to manufacture, market and sell our products. The results of our operations will vary significantly from year-to-year and quarter-to-quarter and depend on a number of factors, including risks related to our business, risks related to our industry, and other risks that are detailed in Part I, Item 1A, Risk Factors, of our annual report on Form 10-K (Annual Report) for the year ended December 31, 2023 and Item 1A, Risk Factors, of this Quarterly Report. 25Table of ContentsCritical Accounting Policies and EstimatesThe preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenues and expenses during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes in our critical accounting policies including estimates, assumptions and judgments from those described in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in the Annual Report. A summary of our significant accounting policies appears in the notes to our audited consolidated financial statements included in the Annual Report. However, we believe that the following accounting policies are important to understanding and evaluating our reported financial results as they involve the most significant judgments and estimates used in the preparation of our condensed consolidated financial statements, and we have accordingly included them in this discussion. Revenue from net product sales. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. We recognize revenue when control of the product is transferred to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. Fanapt is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. HETLIOZA is available in the U.S. for distribution through a limited number of specialty pharmacies and is not available in retail pharmacies. PONVORYA is available in the U.S. for distribution primarily through specialty distributors. We invoice and record revenue when customers, wholesalers, specialty pharmacies and specialty distributors, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., we have a distribution agreement for the commercialization of Fanapt in Israel and sell HETLIOZA in Germany. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates. The transaction price is determined based upon the consideration to which we will be entitled in exchange for transferring product to the customer. Our product sales are recorded net of applicable product revenue allowances for which reserves are established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. Where appropriate, our estimates of variable consideration included in the transaction price consider a range of possible outcomes. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which we have validated the insurance benefits. A variable consideration may be constrained and is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. If actual results in the future vary from our estimates, we adjust our estimate in the period identified, which would affect net product sales in the period such variances become known. During the six months ended June 30, 2024 and 2023, we constrained the variable consideration for HETLIOZA net product sales. The constrained revenue relates to the uncertainties of payor utilization, patient demand and chargeback and rebate amounts, including Medicaid, and other reserves related to transactions that resulted in elevated levels of inventory at specialty pharmacy customers. Reserves for variable consideration are classified as product revenue allowances on the Condensed Consolidated Balance Sheets, with the exception of prompt-pay discounts, which are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities in the Condensed Consolidated Balance Sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, Medicare inflationary rebates, and product returns that are resolved during the product expiry period specified in the customer contract. Due to transactions that resulted in increased inventory stocking at specialty pharmacy customers of HETLIOZA in 2024 and 2023, the time it takes to resolve these uncertainties is expected to be longer than we have historically experienced. We currently record sales allowances for the following: 26Table of Contents Prompt-pay: Specialty pharmacies and wholesalers are generally offered discounts for prompt payment. We expect that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deduct the full amount of these discounts from total product sales when revenues are recognized. Rebates: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors, including the new Medicare Part D inflationary rebate effective October 1, 2022. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid and Medicare. The allowances for rebates are based on statutory or contracted discount rates and estimated patient utilization. Chargebacks: Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the

discounted price paid to the specialty pharmacy or wholesaler by the contracted customer. Medicare Part D coverage gap:Â The Medicare PartÂ D prescription drug benefit requires manufacturers to fund approximately 70% of the Medicare PartÂ D insurance coverage gap for prescription drugs sold to eligible patients for applicable drugs. We account for the Medicare Part D coverage gap using a point of sale model.Â Estimates for expected Medicare PartÂ D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions when we have validated the insurance benefits. Beginning January 1, 2025, the Medicare Part D coverage gap discount program will be replaced with a new discounting program under the Inflation Reduction Act of 2022. Service fees: We receive sales order management, data and distribution services from certain customers, for which we are assessed fees. These fees are based on contracted terms and are known amounts. We accrue service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense. Co-pay assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. Co-pay assistance utilization is based on information provided by our third-party administrator. Product returns: We generally offer direct customers a limited right to return as contractually defined with our customers. We consider several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. We do not expect returned products to be resalable. There was no right of return asset as of June 30, 2024 or December 31, 2023. The following table summarizes sales discounts and allowance activity as of and for the six months ended June 30, 2024: (in thousands) Rebates & Chargebacks Discounts, Returns & Other Total Balances at December 31, 2023 \$40,151Â \$10,427Â \$50,578Â Provision related to current period sales 41,462Â 14,808Â 56,270Â Adjustments for prior period sales (3,008) 127Â (2,881) Credits/payments made (33,503) (14,883) (48,386) Balances at June 30, 2024 \$45,102Â \$10,479Â \$55,581Â The provision of \$41.5 million for rebates and chargebacks for the six months ended June 30, 2024 and its ending balance at June 30, 2024 primarily represents Medicaid rebates applicable to sales of FanaptÂ® and, to a lesser extent, HETLIOZÂ®. The provision of \$14.8 millionÂ for discounts, returns and other for the six months ended June 30, 2024 primarily represents wholesaler distribution fees applicable to sales of FanaptÂ® and estimated product returns of FanaptÂ®, and co-pay assistance costs and prompt-pay discounts applicable to the sales of both FanaptÂ® and HETLIOZÂ®. Stock-based compensation. Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. We use the Black-Scholes-Merton option pricing model to determine the fair value of stock options. The determination of the fair value of stock options on the date of grant using an option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the expected stock price volatility over the expected term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility rates are based on the historical volatility. 27 Table of Contents of our publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have never paid cash dividends to our stockholders and do not plan to pay dividends in the foreseeable future. As stock-based compensation expense recognized in the Condensed Consolidated Statements of Operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Research and development expenses. Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services for clinical trial use, milestone payments made under licensing agreements prior to regulatory approval, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. We expense research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments made under license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with our research and development efforts and has no alternative future use. Clinical trials are inherently complex, often involve multiple service providers and can include payments made to investigator physicians at study sites. Because billing for services often lags delivery of service by a substantial amount of time, we often are required to estimate a significant portion of our accrued clinical expenses. Our assessments include, but are not limited to: (i)Â an evaluation by the project manager of the work that has been completed during the period, (ii)Â a measurement of progress prepared internally and/or provided by the third-party service provider, (iii)Â analyses of data that justify the progress, and (iv)Â management's judgment. In the event that we do not identify certain costs that have begun to be incurred or we under- or over-estimate the level of services performed or the costs of such services, our reported expenses for such period would be too low or too high. Intangible assets and impairment of long-lived assets. Our intangible assets consist of capitalized license costs for products approved by the FDA or costs to acquire already commercialized products. We amortize our intangible assets on a straight-line basis over the estimated useful economic life of the related product patents. We assess the impairment of intangible assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include significant underperformance relative to expected historical or projected future operating results, a significant adverse change in legal or regulatory factors that could affect the value or patent life including our ability to defend and enforce patent claims and other intellectual property rights and significant negative industry or economic trends. When we determine that the carrying value of our intangible assets may not be recoverable based upon the existence of one or more of the indicators of impairment, we measure any impairment based on the amount that carrying value exceeds fair value. As a result of the unfavorable events and subsequent developments in 2022 and 2023 related to the HETLIOZÂ® patent litigation (see Note 14, Legal Matters, to the condensed consolidated financial statements included in Part I of this quarterly report on Form 10-Q (Quarterly Report)) we performed impairment reviews for our HETLIOZÂ® asset group in those years and determined, based upon our review of undiscounted cash flows, that the carrying value of our HETLIOZÂ® asset group, inclusive of the intangible asset, is recoverable. Accordingly, we have not recorded an intangible asset impairment charge in any period. The litigation and subsequent developments do not affect the sale of HETLIOZÂ® in the E.U. and there is no generic litigation pending outside of the U.S. with respect to HETLIOZÂ®. Furthermore, the litigation and subsequent events do not relate to the HETLIOZ LQÂ® oral suspension formulation. Our expected cash flows continue to support our estimated useful economic life of the intangible asset through 2035. Income taxes.Â We assess the need for a valuation allowance against our deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis is highly dependent upon historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities, which could be affected by the HETLIOZÂ® generic competition and our ability to obtain regulatory approval from the FDA for products or new indications in development, among other factors. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. 28 Table of Contents Recent Accounting Pronouncements See Note 2, Summary of Significant Accounting Policies, to the condensed consolidated financial statements included in Part I of this Quarterly Report for information on recent accounting pronouncements. Results of Operations We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, including our and our partners' ability to continue to successfully commercialize our products, including activities related to the approval of FanaptÂ® for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults in April 2024 and acquired rights to PONVORYÂ® in the U.S. and Canada in December 2023, any possible payments made or received pursuant to license agreements, progress of our research and development efforts, the timing and outcome of clinical trials and related possible regulatory approvals and the status of existing and future potential litigation involving our products and intellectual property. For HETLIOZÂ®, the FDA has approved ANDAs for Teva and Apotex, both of which have since launched their generic versions of HETLIOZÂ® at risk in the U.S. In December 2022, the U.S. District Court for the District of Delaware (Delaware District Court) ruled in favor of Teva and Apotex in our patent litigation relating to their filing of ANDAs for generic versions of HETLIOZÂ® in the U.S. The Federal Circuit affirmed this ruling, and the U.S. Supreme Court denied our petition for a writ of certiorari in April 2024. The FDA has also approved the ANDA for MSN Pharmaceuticals, Inc. and MSN Laboratories Private Limited (MSN). The license agreement that we entered into when we settled our patent litigation with MSN (MSN/Impax License Agreement) grants MSN and Impax Laboratories LLC (Impax) a non-exclusive license to manufacture and commercialize MSN's generic version of HETLIOZÂ® in the U.S. effective as of March 13, 2035, unless prior to that date we obtain pediatric exclusivity for HETLIOZÂ®, in which case the license will be effective as of July 27, 2035, or earlier under certain limited circumstances. In January 2023, MSN and its commercial partner, Amneal Pharmaceuticals, Inc., informed us of their belief that such circumstances had occurred and have since launched their generic version. In April 2024, we filed litigation against MSN, Impax, and Amneal alleging fraudulent inducement of the license agreement. See Note 14, Legal Matters, to the condensed consolidated financial statements in Part I of this Quarterly Report. HETLIOZÂ® could face even more competition from other generic companies in the U.S. in the near term in light of the patent litigation rulings against us. In addition, sales of generic versions of HETLIOZÂ® have resulted in and could continue to result in a reduction in the demand for HETLIOZÂ® and/or the price at which we can sell it and/or create volatility in net product sales in future periods, which could have a material impact on our revenues and results of operations. The NDA for tradipitant for the treatment of symptoms of gastroparesis remains under review by the FDA with a PDUFA target action date of September 18, 2024. We continue to believe that the evidence provided in the NDA "including from qualified experts" constitutes both substantial evidence of efficacy, and sufficient safety information to support the approval of tradipitant to treat the symptoms of gastroparesis. We believe that the agency should convene an advisory committee to assist in reviewing this application with experts in the field given the novelty of the mechanism of action pursued for this indication and the lack of approval of any drug in this indication in over 40 years. However, despite our repeated requests for an advisory committee meeting to consider the NDA, the FDA has yet to grant one. In a late-cycle meeting held in June, the FDA stated that it would take into consideration our request for an advisory committee meeting. We have followed up on this request several times, but have yet to receive a response. On May 31, 2024, we received a discipline review letter from the FDA providing preliminary notice that, at the time of the letter, deficiencies had been identified that preclude discussion of labeling and post-marketing requirements and commitments. The letter also stated that the comments do not reflect a final decision on the information reviewed. We requested clarification as to whether we should expect labeling communication prior to the PDUFA target action date, but the FDA has yet to respond. Three months ended June 30, 2024 compared to three months ended June 30, 2023 Revenues. Total revenues increased by \$4.4 million, or 10%, to \$50.5 million for the three months ended June 30, 2024 compared to \$46.1 million for the three months ended June 30, 2023. Revenues were as follows:Â Three Months Ended (in thousands) June 30, 2024 June 30, 2023 Net Change Percent FanaptÂ® net product sales \$23,150Â \$24,077Â \$(927) (4)% HETLIOZÂ® net product sales 18,708Â 21,979Â \$(3,271) (15)% PONVORYÂ® net product sales 8,616Â \$6,164Â \$2,452 40% Total net product sales \$50,474Â \$46,056Â \$4,418 10% 29 Table of Contents FanaptÂ® net product sales decreased by \$0.9 million, or 4%, to \$23.2 million for the three months ended June 30, 2024 compared to \$24.1 million for the three months ended June 30, 2023. We initiated the commercial launch of FanaptÂ® for bipolar I disorder in adults in the third quarter of 2024. HETLIOZÂ® net product sales decreased by \$3.3 million, or 15%, to \$18.7 million for the three months ended June 30, 2024 compared to \$22.0 million for the three months ended June 30, 2023. The decrease to net product sales was attributable to a decrease in price net of deductions, including the impact of changes in constrained revenue. Our HETLIOZÂ® net product sales as reported for the three months ended March 31, 2023 reflected higher unit sales as compared to recent prior periods. The higher unit sales during the three months ended March 31, 2023 resulted in a significant increase of inventory stocking at specialty pharmacy customers at March 31, 2023. During the remainder of 2023, although there was continued destocking at specialty pharmacy customers, inventory levels remained elevated relative to inventory levels prior to the entrance of generic competition and remained elevated at March 31, 2024 and June 30, 2024. Going forward, HETLIOZÂ® net product sales may reflect lower unit sales as a result of reduction of the elevated inventory levels at specialty pharmacy customers or may be variable depending upon when specialty pharmacy customers need to purchase again. Further, HETLIOZÂ® net product sales will likely decline in future periods, potentially significantly, related to continued generic competition in the U.S. We constrained HETLIOZÂ® net product sales for the three months ended June 30, 2024 and 2023 to an amount not probable of significant revenue reversal. The amount of revenue recognized during the three months ended June 30, 2024 related to changes in estimates on revenue constrained during the first quarter of 2024 and 2023 was \$0.7 million and \$4.8 million, respectively. HETLIOZÂ® net product sales could experience variability in future periods as the remaining uncertainties associated with variable consideration related to inventory stocking by specialty pharmacy customers are resolved. In December 2023, we completed the acquisition of the U.S. and Canadian rights to PONVORYÂ® from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. PONVORYÂ® net product sales increased by \$1.8 million, or 26%, to \$8.6 million for the three months ended June 30, 2024 compared to \$6.8 million for the three months ended March 31, 2024. The increase in net product sales was attributable to an increase in price net of deductions, partially offset by a decrease in volume. We initiated the commercial launch of PONVORYÂ® in relapsing forms of MS in the third quarter of 2024. Cost of goods sold. Cost of goods sold decreased by \$0.8 million, or 22%, to \$2.7 million for the three months ended June 30, 2024 compared to \$3.5 million for the three months ended June 30, 2023. Cost of goods sold includes third-party manufacturing costs of product sold, third-party royalty costs and distribution and other costs. Third-party royalty costs were 6% of FanaptÂ® net product sales and 5% of HETLIOZÂ® net product sales in Germany. Third-party royalty costs on HETLIOZÂ® net product sales in the U.S. decreased from 10% to 5% in December 2022 and ended in April 2024. We evaluate the risk of excess inventory and product expiry by evaluating current and future product demand relative to product shelf life and build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, patient usage, and generic competition. Our inventory balance included \$2.2 million and \$3.0 million of FanaptÂ® product as of June 30, 2024 and December 31, 2023, respectively, and \$7.2 million of HETLIOZÂ® product as of June 30, 2024 and December 31, 2023. Research and development expenses. Research and development expenses were \$16.7 million for the three months ended June 30, 2024 compared to \$16.6 million for the three months ended June 30, 2023. 30 Table of Contents The following table summarizes the costs of our product development initiatives for the three months ended June 30, 2024 and 2023:Â Three Months Ended (in thousands) June 30, 2024 June 30, 2023 Direct project costs (1) FanaptÂ® \$1,534Â \$2,588Â Milsaperidone 619Â 1,280Â HETLIOZÂ® 2,024Â 2,450Â PONVORYÂ® 1,951Â "Â Tradipitant 5,748Â 6,027Â VTR-297720A 369Â CFTR1,764Â 378Â VQW-765174Â 278Â Other 394Â 1,421Â Total direct project costs 14,928Â 14,791Â Indirect project costs (1) Stock-based compensation 674Â 733Â Other indirect overhead 1,059Â 1,123Â Total indirect project costs 1,733Â 1,856Â Total research and development expense \$16,661Â \$16,647Â (1) We record direct costs, including personnel costs and related benefits, on a project-by-project basis. Many of our research and development costs are not attributable to any individual project because we share resources across several development projects. We record indirect costs that support a number of our research and development activities in the aggregate, including stock-based compensation. We expect to incur significant research and development expenses as we continue to develop our products. In addition, we expect to incur licensing costs in the future that could be substantial, as we continue our efforts to expand our product pipeline. Selling, general and administrative expenses. Selling, general and administrative expenses increased by \$11.1 million, or 39%, to \$39.5 million for the three months ended June 30, 2024 compared to \$28.4 million for the three months ended June 30, 2023. The increase in selling, general and administrative expenses was primarily the result of an increase in spending on commercial activities related to our commercial launches of Fanapt in bipolar disorder and PONVORYÂ® in relapsing forms of MS, as well as legal and other corporate activities. During the first half of 2024, we commenced a host of commercial activities, including an expansion of our sales force, primarily in the second quarter of 2024, as well as the development of prescriber awareness and comprehensive marketing programs in preparation for the launches of FanaptÂ® in bipolar disorder and PONVORYÂ® in relapsing forms of MS which were initiated in the third quarter of 2024. Selling, general and administrative expenses may increase in future periods as a result of the ongoing commercial launches of Fanapt in bipolar disorder and PONVORYÂ® in relapsing forms of MS. Intangible asset amortization. Intangible asset amortization was \$1.8Â million and \$0.4 million for the three months ended June 30, 2024 and 2023, respectively. Amortization expense increased in 2024 due to amortization on the intangible asset from the rights to PONVORYÂ® in the U.S. and Canada which were acquired in December

2023.Other income. Other income was \$4.6 million for the three months ended June 30, 2024 compared to \$5.5 million for the three months ended June 30, 2023. Other income primarily consists of investment income on our marketable securities.Provision for income taxes. An income tax benefit of \$1.0Å million and a provision for income taxes of \$1.1Å million was recorded for the three months ended June 30, 2024 and 2023, respectively. The income tax expense (benefit) for each of the three months ended June 30, 2024 and 2023 was primarily driven by the estimated effective tax rate for the year as well as discrete income tax expense of \$0.2Å million and \$0.8Å million, respectively.31Table of ContentsSix months ended June 30, 2024 compared to six months ended June 30, 2023 Revenues. Total revenues decreased by \$10.6 million, or 10%, to \$97.9 million for the six months ended June 30, 2024 compared to \$108.6 million for the six months ended June 30, 2023. Revenues were as follows:Å Å Six Months Ended (in thousands)June 30,2024June 30,2023NetChangePercentFanaptÅ® net product sales\$43,729Å \$46,959Å \$(3,230)(7)%HETLIOZÅ® net product sales38,761Å 61,595Å (22,834)(37)%PONVORYÅ® net product sales15,446Å Å 15,446Å N/ATotal net product sales\$97,936Å \$108,554Å \$(10,618)(10)%FanaptÅ® net product sales decreased by \$3.2 million, or 7%, to \$43.7 million for the six months ended June 30, 2024 compared to \$47.0 million for the six months ended June 30, 2023. The decrease to net product sales was attributable to a decrease in volume. We initiated the commercial launch of FanaptÅ® for bipolar I disorder in adults in the third quarter of 2024.HETLIOZÅ® net product sales decreased by \$22.8 million, or 37%, to \$38.8 million for the six months ended June 30, 2024 compared to \$61.6 million for the six months ended June 30, 2023. The decrease to net product sales was attributable to a decrease in volume, partially offset by an increase in price net of deductions. Our HETLIOZÅ® net product sales as reported for the three months ended March 31, 2023 reflected higher unit sales as compared to recent prior periods. The higher unit sales during the three months ended March 31, 2023 resulted in a significant increase of inventory stocking at specialty pharmacy customers at March 31, 2023. During the remainder of 2023, although there was continued destocking at specialty pharmacy customers, inventory levels remained elevated relative to inventory levels prior to the entrance of generic competition and remained elevated at March 31, 2024 and June 30, 2024. Going forward, HETLIOZÅ® net product sales may reflect lower unit sales as a result of reduction of the elevated inventory levels at specialty pharmacy customers or may be variable depending on when specialty pharmacy customers need to purchase again. Further, HETLIOZÅ® net product sales will likely decline in future periods, potentially significantly, related to continued generic competition in the U.S. We constrained HETLIOZÅ® net product sales for the six months ended June 30, 2024 and 2023 to an amount not probable of significant revenue reversal. The amount of revenue recognized during the six months ended June 30, 2024 related to changes in estimates on revenue constrained during 2023 was \$1.6 million. HETLIOZÅ® net product sales could experience variability in future periods as the remaining uncertainties associated with variable consideration related to inventory stocking by specialty pharmacy customers are resolved.In December 2023, we completed the acquisition of the U.S. and Canadian rights to PONVORYÅ® from Janssen. PONVORYÅ® net product sales were \$15.4 million for the six months ended June 30, 2024. We initiated the commercial launch of PONVORYÅ® in relapsing forms of MS in the third quarter of 2024. Cost of goods sold. Cost of goods sold decreased by \$2.1 million, or 25%, to \$6.2 million for the six months ended June 30, 2024 compared to \$8.3 million for the six months ended June 30, 2023. Cost of goods sold includes third-party manufacturing costs of product sold, third-party royalty costs and distribution and other costs. Third-party royalty costs were 6% of FanaptÅ® net product sales and 5% of HETLIOZÅ® net product sales in Germany. Third-party royalty costs on HETLIOZÅ® net product sales in the U.S. decreased from 10% to 5% in December 2022 and ended in April 2024. We evaluate the risk of excess inventory and product expiry by evaluating current and future product demand relative to product shelf life and build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, patient usage, and generic competition. Our inventory balance included \$2.2 million and \$3.0 million of FanaptÅ® product as of June 30, 2024 and December 31, 2023, respectively, and \$7.2 million of HETLIOZÅ® product as of June 30, 2024 and December 31, 2023.Research and development expenses. Research and development expenses increased by \$1.9 million, or 5%, to \$37.8 million for the six months ended June 30, 2024 compared to \$35.9 million for the six months ended June 30, 2023. The increase in research and development expenses was associated an increase in expenses associated with our PONVORYÅ® and CFTR development programs, partially offset by a decrease in expenses associated with our other development programs, which include expenses incurred on product discovery such as ASO.The following table summarizes the costs of our product development initiatives for the six months ended June 30, 2024 and 2023:32Table of ContentsÅ Å Six Months Ended (in thousands)June 30,2024June 30,2023Direct project costs(1)FanaptÅ®\$3,972Å \$4,618Å Milsaperidone1,526Å 2,075Å HETLIOZÅ®4,431Å 4,928Å PONVORYÅ®3,025Å Å 3,025Å Å Tradiptant14,217Å 14,366Å VTR-2971,273Å 813Å CFTR4,121Å 756Å VQW-765370Å 640Å Other836Å 3,440Å Total direct project costs33,771Å 31,636Å Indirect project costs(1)Stock-based compensation1,538Å 1,799Å Other indirect overhead2,506Å 2,449Å Total indirect project costs4,044Å 4,248Å Total research and development expense\$37,815Å \$35,884Å (1)We record direct costs, including personnel costs and related benefits, on a project-by-project basis. Many of our research and development costs are not attributable to any individual project because we share resources across several development projects. We record indirect costs that support a number of our research and development activities in the aggregate, including stock-based compensation.We expect to incur significant research and development expenses as we continue to develop our products. In addition, we expect to incur licensing costs in the future that could be substantial, as we continue our efforts to expand our product pipeline.Selling, general and administrative expenses. Selling, general and administrative expenses increased by \$5.1 million, or 8%, to \$69.6 million for the six months ended June 30, 2024 compared to \$64.5 million for the six months ended June 30, 2023. The increase in selling, general and administrative expenses was primarily the result of an increase in spending on commercial activities related to our commercial launches of Fanapt in bipolar disorder and PONVORYÅ® in relapsing forms of MS, as well as legal and other corporate activities. During the first half of 2024, we commenced a host of commercial activities, including an expansion of our sales force, primarily in the second quarter of 2024, as well as the development of prescriber awareness and comprehensive marketing programs in preparation for the launches of FanaptÅ® in bipolar disorder and PONVORYÅ® in relapsing forms of MS which were initiated in the third quarter of 2024. Selling, general and administrative expenses may increase in future periods as a result of the ongoing commercial launches of Fanapt in bipolar disorder and PONVORYÅ® in relapsing forms of MS.Intangible asset amortization. Intangible asset amortization was \$3.8 million and \$0.8 million for the six months ended June 30, 2024 and 2023, respectively. Amortization expense increased in 2024 due to amortization on the intangible asset from the rights to PONVORYÅ® in the U.S. and Canada which were acquired in December 2023.Other income. Other income was \$9.2 million for the six months ended June 30, 2024 compared to \$9.0 million for the six months ended June 30, 2023. Other income primarily consists of investment income on our marketable securities.Provision for income taxes. We recorded an income tax benefit of \$1.5 million and provision for income taxes of \$3.3 million for the six months ended June 30, 2024 and 2023, respectively. The income tax expense (benefit) for the six months ended June 30, 2024 and 2023 was primarily driven by the estimated effective tax rate for the year, as well as discrete income tax expense of \$0.8 million and \$1.8 million, respectively.Liquidity and Capital Resources33Table of ContentsAs of June 30, 2024, our total cash and cash equivalents and marketable securities were \$387.7 million compared to \$388.3 million at December 31, 2023. Our cash and cash equivalents are deposits in operating accounts and highly liquid investments with an original maturity of 90 days or less at date of purchase and consist of investments in money market funds with commercial banks and financial institutions and commercial paper of high-quality corporate issuers. Our marketable securities consist of investments in government sponsored and corporate enterprises and commercial paper.Our liquidity resources as of June 30, 2024 and December 31, 2023 are summarized as follows:(in thousands)June 30,2024December 31, 2023Cash and cash equivalents\$102,953Å \$135,821Å Marketable securities:U.S. Treasury and government agencies143,818Å 185,115Å Corporate debt140,905Å 67,328Å Total marketable securities284,723Å 252,443Å Total cash, cash equivalents and marketable securities\$387,676Å \$388,264Å As of June 30, 2024, we maintained all of our cash, cash equivalents and marketable securities in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits, but we do not anticipate any losses with respect to such deposits.In the normal course of our business, we regularly enter into agreements with third-party vendors under fee service arrangements which generally may be terminated on 90 daysÅ notice without incurring additional charges, other than charges for work completed or materials procured but not paid for through the effective date of termination and other costs incurred by our contractors in closing out work in progress as of the effective date of termination. Our non-cancellable purchase commitments for agreements longer than one year primarily relate to commitments for data services. Various other long-term agreements entered into for services with other third-party vendors, such as inventory purchase arrangements, are cancellable in nature or contain variable commitment terms within the agreement that are within our control. We also have long-term contractual obligations related to our operating leases and license agreements. There have been no material changes to our long-term contractual obligations as disclosed in Part II, Item 7, ManagementÅ Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report. For further information regarding our license agreements, see Note 9, Commitments and Contingencies, to the condensed consolidated financial statements included in Part I of this Quarterly Report.We do not have any off-balance sheet arrangements.Based on our current operating plans, which include costs and expenses in connection with our U.S. commercial activities, continued clinical development of traditpant and our other products, pursuit of regulatory approval of traditpant, pursuit of further regulatory approvals of our current approved products and payments due upon achievement of milestones under our license agreements, we believe that our cash, cash equivalents and marketable securities and cash received from product sales will be sufficient for at least the next 12 months. Our future cash requirements and the adequacy of our available funds will depend on many factors, primarily including our ability to generate revenue, the scope and costs of our commercial, manufacturing and process development activities, the magnitude of our discovery, preclinical and clinical development programs, and potential costs to acquire or license the rights to additional products. We may need or desire to obtain additional capital to finance our operations through debt, equity or alternative financing arrangements. We may also seek capital through collaborations or partnerships with other companies. The issuance of debt could require us to grant liens on certain of our assets that may limit our flexibility and debt securities may be convertible into common stock. If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders. These financings also may significantly dilute the ownership of our existing stockholders. If we are unable to obtain additional financing, we may be required to reduce the scope of our future activities, which could harm our business, financial condition and operating results. There can be no assurance that any additional financing required in the future will be available on acceptable terms, if at all.34Table of ContentsCash FlowThe following table summarizes our net cash flows from operating and investing activities for the six months ended June 30, 2024 and 2023:Å Å Six Months Ended (in thousands)June 30,2024June 30,2023NetChangeNet cash provided by (used in):Operating activities:Net income (loss)\$ (8,664)\$ 4,772Å \$(13,436)Non-cash charges6,940Å 10,599Å (3,659)Net change in operating assets and liabilities2,365Å 3,212Å (847)Operating activities641Å 18,583Å (17,942)Investing activities:Asset acquisition(4,229)Å 4,229Å Purchases of property and equipment(115)(106)(9)Net purchases, sales and maturities of marketable securities(29,136)(3,494)(25,642)Investing activities(33,480)(3,600)(29,880)Effect of exchange rate changes on cash, cash equivalents and restricted cash(29)19Å (48)Net change in cash, cash equivalents and restricted cash\$(32,868)\$15,002Å \$(47,870)Operating Activities: Cash flows provided by operating activities during the six months ended June 30, 2024 were \$0.6 million, a decrease of \$17.9 million compared to \$18.6 million during the six months ended June 30, 2023. The decrease reflects a decrease of \$13.4 million in net income as well as non-cash charges, including the change in deferred income taxes. Investing Activities: Cash flows used in investing activities during the six months ended June 30, 2024 were \$33.5 million, an increase of \$29.9 million compared to \$3.6 million during the six months ended June 30, 2023. The change in investing activities primarily reflects the timing of net reinvestment of available cash and cash equivalents in our portfolio of marketable securities. Additionally, the \$4.2 million asset acquisition cash flow during the six months ended June 30, 2024 relates to the payment of the remaining consideration for the PONVORYÅ® acquisition that was accrued as of December 31, 2023.ITEMÅ 3Quantitative and Qualitative Disclosures about Market RiskOur exposure to market risk is currently confined to our cash and cash equivalents, marketable securities and restricted cash. We currently do not hedge interest rate exposure. We have not used derivative financial instruments for speculation or trading purposes. We deposit our cash with financial institutions that we consider to be of high credit quality and purchase marketable securities that are generally investment grade, liquid, short-term fixed income securities and money-market instruments denominated in U.S. dollars. Our marketable securities consist of commercial paper, corporate notes and U.S. government agency notes and have maturities of less than two years. We do not believe that an increase in market rates would have any significant impact on the realized value of our cash equivalents and marketable securities.We are also exposed to risks related to changes in foreign currency exchange rates relating to our foreign operations. The functional currency of our international subsidiaries is the local currency. We are exposed to foreign currency risk to the extent that we enter into transactions denominated in currencies other than our subsidiariesÅ respective functional currencies. We are also exposed to unfavorable fluctuations of the U.S. dollar, which is our reporting currency, against the currencies of our operating subsidiaries when their respective financial statements are translated into U.S. dollars for inclusion in our condensed consolidated financial statements. We do not currently hedge our foreign currency exchange rate risk. Foreign currency has not had, nor do we believe that a decrease or increase in any foreign currency exchange rates would have, a material impact on our results of operations.35Table of ContentsITEMÅ 4Controls and ProceduresConclusion Regarding the Effectiveness of Disclosure Controls and ProceduresUnder the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in RulesÅ 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)) as of June 30, 2024. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of June 30, 2024, the end of the period covered by this quarterly report on Form 10-Q, to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange CommissionÅ rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.Changes in Internal Control over Financial ReportingThere has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the second quarter of 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. PART II Å OTHER INFORMATIONÅ ITEMÅ 1Legal ProceedingsInformation with respect to this item may be found in Note 14, Legal Matters, to the condensed consolidated financial statements in Part I of this quarterly report on Form 10-Q, which is incorporated herein by reference. ITEMÅ 1ARisk FactorsWe previously disclosed in Part I, Item 1A of our annual report on Form 10-K (Annual Report) for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 8, 2024, important factors which could affect our business, financial condition, results of operations and future operations under the heading Risk Factors. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described as risk factors, any one or more of which could, directly or indirectly, cause our actual operating results and financial condition to vary materially from past, or anticipated future, operating results and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and the price of our common stock. Other than as set forth below, there have been no material changes in our risk factors subsequent to the filing of our Annual Report for the fiscal year ended December 31, 2023.Anti-takeover provisions in our charter and bylaws and under Delaware law, and the adoption of a rights plan, could prevent or delay a change in control of our company.We are a Delaware corporation and the anti-takeover provisions of Section 203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and bylaws may discourage, delay or prevent a change in our management or control over us that stockholders may consider favorable. Our amended and restated certificate of incorporation and bylaws:Å Å authorize the issuance of Å blank checkÅ preferred stock that could be issued by our board of directors to thwart a takeover attempt;Å Å do not provide for cumulative voting in the election of directors, which would allow holders of less than a majority of the stock to elect some directors;Å Å establish a classified board of directors, as a result of which the successors to the directors whose terms have expired will be elected to serve from the time of election and qualification until the third annual meeting following their election;36Table of ContentsÅ Å require that directors only be removed from office for cause;Å Å provide that vacancies on the board of directors, including newly created directorships, may be filled only by a majority vote of directors then in office;Å Å limit who may call special meetings of stockholders;Å Å prohibit stockholder action by written consent, requiring all actions to be taken at a meeting of the stockholders; andÅ Å establish advance notice requirements for nominating candidates for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings.Moreover, in April 2024, our board of directors adopted a rights agreement which provided each stockholder of record as of the close of business on April

29, 2024 a right for each outstanding share of common stock of the Company held by such stockholder (each, a Right), which entitles the registered holder to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value \$0.001 per share, of the Company at an exercise price of \$25.00, subject to adjustment. The complete terms of the Rights are set forth in the rights agreement, dated as of April 17, 2024, between the Company and Equiniti Trust Company, LLC, as rights agent (Rights Agent), as amended by that certain Amendment No. 1 to the Rights Agreement, by and between the Company and the Rights Agent (as amended, the Rights Agreement). The Rights Agreement has a one-year term, expiring on April 16, 2025, and could have the effect of discouraging, delaying or preventing a change in management or control over us. While there is no plan to do so at this time, our board of directors may choose to adopt a new rights plan in the future.ITEMÂ 2Unregistered Sales of Equity Securities and Use of ProceedsNone.ITEMÂ 3Defaults Upon Senior SecuritiesNone.ITEMÂ 4Mine Safety DisclosuresNot applicable.ITEMÂ 5Other InformationDuring the fiscal quarter ended June 30, 2024, none of our directors or officers informed us of the adoption, modification or termination of a ÆRule 10b5-1 trading arrangementÆ or æœnon-Rule 10b5-1 trading arrangement,æ as those terms are defined in Regulation S-K, Item 408. Furthermore, during the fiscal quarter ended June 30, 2024, we did not adopt or terminate a æœRule 10b5-1 trading arrangementÆ or æœnon-Rule 10b5-1 trading arrangement,æ as those terms are defined in Regulation S-K, Item 408.37ITEMÂ 6ExhibitsExhibitNumberDescription3.1Form of Amended and Restated Certificate of Incorporation of the registrant (filed as Exhibit 3.8 to Amendment No. 2 to the registrantÆ™s registration statement on Form S-1 (File No.Ä 333-130759) on MarchÄ 17, 2006 and incorporated herein by reference).3.2Amended and Restated Bylaws of the registrant, as amended and restated on DecemberÄ 13, 2023 (filed as ExhibitÄ 3.1 to the registrantÆ™s current report on Form 8-K (File No.Ä 001-34186) on DecemberÄ 15, 2023 and incorporated herein by reference).3.3Amended and Restated Certificate of Designation of Rights, Preferences and Privileges of Series A Junior Participating Preferred Stock of Vanda Pharmaceuticals Inc. (filed as Exhibit 3.1 to the registrantÆ™s current report on Form 8-K (File No. 001-34186) on April 17, 2024 and incorporated herein by reference).4.1Rights Agreement, dated as of April 17, 2024, by and between Vanda Pharmaceuticals Inc. and Equiniti Trust Company, LLC as rights agent (filed as Exhibit 4.1 to the registrantÆ™s current report on Form 8-K (File No. 001-34186) on April 17, 2024 and incorporated herein by reference).4.2Amendment No. 1 to the Rights Agreement, dated as of May 3, 2024, by and between Vanda Pharmaceuticals Inc. and Equiniti Trust Company, LLC as rights agent (filed as Exhibit 4.1 to the registrantÆ™s current report on Form 8-K (File No. 001-34186) on May 3, 2024 and incorporated herein by reference).31.1*Certification of the Chief Executive Officer, as required by SectionÄ 302 of the Sarbanes-Oxley Act of 2002.31.2*Certification of the Chief Financial Officer, as required by SectionÄ 302 of the Sarbanes-Oxley Act of 2002.32.1**Certification of the Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), as required by SectionÄ 906 of the Sarbanes-Oxley Act of 2002.101The following financial information from this quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2024 formatted in Inline Extensible Business Reporting Language (iXBRL) and filed electronically herewith: (i)Ä Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023; (ii) Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023; (iii) Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended June 30, 2024 and 2023; (iv) Condensed Consolidated Statements of Changes in StockholdersÆ™ Equity for the three and six months ended June 30, 2024 and 2023; (v) Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023; and (vi)Ä Notes to Condensed Consolidated Financial Statements.104Cover Page Interactive Data File (embedded within the Inline XBRL document).*Filed herewith.**Furnished herewith.38Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.Ä Ä Ä Vanda Pharmaceuticals Inc.August 1, 2024Ä Ä /s/Ä Mihael H. Polymeropoulos, M.D.Ä Ä Mihael H. Polymeropoulos, M.D.Ä Ä President, Chief Executive Officer and Chairman of the Board(Principal Executive Officer)August 1, 2024Ä Ä /s/Ä Kevin MoranÄ Ä Kevin MoranÄ Ä Senior Vice President, ChiefÄ FinancialÄ Officer and Treasurer(PrincipalÄ FinancialÄ OfficerÄ andÄ PrincipalÄ AccountingÄ Officer)39 EX-31.1 2 vndaex311630202410q.htm EX-31.1 DocumentEXHIBIT 31.1CERTIFICATION OF CHIEF EXECUTIVE OFFICERPURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 20021, Mihael H. Polymeropoulos, certify that:1.I have reviewed this quarterly report on Form 10-Q of Vanda Pharmaceuticals Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantÆ™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrantÆ™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrantÆ™s internal control over financial reporting that occurred during the registrantÆ™s most recent fiscal quarter (the registrantÆ™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantÆ™s internal control over financial reporting; and5.The registrantÆ™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantÆ™s auditors and the audit committee of the registrantÆ™s board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantÆ™s ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantÆ™s internal control over financial reporting.Ä Ä August 1, 2024/s/Ä Mihael H. Polymeropoulos, M.D.Mihael H. Polymeropoulos, M.D.President, Chief Executive Officer and Chairman of the Board(Principal Executive Officer) EX-31.2 3 vndaex312630202410q.htm EX-31.2 DocumentEXHIBIT 31.2CERTIFICATION OF CHIEF FINANCIAL OFFICERPURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 20021, Kevin Moran, certify that:1.I have reviewed this quarterly report on Form 10-Q of Vanda Pharmaceuticals Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantÆ™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrantÆ™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrantÆ™s internal control over financial reporting that occurred during the registrantÆ™s most recent fiscal quarter (the registrantÆ™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantÆ™s internal control over financial reporting; and5.The registrantÆ™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantÆ™s auditors and the audit committee of the registrantÆ™s board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantÆ™s ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantÆ™s internal control over financial reporting.August 1, 2024/s/Ä Kevin MoranKevin MoranSenior ViceÄ President, ChiefÄ FinancialÄ OfficerÄ andÄ Treasurer(PrincipalÄ FinancialÄ OfficerÄ andÄ PrincipalÄ AccountingÄ Officer) EX-32.1 4 vndaex321630202410q.htm EX-32.1 DocumentEXHIBIT 32.1CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICERPursuant to SectionÄ 906 of the Sarbanes-Oxley Act of 2002.(Subsections (a)Ä and (b)Ä of SectionÄ 1350, Chapter 63 of Title 18, United States Code)Pursuant to SectionÄ 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)Ä and (b)Ä of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Vanda Pharmaceuticals Inc. (the Company), does hereby certify, to the best of such officerÆ™s knowledge, that:The Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the Form 10-Q) of the Company fully complies with the requirements of SectionÄ 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the consolidated financial condition and results of operations of the Company.Ä August 1, 2024/s/Ä Mihael H. Polymeropoulos, M.D.Mihael H. Polymeropoulos, M.D.President, Chief Executive Officer and Chairman of the Board(Principal Executive Officer)August 1, 2024/s/Ä Kevin MoranKevin MoranSenior ViceÄ President,Ä ChiefÄ FinancialÄ OfficerÄ andÄ Treasurer(PrincipalÄ FinancialÄ OfficerÄ andÄ PrincipalÄ AccountingÄ Officer)Ä signed original of this written statement required by SectionÄ 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission (SEC) or its staff upon request. This certification æœaccompaniesæ the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. EX-101.SCH 5 vnda-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Business Organization and Presentation link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - PONVORYÄ® Acquisition link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Legal Matters link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Business Organization and Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Summary of Significant Accounting Policies - Schedule of Net Product Sales (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Summary of Significant Accounting Policies - Major Customers - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - PONVORYÄ® Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Inventory - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Inventory - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Intangible Assets - Schedule of Future Intangible Asset Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Commitments and Contingencies - Fanapt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Commitments and Contingencies - HETLIOZ - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Commitments and Contingencies - Tradipitant - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Commitments and Contingencies - CFTR Activators and Inhibitors - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Commitments and Contingencies - VQW-765 - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Commitments and Contingencies - Other Agreements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Commitments and Contingencies - Purchase Commitments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Stock-Based Compensation - Stock Option - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Stock-Based Compensation - Schedule of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Stock-Based Compensation - Restricted Stock Units - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Stock-

Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 99545110 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99545111 - Disclosure - Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 vnda-20240630 cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 vnda-20240630 def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 vnda-20240630 lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Series A Junior Participating Preferred Stock Purchase Right, par value \$0.001 per share Series A Junior Participating Preferred Stock Purchase Right [Member] Series A Junior Participating Preferred Stock Purchase Right Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] CFTR Activators and Inhibitors CFTR activators and inhibitors [Member] CFTR activators and inhibitors [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Underlying Security Market Price Change Underlying Security Market Price Change, Percent Royalties payable Accrued Royalties, Current Share based compensation option awards contractual term Share Based Compensation Option Awards Contractual Term Contractual term of stock option awards. Schedule of Net Product Sales Revenue from External Customers by Products and Services [Table Text Block] Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Amortization of premiums and accretion of discounts on marketable securities Investment Income, Net, Amortization of Discount and Premium Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Royalty payable percentage on net sales Royalty Payable On Net Sales Percentage Royalty payable percentage under a contractual arrangement for use of technology or intellectual property. MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Exercisable at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restatement Determination Date: Restatement Determination Date [Axis] Corporate debt Corporate Debt Securities [Member] Shares subject to outstanding options and RSUs (in shares) Share Based Compensation Arrangement by Share Based Payment Award Options and Restricted Stock Units Outstanding Number Number of options outstanding, including vested and non-vested options, as of the balance sheet, plus the number of non-vested restricted stock units outstanding as of the balance sheet date. Commitments and contingencies (Notes 9 and 14) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Vested and expected to vest at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Geographical [Axis] Geographical [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Taxes Income Tax Disclosure [Text Block] Business Organization and Presentation Business Description and Basis of Presentation [Text Block] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, \$0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at June 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Finished goods Inventory, Finished Goods, Net of Reserves, Non Current Finished goods inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. Current assets Inventory, Net [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Inventory Schedule Of Inventories [Table Text Block] Schedule of inventories. Diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Service option awards Service Option Awards [Member] Service Option Awards [Member] Vested and expected to vest at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Work-in-process Inventory, Work in Process, Net of Reserves, Non Current Work in process inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted, weighted average fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Tax benefit (provision) on other comprehensive income (loss) Other Comprehensive Income (Loss), Tax Net income (loss) Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] PONVORYA® net product sales PONVORYA® PONVORY [Member] PONVORY Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders' equity: Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Schedule of Basic and Diluted Net Income Per Share of Common Stock Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current Executive Category: Executive Category [Axis] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Future percentage of royalty payments based net sales Future Percentage Of Royalty Payments Based On Net Sales Future Percentage Of Royalty Payments Based On Net Sales. Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Development and Milestone Payment, Conclusion of Clinical Studies Development and Milestone Payment, Conclusion Of Clinical Studies [Member] Development And Milestone Payment, Conclusion Of Clinical Studies [Member] Name Forgone Recovery, Individual Name Equity Components [Axis] Equity Components [Axis] Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Number of shares of common stock available for future grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Asset Acquisition [Domain] Asset Acquisition [Domain] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Weighted average expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Selling, general and administrative Selling, General and Administrative Expenses [Member] Accounts Receivable Accounts Receivable [Member] Operating lease non-current liabilities Operating Lease, Liability, Noncurrent Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Percentage of future sublicense fees payable to third-party Percentage Of Future Sublicense Fees Payable Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property. Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Net income (loss) per share, basic and diluted: Earnings Per Share, Basic And Diluted EPS [Abstract] Earnings Per Share, Basic And Diluted EPS HETLIOZA® net product sales HETLIOZA® Hetlioz [Member] Hetlioz [Member] Depreciation of property and equipment Depreciation Income Statement Location [Axis] Income Statement Location [Axis] Consideration for entering into the arrangement Research and Development Expense (Excluding Acquired in Process Cost) Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment E.U. Europe [Member] Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Policy [Policy Text Block] Portion of initial stock options granted to employees and new directors that vests ratably over three years after completion of first year of service Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards Percentage of new hire stock option award that vests monthly after one year of service. Payables and Accruals [Abstract] Payables and Accruals [Abstract] Total revenues Revenues Product and Service [Domain] Product and Service [Domain] Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventory Increase (Decrease) in Inventories Business Combination, Segment Allocation [Table] Business Combination, Segment Allocation [Table] Research and development Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Antidilutive securities excluded from calculations of diluted net income (loss) per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Pre-NDA Approval Milestones Pre-NDA Approval Milestones [Member] Pre-NDA Approval Milestones [Member] No Trading Symbol Flag No Trading Symbol Flag FanaptA® net product sales FanaptA® Fanapt [Member] Fanapt. Unrecognized compensation expenses related to unvested RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Inventory [Table] Inventory [Table] Inventory [Table] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Number of shares of common stock authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 2024 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Trading Arrangement: Trading Arrangement [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Entity File Number Entity File Number Operating lease liabilities Operating Lease, Liability, Current Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Research and development expenses Accrued Research And Development Expense Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer). Sales and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Intangible asset amortization Intangible asset amortization Amortization of Intangible Assets Entity Shell Company Entity Shell Company Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net Restatement Determination Date Restatement Determination Date Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Beginning of period End of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Traditpant Traditpant [Member] Traditpant [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Ownership acquired percentage Warrants Or Rights Outstanding, Terms Of Agreement, Ownership Percentage Threshold Warrants Or Rights Outstanding, Terms Of Agreement, Ownership Percentage Threshold Common stock, shares issued (in shares) Common Stock, Shares, Issued Grant date fair value of common stock granted (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Schedule of Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Assets measured at fair value Assets, Fair Value Disclosure Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Share-Based Payment Arrangement, Option [Member] Five Major Customers Five Major Customers [Member] Five Major Customers Change in net unrealized gain (loss) on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Unrecognized compensation expenses, weighted average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total operating expenses Costs and Expenses Maximum Maximum [Member] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and contingencies. Entity Address, Address Line Two Entity Address, Address Line Two Outstanding Options and RSUs Stock Options and Restricted Stock Units (RSUs) [Member] Stock Options and Restricted Stock Units (RSUs) [Member] 2006 Plan and 2016 Plan Two Thousand Six Plan and Two Thousand Sixteen Plan [Member] Two Thousand Six Plan and Two Thousand Sixteen Plan [Member] Cost of goods sold excluding amortization Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Intangible assets capitalized Finite-Lived Intangible Assets, Period Increase (Decrease) PONVORYA® Acquisition Asset Acquisition [Text Block] Royalty payment period Royalty Period Royalty Period Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other non-cash adjustments, net Other Noncash Income (Expense) Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Weighted Average Exercise PriceA at Grant Date Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Regulatory Approval Milestone Regulatory Approval Milestone [Member] Regulatory Approval Milestone [Member] Customer Concentration Risk Customer Concentration Risk [Member] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Possible future milestone payment Possible future milestone payments Development And Milestone Payments Potentially Due To Third Party Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones. Income Statement [Abstract] Income Statement [Abstract] Inventory [Line Items] Inventory [Line Items] Operating expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Class of warrant or right, number of securities called by each warrant or right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Product revenue allowances Product Revenue Allowances, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventory Total inventory, current Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Total inventory, non-current Inventory, Noncurrent Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Entity Common Stock, Shares

Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Accounts payable and other accrued liabilities Accounts Payable and Other Accrued Liabilities, Current Non-Current assets Inventory, Noncurrent [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Cash Equivalents Cash Equivalents [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Weighted-Average Remaining-A Term (Years) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Customer [Domain] Customer [Domain] Discrete income tax expense Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Number-A of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Cumulative worldwide sales milestone Cumulative Net Sales To Achieve Milestone Net cumulative worldwide sales to achieve milestone and trigger payment of milestone obligation. Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Total liabilities Liabilities Asset Acquisition [Axis] Asset Acquisition [Axis] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount All Executive Categories All Executive Categories [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Number of reportable segments Number of Reportable Segments Non-current inventory and other inventory and Other Non Current Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets. Net income (loss) per share: Earnings Per Share [Abstract] Marketable Securities Marketable Securities, Policy [Policy Text Block] Net foreign currency translation gain (loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Common stock, \$0.001 par value; 150,000,000 shares authorized; 58,287,308 and 57,534,499 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Consulting and other professional fees Accrued Professional Fees, Current Legal Matters Legal Matters and Contingencies [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Other comprehensive income (loss): Other Comprehensive Income (Loss), before Tax [Abstract] All Individuals All Individuals [Member] Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Earnings per Share Earnings Per Share, Policy [Policy Text Block] 2016 Plan Two Thousand Sixteen Plan [Member] Two Thousand Sixteen Plan [Member] PEO Name PEO Name Concentration risk, percentage Concentration Risk, Percentage Schedule of Accumulated Balances Related to Each Component of Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Thereafter Finite-Lived Intangible Asset, Expected Amortization, After Year Four Finite-Lived Intangible Asset, Expected Amortization, After Year Four Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value U.S. Treasury and government agencies US Treasury and Government [Member] Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Exercisable at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Future Intangible Asset Amortization Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Developmental Milestone Developmental Milestones [Member] Developmental Milestones Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Other income Other Income PONVORY Acquisition PONVORY Acquisition [Member] PONVORY Acquisition Major Customers Major Customers, Policy [Policy Text Block] Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Business Combination and Asset Acquisition [Abstract] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-based Payment Award [Table] Restricted cash included in non-current inventory and other Restricted Cash and Cash Equivalents Concentration Risk Type [Axis] Concentration Risk Type [Axis] Weighted average expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Acquisition of intangible assets Payments to Acquire Intangible Assets Product revenue allowances Increase (Decrease) Product Revenue Allowances The increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances. Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Marketable securities Fair Market Value Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Asset acquisition Payments For Asset Acquisitions Payments For Asset Acquisitions Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Common Stock, par value \$0.001 per share Common Stock Common Stock [Member] Sales Milestone Sales Milestone [Member] Sales Milestone [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Earnings per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property, Plant and Equipment, Net Schedule of Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items] Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items] Other comprehensive income (loss), net of tax Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Total inventory Inventory Inventory Inventory Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Additional Funding Agreement Terms Additional Funding Agreement Terms [Member] Number of vesting equal installments Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments Deferred tax assets Deferred Income Tax Assets, Net Schedule of Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] VWQ-765 VWQ-765 [Member] VWQ-765 [Member] Accumulated Deficit Retained Earnings [Member] Schedule of Stock-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders' equity Liabilities and Equity Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Weighted average risk-free rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized compensation expenses Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Unrealized loss on marketable securities AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Full acceleration of vesting, employee or executive officer subject to involuntary termination, period post change of control of the Company Share-Based Compensation Arrangement By Share-Based Payment Award, Service Option Awards, Full Acceleration Of Vesting, Involuntary Termination, Period Post Change Of Control Share-Based Compensation Arrangement By Share-Based Payment Award, Full Acceleration Of Vesting, Involuntary Termination, Period Post Change Of Control Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Vested and expected to vest at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Number of products in portfolio Number Of Products In Portfolio Number Of Products In Portfolio Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Termination Date Trading Arrangement Termination Date Foreign currency translation Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Common stock, shares authorized (in shares) Common Stock, Shares Authorized Development and milestone obligations paid to third party Development And Milestone Obligations Paid To Third Party Development And Milestone Obligations Paid To Third Party Commitments and Contingencies [Table] Commitments and Contingencies [Table] Commitments and contingencies. Document Information [Table] Document Information [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Future Regulatory Approval and Sales Milestones Future Regulatory Approval And Sales Milestones [Member] Future Regulatory Approval And Sales Milestones [Member] Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments To Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Grant date fair value of common stock vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred income taxes Deferred Income Tax Expense (Benefit) Document Information [Line Items] Document Information [Line Items] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Raw materials Inventory, Raw Materials, Net of Reserves, Non Current Raw materials inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. Beginning balance Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount OilPass Corporation OilPass Corporation [Member] OilPass Corporation Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Amount of net product sales recognized related to a change in estimate Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Entity Central Index Key Entity Central Index Key Total stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Fully amortized intangible assets Gross Carrying Amount Finite-Lived Intangible Assets, Gross Provision (benefit) for income taxes Income Tax Expense (Benefit) Non-US Non-US [Member] Finished goods Inventory, Finished Goods, Net of Reserves Compensation and employee benefits Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Business Organization Description of Business [Policy Text Block] Description of Business Number of operating segments Number of Operating Segments Sales Revenue, Net Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Number of rights (in shares) Dividend Distribution, Number Of Rights Per Common Share Dividend Distribution, Number Of Rights Per Common Share Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventory Inventory Disclosure [Text Block] Net product sales Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Intangible Assets Intangible Assets Disclosure [Text Block] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Diluted (in shares) Weighted average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Loss on sale of marketable securities Debt Securities, Available-for-Sale, Realized Gain (Loss) Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional

Paid-in Capital [Member] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Cover [Abstract] Credit Concentration Risk Credit Concentration Risk [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition U.S. UNITED STATES Series A Junior Participating Preferred Stock Purchase Right, par value \$0.001 per share Series A Preferred Stock [Member] Agreements for clinical and marketing services, termination notice period Agreements For Clinical And Marketing Services, Termination Notice Period Agreements For Clinical And Marketing Services, Termination Notice Period Other non-current liabilities Other Liabilities, Noncurrent Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Portion of initial stock options granted to employees and new directors that vests on first anniversary of grant date Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards Percentage of new hire stock option award that vests after one year of service. Total consideration Asset Acquisition, Consideration Transferred Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Work-in-process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Basic (in shares) Weighted average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Business Combination Segment Allocation [Line Items] Business Combination Segment Allocation [Line Items] Vesting period for subsequent stock options granted to employees and new directors Share Based Compensation Arrangement By Share Based Payment Annual Award Vesting Period Employees And New Directors Period which an employee and new director's right to exercise an annual option award is no longer contingent on satisfaction of either a service, market or a performance condition. Loss from operations Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Revenues: Revenues [Abstract] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Changes in operating assets and liabilities: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Vested and expected to vest at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Schedule of Available-for-Sale Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] EX-101.PRE 9 vnda-20240630.prx.html XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Jul. 25, 2024 Document Information [Line Items] A Document Type 10-Q A Document Quarterly Report true A Document Period End Date Jun. 30, 2024 A Document Transition Report false A Entity File Number 001-34186 A Entity Registrant Name VANDA PHARMACEUTICALS INC. A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 03-0491827 A Entity Address, Address Line One 2200 Pennsylvania Avenue NW A Entity Address, Address Line Two Suite 300E A Entity Address, City or Town Washington A Entity Address, State or Province DC A Entity Address, Postal Zip Code 20037 A City Area Code 202 A Local Phone Number 734-3400 A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Accelerated Filer A Entity Small Business false A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 58,289,808 Entity Central Index Key 0001347178 A Current Fiscal Year End Date -12-31 A Document Fiscal Year Focus 2024 A Document Fiscal Period Focus Q2 A Amendment Flag false A Common Stock, par value \$0.001 per share A A Document Information [Line Items] A A Title of 12(b) Security Common Stock, par value \$0.001 per share A Trading Symbol Vnda A Security Exchange Name NASDAQ A Series A Junior Participating Preferred Stock Purchase Right, par value \$0.001 per share A A Document Information [Line Items] A A Title of 12(b) Security Series A Junior Participating Preferred Stock Purchase Right, par value \$0.001 per share A Security Exchange Name NASDAQ A No Trading Symbol Flag true A X - DefinitionBoolean flag that is true when the XBRL content amends previously filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:gMonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:gYearItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_Data Type: dei:submissionTypeItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceItem Type Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItem Type Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei:filerCategoryItem Type Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItem Type Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a security having no trading symbol. + ReferencesNo definition available. + Details Name: dei_NoTradingSymbolFlag Namespace Prefix: dei_Data Type: dei:trueItem Type Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItem Type Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:edgarExchangeCodeItem Type Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei:tradingSymbolItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: A Cash and cash equivalents \$ 102,953 \$ 135,821 Marketable securities 284,723 252,443 Accounts receivable, net 41,864 34,155 Inventory 1,469 1,357 Prepaid expenses and other current assets 8,171 9,170 Total current assets 439,180 432,946 Property and equipment, net 2,303 2,037 Operating lease right-of-use assets 6,375 7,103 Intangible assets, net 117,599 121,369 Deferred tax assets 76,559 75,000 Non-current inventory and other 9,355 9,985 Total assets 651,371 648,440 Current liabilities: A Accounts payable and accrued liabilities 39,598 38,460 Product revenue allowances 54,193 49,237 Total current liabilities 93,791 87,697 Operating lease non-current liabilities 6,005 7,006 Other non-current liabilities 9,059 8,827 Total liabilities 108,855 103,530 Commitments and contingencies (Notes 9 and 14) Stockholders' equity: A A Preferred stock, \$0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at June 30, 2024 and December 31, 2023 0 0 Common stock, \$0.001 par value; 150,000,000 shares authorized; 58,287,308 and 57,534,499 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 58 58 Additional paid-in capital 706,844 700,274 Accumulated other comprehensive loss (330) (30) Accumulated deficit (164,056) (155,392) Total stockholders' equity 542,516 544,910 Total liabilities and stockholders' equity \$ 651,371 \$ 648,440 X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19.20) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-9 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-

1-Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14:

one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-10](http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-10)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02-26))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details Name: us-gaap InventoryNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X-DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(14\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(14))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.f](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)

gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets. + ReferencesNo definition available. + Details Name: vnda InventoryAndOtherNonCurrent Namespace Prefix: vnda Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionProduct Revenue Allowances, Current + ReferencesNo definition available. + Details Name: vnda ProductRevenueAllowancesCurrent Namespace Prefix: vnda Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X 13 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - \$ / shares Jun. 30, 2024 Dec. 31, 2023 Stockholders' equity: A. A Preferred stock, par value (in dollars per share) \$ 0.001 \$ 0.001 Preferred stock, shares authorized (in shares) 20,000,000 20,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par value (in dollars per share) \$ 0.001 \$ 0.001 Common stock, shares authorized (in shares) 150,000,000 150,000,000 Common stock, shares issued (in shares) 58,287,308 57,534,499 Common stock, shares outstanding (in shares) 58,287,308 57,534,499 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dt-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dt-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us

Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI

<http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue and income classified as other. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column E\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column E\)\(Footnote 4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column E\)\(Footnote 6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(1\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1) + Details Name: us-gaap_OtherIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/commonPracticeRef-Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482517/912-730-25-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-1> + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4) + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 19: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-05\(b\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479557/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479557/942-235-S99-1) + Details Name: us-gaap_RevenuesNamespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03.4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPS), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16) + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units or other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10> + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD (\$) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Statement of Comprehensive Income [Abstract] Á Á Á Net income (loss) \$ (4,518) \$ 1,520 \$ (8,664) \$ 4,772 Other comprehensive income (loss): Á Á Á Net foreign currency translation gain (loss) (3) (3) (22) 12 Change in net unrealized gain (loss) on marketable securities 71 (796) (359) 410 Tax benefit (provision) on other comprehensive income (loss) (15) 183 81 (94) Other comprehensive income (loss), net of tax 53 (610) (300) 328 Comprehensive income (loss) \$ (4,465) \$ 910 \$ (8,964) \$ 5,100 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Reference 3:

Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-599-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-599-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-599-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-599-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-599-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-599-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-599-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-599-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-599-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-599-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-599-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-599-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-599-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-599-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-599-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-599-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-599-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-599-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-599-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-599-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-599-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2 + Details Name: us-gaap_OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD (\$) in Thousands Total Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Beginning balance (in shares) at Dec. 31, 2022 \$ 56,783,764 \$ \$ Beginning balance at Dec. 31, 2022 \$ 527,198 \$ 57 \$ 686,235 \$ (1,193) \$ (157,901) Increase (Decrease) in Stockholders' Equity [Roll Forward] \$ \$ \$ Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares) \$ 657,228 \$ \$ Stock-based compensation expense \$ 4,351 \$ 4,351 \$ \$ Net income (loss) \$ 3,252 \$ \$ 3,252 Other comprehensive income (loss), net of tax \$ 938 \$ \$ 938 Ending balance (in shares) at Mar. 31, 2023 \$ 57,440,992 \$ \$ Ending balance at Mar. 31, 2023 \$ 535,739 \$ 57 \$ 690,586 (255) (154,649) Beginning balance (in shares) at Dec. 31, 2022 \$ 56,783,764 \$ \$ Beginning balance at Dec. 31, 2022 \$ 527,198 \$ 57 \$ 686,235 (1,193) (157,901) Increase (Decrease) in Stockholders' Equity [Roll Forward] \$ \$ \$ Net income (loss) \$ 4,772 \$ \$ 4,772 Other comprehensive income (loss), net of tax \$ 328 \$ \$ 328 Ending balance (in shares) at Jun. 30, 2023 \$ 57,496,913 \$ \$ Ending balance at Jun. 30, 2023 \$ 539,898 \$ 57 \$ 693,835 (865) (153,129) Beginning balance (in shares) at Mar. 31, 2023 \$ 57,440,992 \$ \$ Beginning balance at Mar. 31, 2023 \$ 535,739 \$ 57 \$ 690,586 (255) (154,649) Increase (Decrease) in Stockholders' Equity [Roll Forward] \$ \$ \$ Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares) \$ 55,921 \$ \$ Stock-based compensation expense \$ 3,249 \$ 3,249 \$ \$ Net income (loss) \$ 1,520 \$ \$ 1,520 Other comprehensive income (loss), net of tax (610) \$ \$ (610) Ending balance (in shares) at Jun. 30, 2023 \$ 57,496,913 \$ \$ Ending balance at Jun. 30, 2023 \$ 539,898 \$ 57 \$ 693,835 (865) (153,129) Beginning balance (in shares) at Dec. 31, 2023 \$ 57,534,499 \$ 57,534,499 \$ \$ Beginning balance at Dec. 31, 2023 \$ 544,910 \$ 58 \$ 700,274 (30) (155,392) Increase (Decrease) in Stockholders' Equity [Roll Forward] \$ \$ \$ Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares) \$ 662,024 \$ \$ Stock-based compensation expense \$ 3,584 \$ 3,584 \$ \$ Net income (loss) (4,146) \$ \$ (4,146) Other comprehensive income (loss), net of tax (353) \$ \$ (353) Ending balance (in shares) at Mar. 31, 2024 \$ 58,196,523 \$ \$ Ending balance at Mar. 31, 2024 \$ 543,995 \$ 58 \$ 703,858 (383) (159,538) Beginning balance (in shares) at Dec. 31, 2023 \$ 57,534,499 \$ 57,534,499 \$ \$ Beginning balance at Dec. 31, 2023 \$ 544,910 \$ 58 \$ 700,274 (30) (155,392) Increase (Decrease) in Stockholders' Equity [Roll Forward] \$ \$ \$ Net income (loss) (8,664) \$ \$ (8,664) Other comprehensive income (loss), net of tax \$ (300) \$ \$ (300) Ending balance (in shares) at Jun. 30, 2024 \$ 58,287,308 \$ 58,287,308 \$ \$ Ending balance at Jun. 30, 2024 \$ 542,516 \$ 58 \$ 706,844 (330) (164,056) Beginning balance (in shares) at Mar. 31, 2024 \$ 58,196,523 \$ \$ Beginning balance at Mar. 31, 2024 \$ 543,995 \$ 58 \$ 703,858 (383) (159,538) Increase (Decrease) in Stockholders' Equity [Roll Forward] \$ \$ \$ Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares) \$ 90,785 \$ \$ Stock-based compensation expense \$ 2,986 \$ 2,986 \$ \$ Net income (loss) (4,518) \$ \$ (4,518) Other comprehensive income (loss), net of tax \$ 53 \$ \$ 53 Ending balance (in shares) at Jun. 30, 2024 \$ 58,287,308 \$ 58,287,308 \$ \$ Ending balance at Jun. 30, 2024 \$ 542,516 \$ 58 \$ 706,844 (330) (164,056) X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a

corporation. + ReferencesReference 1:

restricted cash (29) 19 Net change in cash, cash equivalents and restricted cash (32,868) \$5,400 Cash, cash equivalents and restricted cash \$ Beginning of period 136,290 135,498 End of period \$ 103,422 \$ 150,500 X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482686/350-30-45-28>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2> + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-9> + Details Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479360/740-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479360/740-10-S99-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479360/740-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-9> + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481877/830-230-45-1> + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accretion (amortization) of purchase discount (premium) on nonoperating securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483581/946-220-45-7>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483586/944-220-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-3>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap OtherNoncashIncomeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11 + Details Name: us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap ShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances. + ReferencesNo definition available. + Details Name: vnda IncreaseDecreaseProductRevenueAllowances Namespace Prefix: vnda Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayments For Asset Acquisitions + ReferencesNo definition available. + Details Name: vnda PaymentsForAssetAcquisitions Namespace Prefix: vnda Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Business Organization and Presentation 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Á Business Organization and Presentation Business Organization and Presentation Business Organization Vanda Pharmaceuticals Inc. (the Company) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in one reporting segment. The Companyâ€™s commercial portfolio is currently comprised of three products, Fanapt® for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZÂ® for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), and PONVORYÂ® for the treatment of relapsing forms of multiple sclerosis (MS) to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, in adults. HETLIOZÂ® is the first product approved by the United States Food and Drug Administration (FDA) for patients with Non-24 and for patients with SMS. In addition, the Company has a number of drugs in development, including: â€¢Milsaperidone (VHX-896), the active metabolite of Fanapt® (iloperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia; â€¢FanaptÂ® (iloperidone) long acting injectable (LAI) formulation for the treatment of schizophrenia; â€¢HETLIOZÂ® (tasimelteon) for the treatment of jet lag disorder, insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24; â€¢PONVORYÂ® (ponesimod) for the treatment of psoriasis and ulcerative colitis;â€¢Tradipitant (VLY-686), a small molecule neurokinin-1 (NK-1) receptor antagonist, for the treatment of gastroparesis, motion sickness and atopic dermatitis; â€¢Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and VPO-227 for the treatment of secretory diarrhea disorders, including cholera; â€¢VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of onychomycosis and hematologic malignancies and with potential use as a treatment for several oncology indications; â€¢VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, for the treatment of social/performance anxiety and psychiatric disorders; and â€¢Antisense oligonucleotide (ASO) molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease, Type 2S (CMT2S), caused by cryptic splice site variants within the IGHMBP2 gene.Basis of PresentationThe accompanying unaudited condensed consolidated financial statements include the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with United States generally accepted accounting principles (GAAP) for interim financial information and the instructions to Formâ€”10-Q and ArticleÂ€10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Companyâ€™s consolidated financial statements and accompanying notes included in the Companyâ€™s annual report on Form 10-K (Annual Report) for the fiscal year ended December 31, 2023. The financial information as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023 is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheet data as of December 31, 2023 was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Companyâ€™s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details Name: us-gaap BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Á Summary of Significant Accounting PoliciesSummary of Significant Accounting PoliciesThere have been no material changes to the significant accounting policies previously disclosed in the Annual Report. Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and managementâ€™s evaluation could change. Actual results could differ from those estimates.Cash, Cash Equivalents and Restricted CashFor purposes of the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.Á Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Companyâ€™s Washington, D.C. headquarters.Á The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Condensed Consolidated Statements of Cash Flows:(in thousands)June 30,2024June 30,2023Cash and cash equivalents\$102,953Á \$150,031Á Restricted cash included in non-current inventory and other469Á 469Á Total cash, cash equivalents and restricted cash\$103,422Á \$150,500Á Revenue from Net Product SalesThe Companyâ€™s net product sales consist of sales of FanaptÂ®, HETLIOZÂ® and PONVORYÂ®. Net sales by product for the three and six months ended June 30, 2024 and 2023 were as follows:Á Three Months EndedSix Months Ended(in thousands)June 30,2024June 30,2023June 30,2024June 30,2023FanaptÂ® net product sales\$23,150Á \$24,077Á \$43,729Á \$46,959Á HETLIOZÂ® net product sales18,708Á 21,979Á 38,761Á 61,595Á PONVORYÂ® net product sales8,616Á â€”Á \$15,446Á â€”Á Total net product sales\$50,474Á \$46,056Á \$97,936Á \$108,554Á The Companyâ€™s HETLIOZÂ® net product sales as reported for the three months ended March 31, 2023 reflected higher unit sales as compared to recent prior periods. The higher unit sales during the three months ended March 31, 2023 resulted in a significant increase of inventory stocking at specialty pharmacy customers at March 31, 2023. During the remainder of 2023, although there was continued destocking at specialty pharmacy customers, inventory levels remained elevated relative to inventory levels prior to the entrance of generic competition and remained elevated at March 31, 2024 and June 30, 2024. Going forward, HETLIOZÂ® net product sales may reflect lower unit sales as a result of reduction of the elevated inventory levels at specialty pharmacy customers or may be variable depending upon when specialty pharmacy customers need to purchase again. Further, HETLIOZÂ® net product sales will likely decline in future periods, potentially significantly, related to continued generic competition in the U.S. The Company constrained HETLIOZÂ® net product sales for the three and six months ended June 30, 2024 and 2023 to an amount not probable of significant revenue reversal. The amount of revenue recognized during the three months ended June 30, 2024 and 2023 related to changes in estimates on revenue constrained during the first quarter of 2024 and 2023 was \$0.7 million and \$4.8 million, respectively. The amount of revenue recognized during the six months ended June 30, 2024 related to changes in estimates on revenue constrained during the year ended December 31, 2023 was \$1.6 million. HETLIOZÂ® net product sales could experience variability in future periods as the remaining uncertainties associated with variable consideration related to inventory stocking by specialty pharmacy customers are resolved.Major CustomersFanaptÂ® is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. HETLIOZÂ® is available in the United States (U.S.) for distribution through a limited number of specialty pharmacies and is not available in retail pharmacies. PONVORYÂ® is available in the U.S. for distribution primarily through specialty distributors. The Company invoices and records revenue when its customers, wholesalers, specialty pharmacies and specialty distributors, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Outside the U.S., the Company has a distribution agreement for the commercialization of FanaptÂ® in Israel and sells HETLIOZÂ® in Germany. There were five major customers that each accounted for more than 10% of total revenues and, as a group, represented 73% of total revenues for the six months ended June 30, 2024. There were five major customers that each accounted for more than 10% of accounts receivable and, as a group, represented 73% of total accounts receivable at June 30, 2024. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.Recent Accounting PronouncementsIn November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Companyâ€™s consolidated financial statements.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Companyâ€™s consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent + Details Name: us-gaap SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 PONVORYÂ® Acquisition 6 Months Ended Jun. 30, 2024 Business Combination and Asset Acquisition [Abstract] Á

PONVORYA® Acquisition PONVORYA® Acquisition On December 7, 2023, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") to acquire the U.S. and Canadian rights to PONVORYA® from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company, and the closing of the transaction took place simultaneously with signing. PONVORYA® is a once-daily oral selective sphingosine-1-phosphate receptor 1 modulator, indicated to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. The total consideration for the acquisition was \$104.9 million consisting of cash paid to Janssen and acquisition-related transaction costs. The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties. Janssen has agreed to indemnify the Company against losses arising from its activities prior to the closing, and the Company has agreed to indemnify Janssen against losses arising from the Company's activities pertaining to PONVORYA® after the closing. Simultaneously and in connection with the Purchase Agreement, the parties also entered into certain supporting agreements, including a customary transition agreement, pursuant to which, during a transition period, Janssen will continue PONVORYA® operations. The Company announced in May 2024 that ownership of the U.S. New Drug Application (NDA) and Investigational New Drug applications for PONVORYA® had been transferred to Vanda from a Johnson & Johnson Company, fully allowing the Company to commercialize PONVORYA® in the U.S. The acquisition of PONVORYA® has been accounted for as an asset acquisition in accordance with ASC 805-50 because substantially all of the fair value of the assets acquired is concentrated in a single asset, the PONVORYA® product rights. The PONVORYA® products rights consist of certain patents and trademarks, regulatory approvals, marketing assets, and other records, and are considered a single asset as they are inextricably linked. The total consideration of \$104.9 million was fully allocated to the acquired intangible asset for the U.S. and Canadian rights to PONVORYA®. The straight-line method is used to amortize the intangible asset, as disclosed in Note 7, Intangible Assets. X - DefinitionThe entire disclosure for asset acquisition. + ReferencesReference 1:

conditions for a period of up to 10 years in markets where the new chemical entity (NCE) patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026. HETLIOZÄ®.Ä In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZÄ®. As of June 30, 2024, the Company has paid BMS \$37.5 million in upfront fees and milestone obligations, including \$33.0 million of regulatory approval and commercial milestones capitalized as intangible assets (see Note 7, Intangible Assets). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZÄ®Ä net sales to BMS. The royalty period in each territory where the Company commercializes HETLIOZÄ®Ä is 10 years following the first commercial sale in the territory. In territories outside the U.S., the royalty is 5% on net sales. In the U.S., the royalty on net sales in the U.S. decreased from 10% to 5% in December 2022. This U.S. royalty ended in April 2024. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in theÄ mid-twenties.Ä The Company is obligatedÄ to use its commercially reasonable efforts to develop and commercialize HETLIOZÄ®.Tradipitant.Ä In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize anÄ NK-1 receptorÄ antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. As of June 30, 2024, the Company has paid Lilly \$5.0 million in upfront fees and development milestones. These payments for upfront fees and development milestones include a \$2.0 million milestone paid to Lilly during the year ended December 31, 2023 for the filing of the first application for marketing authorization for tradipitant in either the U.S. or European Union (E.U.). As of June 30, 2024, remaining milestone obligations include \$10.0 million and \$5.0 million milestones for the first approval of an application for marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to \$80.0 million for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant.Portfolio of CFTR activators and inhibitors. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well asÄ single-digitÄ royalties on net sales. As of June 30, 2024, the Company has paid UCSF \$1.6 million in upfront fees and development milestones. As of June 30, 2024, remaining milestone obligations include \$11.9 millionÄ for development milestones andÄ \$33.0 millionÄ for future regulatory approval and sales milestones. Included in theÄ \$11.9 millionÄ of development milestones are \$1.1 million of milestone obligations due upon the conclusion of clinical studies for each licensed product but not to exceedÄ \$3.2 millionÄ in total for the CFTR portfolio.VQW-765.Ä In connection with a settlement agreement with Novartis relating to FanaptÄ®, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765.Ä A Phase IIA alpha-7Ä nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercializeÄ VQW-765Ä and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to theÄ mid-teens.Other AgreementsOlipass. In September 2022, the Company entered into an agreement with OliPass Corporation (OliPass) to jointly develop a set of ASO molecules based on OliPassÄ™ proprietary modified peptide nucleic acids. As consideration for entering into the arrangement, the Company paid OliPass an upfront fee of \$3.0Ä million, which was recorded as research and development expense in 2022. The Company is funding the research and development activities and has the option to license jointly developed intellectual property upon successful development. Shareholder Rights Plan. On April 17, 2024, the CompanyÄ™s board of directors authorized and declared a dividend distribution of one right (each, a Right) for each outstanding share of common stock of the Company to stockholders of record as of the close of business on April 29, 2024 (the Record Date). Each Right entitles the registered holder to purchase from the Company, subject to certain conditions which have not yet occurred, one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value \$0.001 per share (the Preferred Stock), of the Company at an exercise price of \$25.00 (the Exercise Price), subject to adjustment. The complete terms of the Rights are set forth in a Rights Agreement, dated as of April 17, 2024, between the Company and Equiniti Trust Company, LLC, as rights agent (the Rights Agent), as amended by that certain Amendment No. 1 to the Rights Agreement, by and between the Company and the Rights Agent (as amended, the Rights Agreement).In general terms, subject to certain enumerated exceptions, the Rights Agreement works by imposing a significant penalty upon any person or group that acquires beneficial ownership of 10% or more of the shares of common stock without the prior approval of the board of directors. In general, any person will be deemed to beneficially own any securities (a) as to which such person has any agreement, arrangement or understanding with another person for the purpose of acquiring, holding, voting or disposing of any shares of Common Stock or (b) that are the subject of a derivative transaction or constitute a derivative security. As a result, the overall effect of the Rights Agreement and the issuance of the Rights may be to render more difficult or discourage a merger, tender or exchange offer or other business combination involving the Company that is not approved by the board of directors. However, neither the Rights Agreement nor the Rights should interfere with any merger, tender or exchange offer or other business combination approved by the board of directors.Purchase CommitmentsIn the course of its business, the Company regularly enters into agreements with third-party vendors under fee service arrangements, which generally may be terminated on 90 daysÄ™ notice without incurring additional charges, other than charges for work completed or materials procured but not paid for through the effective date of termination and other costs incurred by the CompanyÄ™s contractors in closing out work in progress as of the effective date of termination. The CompanyÄ™s non-cancellable purchase commitments for agreements longer than one year primarily relate to commitments for data services. Various other long-term agreements entered into for services with other third-party vendors, such as inventory purchase commitments, are cancellable in nature or contain variable commitment terms within the agreement. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480327/954-440-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480327/954-440-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent> + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accumulated Other Comprehensive Loss 6 Months Ended Jun. 30, 2024 Equity [Abstract] Ä Accumulated Other Comprehensive Loss Accumulated Other Comprehensive LossThe accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows as of June 30, 2024 and December 31, 2023:(in thousands)June 30, 2024December 31, 2023Foreign currency translation\$(1)\$21Ä Unrealized loss on marketable securities (329)(51)Accumulated other comprehensive loss\$(330)\$(30) X - DefinitionThe entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\)\(19\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04)(19) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\)\(21\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03)(21) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\)\(23\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04)(23) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/220/tableOfContent> + Details Name: us-gaap_ComprehensiveIncomeNoteTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Ä Stock-Based Compensation Stock-Based CompensationAs of June 30, 2024, there were 7,677,419 shares subject to outstanding options and restricted stock units (RSUs) under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms in April 2016, and the Company adopted the 2016 Plan. Outstanding options under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the CompanyÄ™s stockholders approved the 2016 Plan. The 2016 Plan has been amended a number of times since to increase the number of shares reserved for issuance, among other administrative changes. Each of the amendments to the 2016 Plan was approved by the CompanyÄ™s stockholders. There is a total of 15,690,000 shares of common stock authorized for issuance under the 2016 Plan, 4,673,878 shares of which remained available for future grant as of June 30, 2024.Stock OptionsThe Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have 10-year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over four years, with the first 25% of the shares subject to service option awards vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the service option awards in 36 equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Service option awards granted to executive officers and certain other employees provide for partial acceleration of vesting if the executive officer or employee is subject to an involuntary termination, and full acceleration of vesting if the executive officer or employee is subject to an involuntary termination within 24 months after a change in control of the Company. Service option awards granted to directors provide for accelerated vesting if there is a change in control of the Company or if the directorÄ™s service terminates as a result of the directorÄ™s death or total and permanent disability. As of June 30, 2024, \$4.6 million of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of 1.0 years. No option awards are classified as a liability as of June 30, 2024.A summary of option activity under the Plans for the six months ended June 30, 2024 follows:(in thousands, except for share and per share amounts)NumberÄ of SharesWeightedÄ AverageExerciseÄ PriceÄ at GrantDateWeightedÄ AverageRemainingÄ Term(Years)AggregateIntrinsicValueOutstanding at December 31, 20234,792,506Ä \$12.95Ä 6.00Ä \$Ä 190,514Ä 5.41Ä \$Ä Expired(31,000)11.39Ä Outstanding at June 30, 20244,952,020Ä 12.67Ä 5.70Ä 46Ä Exercisable at June 30, 20243,873,090Ä 13.68Ä 4.95Ä Ä Vested and expected to vest at June 30, 20244,848,508Ä 12.78Ä 5.64Ä 39Ä The weighted average grant date fair value of options granted was \$2.95 and \$3.53 per share for the six months ended June 30, 2024 and 2023. There were no proceeds from the exercise of stock options for the six months ended June 30, 2024 and 2023. Restricted Stock UnitsAn RSU is a stock award that entitles the holder to receive shares of the CompanyÄ™s common stock as the award vests. The fair value of each RSU is based on the closing price of the CompanyÄ™s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that are subject to terms and conditions established by the compensation committee of the board of directors. Service RSUs granted to employees and new directors upon their election vest in four equal annual installments. Subsequent annual service RSUs granted to directors vest on the first anniversary of the date of grant. Service RSUs granted to executive officers and certain other employees provide for accelerated vesting if the executive officer or employee is subject to an involuntary termination within 24 months after a change in control. Service RSUs granted to directors provide for accelerated vesting if there is a change in control of the Company. As of June 30, 2024, \$16.0 million of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of 1.7 years. No RSUs are classified as a liability as of June 30, 2024.A summary of RSU activity for the Plans for the six months ended June 30, 2024 is as follows:Number of SharesWeightedAverageGrantÄ Date FairÄ ValueUnvested at December 31, 20231,905,310Ä \$10.87Ä Granted1,610,903Ä 4.45Ä Forfeited(38,005)10.31Ä Vested(752,809)11.51Ä Unvested at June 30, 20242,725,399Ä 6.90Ä The grant date fair value for the 752,809 shares underlying RSUs that vested during the six months ended June 30, 2024 was \$8.7 million.Stock-Based Compensation ExpenseStock-based compensation expense recognized for the three and six months ended June 30, 2024 and 2023 was comprised of the following:Ä Three Months EndedSix Months Ended(in thousands)June 30, 2024June 30, 2023June 30, 2024June 30, 2023Research and development\$674Ä \$734Ä \$1,538Ä \$1,799Ä Selling, general and administrative2,312Ä 2,516Ä 5,032Ä 5,801Ä Total stock-based compensation expense\$2,986Ä \$3,249Ä \$6,570Ä \$7,600Ä The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the CompanyÄ™s publicly traded common stock and other factors. The expected terms are determined based on a combination of historical exercise data and hypothetical exercise data for unexercised stock options. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the six months ended June 30, 2024 and 2023 were as follows:Ä Six Months EndedJune 30, 2024June 30, 2023Expected dividend yield0Ä %0Ä %Weighted average expected volatility50Ä %47Ä %Weighted average expected term (years)6.276.16Weighted average risk-free rate4.52Ä %3.89Ä % X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes 6 Months Ended Jun. 30, 2024 Income Tax Disclosure [Abstract] Ä Income Taxes Income TaxesFor the three months ended June 30, 2024 and 2023, the Company recorded an income tax benefit ofÄ \$1.0 million and a provision for income taxes of \$1.1 million, respectively. The income tax expense (benefit) for the three months ended June 30, 2024 and 2023 was primarily driven by the estimated effective tax rate for the year, as well as discrete income tax expense of \$0.2Ä million and \$0.8Ä million, respectively.For the six months ended June 30, 2024 and 2023, the Company recorded an income tax benefit ofÄ \$1.5Ä million and a provision for income taxes of \$3.3Ä million, respectively. The income tax expense (benefit) for the six months ended June 30, 2024 and 2023 was primarily driven by the estimated effective tax rate for the year, as well as discrete income tax expense of \$0.8 million and \$1.8 million, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace

Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482526/740-270-50-1>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SAB TOPIC 6.1.5.Q1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB TOPIC 6.1.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph \(SAB TOPIC 11.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SAB TOPIC 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_ IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings per Share 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] A Earnings per Share Earnings per ShareBasic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive, as calculated using the treasury stock method.The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the three and six months ended June 30, 2024 and 2023: A Three Months EndedSix Months Ended(in thousands, except for share and per share amounts)June 30,2024June 30,2023June 30,2024June 30,2023Numerator:Net income (loss)$(4,518)$1,520A $(8,664)$4,772A Denominator:Weighted average shares outstanding, basic58,220,838A 57,453,916A 57,990,890A 57,233,878A Effect of dilutive securities(A) 81,699A (A) 235,227A Weighted average shares outstanding, diluted58,220,838A 57,535,615A 57,990,890A 57,469,105A Net income (loss) per share, basic and diluted:Basic(0.08)0.03A (0.15)0.08A Diluted(0.08)0.03A (0.15)0.08A Antidilutive securities excluded from calculations of diluted net income (loss) per share6,397,303A 6,722,509A 6,713,473A 6,427,780A The Company incurred a net loss for the three and six months ended June 30, 2024 causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in dilutive loss per share and basic loss per share attributable to common stockholders being equivalent. X - ReferencesNo definition available. + Details Name: us-gaap_ EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2>Reference 4:

lawsuit in the U.S. Court of Federal Claims (Federal Claims Court) against the federal government for the uncompensated taking and misuse of the Company’s trade secrets and confidential information. The Company believes that the FDA violated the Fifth Amendment’s due process clause by improperly providing confidential details from the Company’s drug master files for HETLIOZA® and Fanapt® to generic drug manufacturers during the FDA’s review of the manufacturers’ ANDAs. The Company has asked the Federal Claims Court to, among other things, declare that the FDA’s disclosure of the Company’s confidential commercial information constitutes a taking for purposes of the Fifth Amendment and award just compensation. The federal government filed a motion to dismiss the complaint, which the Company opposed. In January 2024, the Federal Claims Court held an oral argument on the motion to dismiss, following which the Federal Claims Court issued a decision denying in part the government’s motion, allowing the Company’s takings claim to proceed. The Company’s lawsuit remains pending. In February 2024, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with its statutory obligations under the FDCA and its implementing regulations, and to challenge the FDA’s complete response letter and 60-day filing regulations, which the Company believes do not absolve the FDA of its statutory responsibilities. Under the FDCA, the FDA has an obligation to either approve the Company’s sNDA for HETLIOZA® in the treatment of insomnia characterized by difficulties with sleep initiation within 180 days of the filing of the sNDA or give the Company a notice of an opportunity for a hearing. The Company submitted the sNDA on May 4, 2023. The Company has asked the DC District Court to, among other things, compel the FDA to comply with its obligations, declare that its lack of compliance violates the FDCA and the FDA regulations and declare the FDA’s complete response letter and 60-day filing regulations unlawful. In June 2024, the Company filed a motion for summary judgment and the FDA published a notice of opportunity for a hearing. In July 2024, the FDA opposed the Company’s motion for summary judgment. The DC District Court has scheduled an oral argument for September 17, 2024. In March 2024, the Company filed a petition for review in the U.S. Court of Appeals for the District of Columbia Circuit seeking review of the FDA’s final order refusing to hold a hearing or to approve the Company’s sNDA for HETLIOZA® in the treatment of jet lag disorder. Under the FDCA, the FDA has an obligation to either approve an sNDA or to hold a hearing on the application’s approvability. The Company’s petition asks the DC Circuit to set aside the FDA’s order refusing to hold a hearing and refusing approval. The Company’s petition remains pending. On April 22, 2024, a purported stockholder of the Company filed a lawsuit in the Court of Chancery of the State of Delaware against the members of the Company’s board of directors and the Rights Agent, along with the Company as nominal defendant (collectively, the Defendants), captioned Steamfitters Local 449 Pension Fund v. Mihal H. Polymeropoulos, et al., CA No. 2024-0416-KSJM. The lawsuit contends, among other things, that the members of the Company’s board of directors breached their fiduciary duties in adopting the Rights Agreement. The lawsuit seeks relief declaring, in part, that provisions of the Rights Agreement be deemed unenforceable and seeks to enjoin the use of such provisions as well as damages, costs, and other remedies, and also sought to enjoin for 30 days the Company’s 2024 Annual Meeting of Stockholders (the Annual Meeting) that was held on May 17, 2024. At a hearing on May 7, 2024, the Delaware Chancery Court denied the plaintiff’s request to enjoin the Annual Meeting. A three-day trial in the case is scheduled to begin on November 4, 2024. The Defendants believe the claims are without merit and intend to vigorously defend the lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient. X - ReferencesNo definition available. + Details Name: us-gaap.CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies. + ReferencesReference 1:

not necessarily indicative of the results that may be expected for any other interim period or any future year or period. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management's evaluation could change. Actual results could differ from those estimates. Cash, Cash Equivalents and Restricted Cash For purposes of the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers. A Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company's Washington, D.C. headquarters. Major Customers Fanapt® is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. HETLIOZA® is available in the United States (U.S.) for distribution through a limited number of specialty pharmacies and is not available in retail pharmacies. PONVORYA® is available in the U.S. for distribution primarily through specialty distributors. The Company invoices and records revenue when its customers, wholesalers, specialty pharmacies and specialty distributors, receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Outside the U.S., the Company has a distribution agreement for the commercialization of Fanapt® in Israel and sells HETLIOZA® in Germany. There were five major customers that each accounted for more than 10% of total revenues and, as a group, represented 73% of total revenues for the six months ended June 30, 2024. There were five major customers that each accounted for more than 10% of accounts receivable and, as a group, represented 73% of total accounts receivable at June 30, 2024. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates. Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements. Marketable Securities The Company's assets classified in Level 1 and Level 2 as of June 30, 2024 and December 31, 2023 consist of cash equivalents and available-for-sale marketable securities. The valuation of Level 1 instruments is determined using a market approach and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of Level 2 instruments is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level 2 securities include certificates of deposit, commercial paper and corporate notes that use as their basis readily observable market parameters. Earnings per Share Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive, as calculated using the treasury stock method. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS), + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1> + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2> + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16> + Details Name: us-gaap_MajorCustomersPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment classified as marketable security. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480832/942-320-50-5> + Details Name: us-gaap_MarketableSecuritiesPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8> + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionDescription of Business + ReferencesNo definition available. + Details Name: vnda_DescriptionOfBusinessPolicyTextBlock Namespace Prefix: vnda_ Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Tables) 6 Months Ended June 30, 2024 Accounting Policies [Abstract] A Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Condensed Consolidated Statements of Cash Flows:(in thousands)June 30,2024June 30,2023Cash and cash equivalents\$102,953A \$150,031A Restricted cash included in non-current inventory and other469A 469A Total cash, cash equivalents and restricted cash\$103,422A \$150,500A Schedule of Net Product Sales Net sales by product for the three and six months ended June 30, 2024 and 2023 were as follows: A Three Months EndedSix Months Ended(in thousands)June 30,2024June 30,2023June 30,2024June 30,2023Fanapt® net product sales\$23,150A \$24,077A \$43,729A \$46,959A HETLIOZA® net product sales\$18,708A 21,979A 38,761A 61,595A PONVORYA® net product sales\$8,616A 15,446A 15,446A 15,446A Total net product sales\$50,474A \$46,056A \$97,936A \$108,554A X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of supplemental cash flow information for the periods presented. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40> + Details Name: us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities (Tables) 6 Months Ended June 30, 2024 Investments, Debt and Equity Securities [Abstract] A Schedule of Available-for-Sale Marketable Securities The following is a summary of the Company's available-for-sale marketable securities as of June 30, 2024, which all have contractual maturities of less than two years:AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFairMarketValue(in thousands)U.S. Treasury and government agencies\$144,155A \$47A \$(384)\$143,818A Corporate debt141,004A 141,004A (99)140,905A Total marketable securities\$285,159A \$47A \$(483)\$284,723A The following is a summary of the Company's available-for-sale marketable securities as of December 31, 2023, which all have contractual maturities of less than two years:AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFairMarketValue(in thousands)U.S. Treasury and government agencies\$185,168A \$227A \$(280)\$185,115A Corporate debt67,352A 2A (26)67,328A Total marketable securities\$252,520A \$229A \$(306)\$252,443A X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 7: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aaa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 9: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3) + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemBalance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Tables) 6 Months Ended June 30, 2024 Fair Value Disclosures [Abstract] A Schedule of Assets Measured at Fair Value on Recurring Basis The Company held certain assets that are required to be measured at fair value on a recurring basis as of June 30, 2024, as follows: A Fair Value Measurement as of June 30, 2024 UsingTotal Fair ValueQuoted Prices inActiveA MarketsA forIdentical AssetsSignificantA OtherObservableA InputsSignificantUnobservableInputs(in thousands)(Level 1)(Level 2)(Level 3)U.S. Treasury and government agencies\$143,818A \$143,818A 143,818A 143,818A 143,818A Corporate debt153,773A 153,773A 153,773A 153,773A Total assets measured at fair values\$297,591A \$143,818A \$153,773A 143,818A The Company held certain assets that are required to be measured at fair value on a recurring basis as of December 31, 2023, as follows:Fair Value Measurement as of December 31, 2023 UsingTotal Fair ValueQuoted Prices inActiveA MarketsA forIdentical AssetsSignificantA OtherObservableA InputsSignificantUnobservableInputs(in thousands)(Level 1)(Level 2)(Level 3)U.S. Treasury and government agencies\$209,103A \$209,103A 209,103A 209,103A 209,103A Corporate debt107,108A 107,108A 107,108A 107,108A Total assets measured at fair values\$316,211A \$209,103A \$107,108A 107,108A 107,108A X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2:

gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory (Tables) 6 Months Ended Jun. 30, 2024 Inventory Disclosure [Abstract] A Inventory Inventory consisted of the following as of June 30, 2024 and December 31, 2023:(in thousands)June 30,2024December 31, 2023Current assetsWork-in-process\$6,271 Finished goods1,469A 1,330A Total inventory, currents\$1,469A 1,357A Non-Current assetsRaw materials\$934A \$934A Work-in-process6,928A 7,177A Finished goods190A 737A Total inventory, non-current8,052A 8,848A Total inventory\$9,521A 10,205A X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionSchedule of inventories. + ReferencesNo definition available. + Details Name: vnda_ScheduleOfInventoriesTableTextBlock Namespace Prefix: vnda_Data Type: dtr-types:1:textBlockItem Type Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Tables) 6 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] A Schedule of Intangible Assets The following is a summary of the Company's amortizing intangible assets as of June 30, 2024 A June 30, 2024(in thousands)EstimatedUseful LifeCrossCarryingAmountAccumulatedAmortizationNetCarryingAmountHETLIOZAA2035\$33,000A \$16,668A \$16,332A PONVORYAA2042104,894A 3,627A 101,267A Total amortizing intangible assets\$137,894A \$20,295A \$117,599A The following is a summary of the Company's amortizing intangible assets as of December 31, 2023: A December 31, 2023(in thousands)EstimatedUseful LifeCrossCarryingAmountAccumulatedAmortizationNetCarryingAmountHETLIOZAA2035\$33,000A \$15,937A \$17,063A PONVORYAA2035104,894A 588A 104,306A Total amortizing intangible assets\$137,894A \$16,525A \$121,369A Schedule of Future Intangible Asset Amortization The following is a summary of the future intangible asset amortization schedule as of June 30, 2024:(in thousands)Total20242025202620272028 ThereafterHETLIOZAA\$16,332A \$731A 1,463A \$1,463A \$1,463A \$9,749A PONVORYAA\$101,267A 2,772A 5,544A 5,544A 5,544A 5,544A 76,311A amortizing intangible assets\$117,599A \$3,503A \$7,007A \$7,007A \$7,007A \$86,068A X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounts Payable and Accrued Liabilities (Tables) 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] A Schedule of Accounts Payable and Accrued Liabilities The following is a summary of the Company's accounts payable and accrued liabilities as of June 30, 2024 and December 31, 2023:(in thousands)June 30,2024December 31, 2023Research and development expenses\$15,290A \$15,691A Consulting and other professional fees13,561A 4,404A Compensation and employee benefits4,545A 6,413A Operating lease liabilities2,426A 2,398A Royalties payable1,510A 2,409A Accounts payable and other accrued liabilities2,266A 7,145A Total accounts payable and accrued liabilities\$39,598A \$38,460A X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accumulated Other Comprehensive Loss (Tables) 6 Months Ended Jun. 30, 2024 Equity [Abstract] A Schedule of Accumulated Balances Related to Each Component of Other Comprehensive Loss The accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows as of June 30, 2024 and December 31, 2023:(in thousands)June 30,2024December 31, 2023Foreign currency translations(1)\$21A Unrealized loss on marketable securities (329)(51)Accumulated other comprehensive loss\$(330)\$(30) X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] A Schedule of Option Activity A summary of option activity under the Plans for the six months ended June 30, 2024 follows:(in thousands, except for share and per share amounts)NumberA ofSharesWeightedA AverageExerciseA PriceA atGrant DateWeightedA AverageRemainingA Term(Years)AggregateIntrinsicValueOutstanding at December 31, 20234,792,506A 12.95A 6.00\$eC A Granted190,514A 5.41A Expired(31,000)11.39A Outstanding at June 30, 20244,952,020A 12.67A 5.7046A Exercisable at June 30, 20243,873,090A 13.68A 4.95\$eC A Vested and expected to vest at June 30, 20244,848,508A 12.78A 5.6439A Schedule of RSU Activity A summary of RSU activity for the Plans for the six months ended June 30, 2024 is as follows:(Number ofSharesWeightedAverageGrantA Date FairA ValueUnvested at December 31, 20231,905,310A 10.87A Grantd1,610,903A 4.45A Forfeited(38,005)10.31A Vested(752,809)11.51A Unvested at June 30, 20242,725,399A 6.90A Schedule of Stock-Based Compensation Expense Stock-based compensation expense recognized for the three and six months ended June 30, 2024 and 2023 was comprised of the following: A Three Months EndedSix Months Ended(in thousands)June 30,2024June 30,2023June 30,2024June 30,2023Research and development\$674A \$733A \$1,538A \$1,799A Selling, general and administrative2,312A 2,516A 5,032A 5,801A Total stock-based compensation expense\$2,986A \$3,249A \$6,570A \$7,600A Schedule of Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the six months ended June 30, 2024 and 2023 were as follows: A Six Months EndedJune 30, 2024June 30, 2023Expected dividend yield0A %0A %Weighted average expected volatility50A %47A %Weighted average expected term (years)6.276.16Weighted average risk-free rate4.52A %3.89A % X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147

gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Schedule of Net Product Sales (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2023 Jun. 30, 2023 Jun. 30, 2023 Revenue from External Customer [Line Items] Á Á Á Net product sales Á Á Á \$ 47,460,56 \$ 97,936 \$ 108,554 Fanaptá® net product sales Á Á Á Á Revenue from External Customer [Line Items] Á Á Á Á Net product sales 23,150 24,077 46,959 HETLIOZA® net product sales Á Á Á Á Revenue from External Customer [Line Items] Á Á Á Á Net product sales 18,708 21,979 38,761 61,595 PONVORYÁ® net product sales Á Á Á Á Revenue from External Customer [Line Items] Á Á Á Á Net product sales \$ 8,616 \$ 0 \$ 15,446 \$ 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap EntityWideInformationRevenueFromExternalCustomerLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt ProductOrServiceAxis=vnda FanaptMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: X - Details Name: srt ProductOrServiceAxis=vnda PONVORYMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Major Customers - Narrative (Details) - USD (\$) \$ in Millions 3 Months Ended 6 Months Ended Mar. 31, 2024 Mar. 31, 2023 Jun. 30, 2024 Summary of Significant Accounting Policies [Line Items] Á Á Á Amount of net product sales recognized related to a change in estimate \$ 0.7 \$ 4.8 \$ 1.6 Customer Concentration Risk | Sales Revenue, Net | Five Major Customers Á Á Á Summary Of Significant Accounting Policies [Line Items] Á Á Á Concentration risk, percentage Á Á 73.00% Credit Concentration Risk | Accounts Receivable | Five Major Customers Á Á Á Summary Of Significant Accounting Policies [Line Items] Á Á Á Concentration risk, percentage Á Á 73.00% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 + Details Name: us-gaap ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSummary Of Significant Accounting Policies [Line Items] + ReferencesNo definition available. + Details Name: vnda SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: vnda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=vnda_FiveMajorCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 PONVORYÁ® Acquisition (Details) \$ in Millions Dec. 07, 2023 USD (\$) PONVORY Acquisition Á Business Combination Segment Allocation [Line Items] Á Total consideration \$ 104.9 X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details Name: us-gaap AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationSegmentAllocationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=vnda PONVORYAcquisitionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities (Details) - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Debt Securities, Available-for-sale [Line Items] Á Á Amortized Cost \$ 285,159 \$ 252,520 Unrealized Gains 47 229 Gross Unrealized Losses (483) (306) Fair Market Value 284,723 252,443 U.S. Treasury and government agencies Á Á Debt Securities, Available-for-sale [Line Items] Á Á Amortized Cost 144,155 185,168 Gross Unrealized Gains 47 227 Gross Unrealized Losses (384) (280) Fair Market Value 143,818 185,115 Corporate debt Á Á Debt Securities, Available-for-sale [Line Items] Á Á Amortized Cost 141,004 67,352 Gross Unrealized Gains 0 2 Gross Unrealized Losses (99) (26) Fair Market Value \$ 140,905 \$ 67,328 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value \$ 297,591 \$ 316,211 U.S. Treasury and government agencies Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 143,818 209,103 Corporate debt Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 153,773 107,108 Quoted Prices in Active Markets for Identical Assets (Level 1) Á Á Fair Value, Assets and

Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 143,818 209,103 Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Treasury and government agencies Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 143,818 209,103 Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate debt Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 0 0 Significant Other Observable Inputs (Level 2) Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 153,773 107,108 Significant Other Observable Inputs (Level 2) | U.S. Treasury and government agencies Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 0 0 Significant Other Observable Inputs (Level 2) | Corporate debt Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 153,773 107,108 Significant Unobservable Inputs (Level 3) Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 0 0 Significant Unobservable Inputs (Level 3) | U.S. Treasury and government agencies Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 0 0 Significant Unobservable Inputs (Level 3) | Corporate debt Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value 0 0 Significant Unobservable Inputs (Level 3) | Corporate debt Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets measured at fair value \$ 0 \$ 0 X - DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1:

SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: srt_ProductOrServiceAxis=vnda_HetliozMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=vnda_PONVORYMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets - Schedule of Future Intangible Asset Amortization (Details) - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Finite-Lived Intangible Assets [Line Items] A A Net Carrying Amount \$ 117,599 \$ 121,369 2024 3,503 A 2025 7,007 A 2026 7,007 A 2027 7,007 A 2028 7,007 A Thereafter 86,068 A HETLIOZA® A A Finite-Lived Intangible Assets [Line Items] A A Net Carrying Amount 16,332 17,063 2024 731 A 2025 1,463 A 2026 1,463 A 2027 1,463 A 2028 1,463 A Thereafter 9,749 A PONVORYA® A A Finite-Lived Intangible Assets [Line Items] A A Net Carrying Amount 101,267 \$ 104,306 2024 2,772 A 2025 5,544 A 2026 5,544 A 2027 5,544 A 2028 5,544 A Thereafter \$ 76,319 A X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionItem items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionFinite-Lived Intangible Asset, Expected Amortization, After Year Four + ReferencesNo definition available. + Details Name: vnda_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour Namespace Prefix: vnda_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: srt_ProductOrServiceAxis=vnda_HetliozMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=vnda_PONVORYMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounts Payable and Accrued Liabilities (Details) - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] A A Research and development expenses \$ 15,290 \$ 15,691 Consulting and other professional fees 13,561 4,404 Compensation and employee benefits 4,545 6,413 Operating lease liabilities 2,426 2,398 Royalties payable 1,510 2,409 Accounts payable and other accrued liabilities 2,266 7,145 Total accounts payable and accrued liabilities \$ 39,598 \$ 38,460 X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19.20) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: vnda_AccruedResearchAndDevelopmentExpense Namespace Prefix: vnda_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Fanapt - Narrative (Details) - FanaptA® 60 Months Ended Dec. 31, 2014 Dec. 31, 2019 Commitments and Contingencies [Line Items] A A Royalty payable percentage on net sales 6.00% 3.00% Royalty payment period 10 years A X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: vnda_CommitmentsAndContingenciesLineItems Namespace Prefix: vnda_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionRoyalty payable percentage under a contractual arrangement for use of technology or intellectual property. + ReferencesNo definition available. + Details Name: vnda_RoyaltyPayableOnNetSalesPercentage Namespace Prefix: vnda_ Data Type: dtr-types1:percentItem Type Balance Type: na Period Type: duration X - DefinitionRoyalty Period + ReferencesNo definition available. + Details Name: vnda_RoyaltyPeriod Namespace Prefix: vnda_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=vnda_FanaptMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - HETLIOZ - Narrative (Details) - HETLIOZA® - USD (\$) 1 Months Ended 6 Months Ended 11 Months Ended 12 Months Ended 245 Months Ended Dec. 31, 2022 Jan. 31, 2014 Jun. 30, 2024 Nov. 30, 2022 Dec. 31, 2018 Jun. 30, 2024 Commitments and Contingencies [Line Items] A A A A Acquisition of intangible assets A \$ 8,000,000.0 A A \$ 25,000,000.0 A \$ 37,500,000 Intangible assets capitalized A A A A \$ 33,000,000.0 Possible future milestone payment A A \$ 0 A A Royalty payment period A A 10 years A A Percentage of future sublicense fees payable to third-party A A mid-twenties A A Non-US A A A A Commitments and Contingencies [Line Items] A A A A Royalty payable percentage on net sales A A 5.00% A A U.S. A A A A Commitments and Contingencies [Line Items] A A A A Royalty payable percentage on net sales 5.00% A A 10.00% A X - DefinitionAmount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: na Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: vnda_CommitmentsAndContingenciesLineItems Namespace Prefix: vnda_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTotal amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones. + ReferencesNo definition available. + Details Name: vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty Namespace Prefix: vnda_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionPercentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property. + ReferencesNo definition available. + Details Name: vnda_PercentageOfFutureSublicenseFeesPayable Namespace Prefix: vnda_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionRoyalty payable percentage under a contractual arrangement for use of technology or intellectual property. + ReferencesNo definition available. + Details Name: vnda_RoyaltyPayableOnNetSalesPercentage Namespace Prefix: vnda_ Data Type: dtr-types1:percentItem Type Balance Type: na Period Type: duration X - DefinitionRoyalty Period + ReferencesNo definition available. + Details Name: vnda_RoyaltyPeriod Namespace Prefix: vnda_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=vnda_HetliozMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUSMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Tradipitant - Narrative (Details) - Tradipitant - USD (\$) \$ in Millions 6 Months Ended 12 Months Ended 147 Months Ended Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2024 Commitments and Contingencies [Line Items] A A A Future percentage of royalty payments based net sales low double digits A A Development and milestone obligations paid to third party A A \$ 5.0 Pre-NDA Approval Milestones A A Commitments and Contingencies [Line Items] A A Development and milestone obligations paid to third party A A \$ 2.0 A Regulatory Approval Milestone | U.S. A A Commitments and Contingencies [Line Items] A A Possible future milestone payment \$ 10.0 A A Regulatory Approval Milestone | E.U. A A Commitments and Contingencies [Line Items] A A Possible future milestone payment 5.0 A A Sales Milestone A A Commitments and Contingencies [Line Items] A A Possible future milestone payment \$ 80.0 A X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: vnda_CommitmentsAndContingenciesLineItems Namespace Prefix: vnda_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDevelopment And Milestone Obligations Paid To Third Party + ReferencesNo definition available. + Details Name: vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty Namespace Prefix: vnda_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionTotal amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones. + ReferencesNo definition available. + Details Name: vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty Namespace Prefix: vnda_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionFuture Percentage Of Royalty Payments Based On Net Sales. + ReferencesNo definition available. + Details Name: vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales Namespace Prefix: vnda_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=vnda_TradipitantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_PreNDAApprovalMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_SalesMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - CFTR Activators and Inhibitors - Narrative (Details) - CFTR Activators and Inhibitors - USD (\$) \$ in Millions 6 Months Ended 88 Months Ended Jun. 30, 2024 Jun. 30, 2024 Commitments and Contingencies [Line Items] A A Future percentage of royalty payments based net sales single-digit A A Development and milestone obligations paid to third party A A \$ 1.6 Developmental Milestone A A Commitments and Contingencies [Line Items] A A Possible future milestone payments \$ 11.9

À Future Regulatory Approval and Sales Milestones À À Commitments and Contingencies [Line Items] À À Possible future milestone payments 33.0 À Development and Milestone Payment, Conclusion of Clinical Studies À À Commitments and Contingencies [Line Items] À À Possible future milestone payments 1.1 À Development and Milestone Payment, Conclusion of Clinical Studies | Maximum À À Commitments and Contingencies [Line Items] À À Possible future milestone payments \$ 3.2 À X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: vnda CommitmentsAndContingenciesLineItems Namespace Prefix: vnda Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDevelopment And Milestone Obligations Paid To Third Party + ReferencesNo definition available. + Details Name: vnda DevelopmentAndMilestoneObligationsPaidToThirdParty Namespace Prefix: vnda Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones. + ReferencesNo definition available. + Details Name: vnda DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty Namespace Prefix: vnda Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFuture Percentage Of Royalty Payments Based On Net Sales. + ReferencesNo definition available. + Details Name: vnda FuturePercentageOfRoyaltyPaymentsBasedOnNetSales Namespace Prefix: vnda Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt ProductOrServiceAxis=vnda CftrActivatorsAndInhibitorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda DevelopmentMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda FutureRegulatoryApprovalAndSalesMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda DevelopmentAndMilestonePaymentConclusionOfClinicalStudiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - VQW-765 - Narrative (Details) 6 Months Ended Jun. 30, 2024 VQW-765 À Commitments and Contingencies [Line Items] À Future percentage of royalty payments based net sales mid-teens X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: vnda CommitmentsAndContingenciesLineItems Namespace Prefix: vnda Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture Percentage Of Royalty Payments Based On Net Sales. + ReferencesNo definition available. + Details Name: vnda FuturePercentageOfRoyaltyPaymentsBasedOnNetSales Namespace Prefix: vnda Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap TypeOfArrangementAxis=vnda VQW765Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Other Agreements - Narrative (Details) - USD (\$) \$ / shares in Units, \$ in Millions 4 Months Ended Dec. 31, 2022 Jun. 30, 2024 Apr. 30, 2024 Apr. Dec. 31, 2023 Commitments and Contingencies [Line Items] À À À Number of rights (in shares) À À 1 À Preferred stock, par value (in dollars per share) À \$ 0.001 À \$ 0.001 Series A Junior Participating Preferred Stock Purchase Right, par value \$0.001 per share À À À Commitments and Contingencies [Line Items] À À À Class of warrant or right, number of securities called by each warrant or right (in shares) À À 0.001 À Preferred stock, par value (in dollars per share) À À \$ 0.001 À Exercise price (in dollars per share) À \$ 25.00 À Ownership acquired percentage À 10.00% À OliPass Corporation | Additional Funding Agreement Terms À À À Commitments and Contingencies [Line Items] À À À Consideration for entering into the arrangement \$ 3.0 À À X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1) + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + ReferencesReference 1: <http://www.xbrl.org/2003/role/commonPracticeRef-Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1> + Details Name: us-gaap ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: vnda CommitmentsAndContingenciesLineItems Namespace Prefix: vnda Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDividend Distribution, Number Of Rights Per Common Share + ReferencesNo definition available. + Details Name: vnda DividendDistributionNumberOfRightsPerCommonShare Namespace Prefix: vnda Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWarrants Or Rights Outstanding, Terms Of Agreement, Ownership Percentage Threshold + ReferencesNo definition available. + Details Name: vnda WarrantsOrRightsOutstandingTermsOfAgreementOwnershipPercentageThreshold Namespace Prefix: vnda Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap StatementClassOfStockAxis=us-gaap SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt CounterpartyNameAxis=vnda OliPassCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap AdditionalFundingAgreementTermsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Purchase Commitments - Narrative (Details) 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] À Agreements for clinical and marketing services, termination notice period 90 days X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAgreements For Clinical And Marketing Services, Termination Notice Period + ReferencesNo definition available. + Details Name: vnda AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod Namespace Prefix: vnda Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accumulated Other Comprehensive Loss (Details) - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Equity [Abstract] À À Foreign currency translation \$ (1) \$ 21 Unrealized loss on marketable securities (329) (51) Accumulated other comprehensive loss \$ (330) \$ (30) X - DefinitionAmount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14> + Details Name: us-gaap AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14) + Details Name: us-gaap AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-599-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14) + Details Name: us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Narrative (Details) Jun. 30, 2024 shares 2006 Plan and 2016 Plan | Outstanding Options and RSUs À Share-based Compensation Arrangement by Share-based Payment Award [Line Items] À Shares subject to outstanding options and RSUs (in shares) 7,677,419 2016 Plan À Share-based Compensation Arrangement by Share-based Payment Award [Line Items] À Number of shares of common stock authorized for issuance (in shares) 15,690,000 Number of shares of common stock available for future grant (in shares) 4,673,878 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1:

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI

Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: <https://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) \(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) (1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: <https://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] + ReferencesNo definition available. + Details Name: vnda ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward Namespace Prefix: vnda_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionShare Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract] + ReferencesNo definition available. + Details Name: vnda ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract Namespace Prefix: vnda_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 RS9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Restricted Stock Units - Narrative (Details) \$ in Millions 6 Months Ended Jun. 30, 2024 USD (\$) installment shares Share Based Compensation Arrangement by Share-based Payment Award [Line Items] A Number of vesting equal installments | installment 36 Restricted Stock Units (RSUs) A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A Number of vesting equal installments | installment 4 Full acceleration of vesting, employee or executive officer subject to involuntary termination, period post change of control of the Company 24 months Unrecognized compensation expenses related to unvested RSUs | \$ \$ 16.0 Unrecognized compensation expenses, weighted average period 1 year 8 months 12 days Grant date fair value of common stock granted (in shares) | shares 752,809 Grant date fair value of common stock vested | \$ \$ 8.7 X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: [http://www.xbrli.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionFair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 26: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(5\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 27: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(6\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 28: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(7\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 29: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(8\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(8) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 30: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(9\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(9) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 31: [http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -](http://www.xbrli.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(10) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

Paragraph 2 - Subparagraph (f)(2)(i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25:

EPS because to do so would increase EPS or E/F amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1:

[illegible]

[illegible]

[illegible]

[illegible]

*/ % styles for font types */ .report .text { text-align: left; white-space: normal; } .report .text.big { margin-bottom: 1em; width: 17em; } .report .text.more { display: none; } .report .text.note { font-style: italic; font-weight: bold; } .report .text.small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 79 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1.html 144 244 1 false 44 0 false 7 false false R1.htm 0000001 - Document - Cover Sheet http://www.vandapharmaceuticals.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) Sheet http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Sheet http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - Business Organization and Presentation Sheet http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation Business Organization and Presentation Notes 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - PONVORY?? Acquisition Sheet http://www.vandapharmaceuticals.com/role/PONVORYAcquisition PONVORY?? Acquisition Notes 10 false false R11.htm 0000011 - Disclosure - Marketable Securities Sheet http://www.vandapharmaceuticals.com/role/MarketableSecurities Marketable Securities Notes 11 false false R12.htm 0000012 - Disclosure - Fair Value Measurements Sheet http://www.vandapharmaceuticals.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Inventory Sheet http://www.vandapharmaceuticals.com/role/Inventory Inventory Notes 13 false false R14.htm 0000014 - Disclosure - Intangible Assets Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssets Intangible Assets Notes 14 false false R15.htm 0000015 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 15 false false R16.htm 0000016 - Disclosure - Commitments and Contingencies Sheet http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 0000017 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 17 false false R18.htm 0000018 - Disclosure - Stock-Based Compensation Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 0000019 - Disclosure - Income Taxes Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 0000020 - Disclosure - Earnings per Share Sheet http://www.vandapharmaceuticals.com/role/EarningsperShare Earnings per Share Notes 20 false false R21.htm 0000021 - Disclosure - Legal Matters Sheet http://www.vandapharmaceuticals.com/role/LegalMatters Legal Matters Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies 24 false false R25.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 9954473 - Disclosure - Marketable Securities (Tables) Sheet http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.vandapharmaceuticals.com/role/MarketableSecurities 26 false false R27.htm 9954474 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vandapharmaceuticals.com/role/FairValueMeasurements 27 false false R28.htm 9954475 - Disclosure - Inventory (Tables) Sheet http://www.vandapharmaceuticals.com/role/InventoryTables Inventory (Tables) Tables http://www.vandapharmaceuticals.com/role/Inventory 28 false false R29.htm 9954476 - Disclosure - Intangible Assets (Tables) Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.vandapharmaceuticals.com/role/IntangibleAssets 29 false false R30.htm 9954477 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilities 30 false false R31.htm 9954478 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveLoss 31 false false R32.htm 9954479 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.vandapharmaceuticals.com/role/StockBasedCompensation 32 false false R33.htm 9954480 - Disclosure - Earnings per Share (Tables) Sheet http://www.vandapharmaceuticals.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://www.vandapharmaceuticals.com/role/EarningsperShare 33 false false R34.htm 9954481 - Disclosure - Business Organization and Presentation (Details) Sheet http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetails Business Organization and Presentation (Details) Details http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation 34 false false R35.htm 9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 35 false false R36.htm 9954483 - Disclosure - Summary of Significant Accounting Policies - Schedule of Net Product Sales (Details) Sheet http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofNetProductSalesDetails Summary of Significant Accounting Policies - Schedule of Net Product Sales (Details) Details 36 false false R37.htm 9954484 - Disclosure - Summary of Significant Accounting Policies - Major Customers - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails Summary of Significant Accounting Policies - Major Customers - Narrative (Details) Details 37 false false R38.htm 9954485 - Disclosure - PONVORY?? Acquisition (Details) Sheet http://www.vandapharmaceuticals.com/role/PONVORYAcquisitionDetails PONVORY?? Acquisition (Details) Details http://www.vandapharmaceuticals.com/role/PONVORYAcquisition 38 false false R39.htm 9954486 - Disclosure - Marketable Securities (Details) Sheet http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables Marketable Securities (Details) Details http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables 39 false false R40.htm 9954487 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) Sheet http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) Details 40 false false R41.htm 9954488 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 41 false false R42.htm 9954489 - Disclosure - Inventory - Schedule of Inventory (Details) Sheet http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails Inventory - Schedule of Inventory (Details) Details 42 false false R43.htm 9954490 - Disclosure - Inventory - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/InventoryNarrativeDetails Inventory - Narrative (Details) Details 43 false false R44.htm 9954491 - Disclosure - Intangible Assets - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails Intangible Assets - Narrative (Details) Details 44 false false R45.htm 9954492 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 45 false false R46.htm 9954493 - Disclosure - Intangible Assets - Schedule of Future Intangible Asset Amortization (Details) Sheet http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails Intangible Assets - Schedule of Future Intangible Asset Amortization (Details) Details 46 false false R47.htm 9954494 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesTables 47 false false R48.htm 9954495 - Disclosure - Commitments and Contingencies - Fanapt - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptNarrativeDetails Commitments and Contingencies - Fanapt - Narrative (Details) Details 48 false false R49.htm 9954496 - Disclosure - Commitments and Contingencies - HETLIOZ - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails Commitments and Contingencies - HETLIOZ - Narrative (Details) Details 49 false false R50.htm 9954497 - Disclosure - Commitments and Contingencies - Tradipitant - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantNarrativeDetails Commitments and Contingencies - Tradipitant - Narrative (Details) Details 50 false false R51.htm 9954498 - Disclosure - Commitments and Contingencies - CFTR Activators and Inhibitors - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails Commitments and Contingencies - CFTR Activators and Inhibitors - Narrative (Details) Details 51 false false R52.htm 9954499 - Disclosure - Commitments and Contingencies - VQW-765 - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765NarrativeDetails Commitments and Contingencies - VQW-765 - Narrative (Details) Details 52 false false R53.htm 9954500 - Disclosure - Commitments and Contingencies - Other Agreements - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails Commitments and Contingencies - Other Agreements - Narrative (Details) Details 53 false false R54.htm 9954501 - Disclosure - Commitments and Contingencies - Purchase Commitments - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsNarrativeDetails Commitments and Contingencies - Purchase Commitments - Narrative (Details) Details 54 false false R55.htm 9954502 - Disclosure - Accumulated Other Comprehensive Loss (Details) Sheet http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Details) Details http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails 55 false false R56.htm 9954503 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 56 false false R57.htm 9954504 - Disclosure - Stock-Based Compensation - Stock Option - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails Stock-Based Compensation - Stock Option - Narrative (Details) Details 57 false false R58.htm 9954505 - Disclosure - Stock-Based Compensation - Schedule of Option Activity (Details) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofOptionActivityDetails Stock-Based Compensation - Schedule of Option Activity (Details) Details 58 false false R59.htm 9954506 - Disclosure - Stock-Based Compensation - Restricted Stock Units - Narrative (Details) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails Stock-Based Compensation - Restricted Stock Units - Narrative (Details) Details 59 false false R60.htm 9954507 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails Stock-Based Compensation - Schedule of RSU Activity (Details) Details 60 false false R61.htm 9954508 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-Based Compensation Expense (Details) Details 61 false false R62.htm 9954509 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted (Details) Sheet http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofBlackScholesMertonOptionPricingModelforEmployeeandDirectorStockOptionsGrantedDetails Stock-Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted (Details) Details 62 false false R63.htm 9954510 - Disclosure - Income Taxes (Details) Sheet http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vandapharmaceuticals.com/role/IncomeTaxes 63 false false R64.htm 9954511 - Disclosure - Earnings per Share (Details) Sheet http://www.vandapharmaceuticals.com/role/EarningsperShareDetails Earnings per Share (Details) Details http://www.vandapharmaceuticals.com/role/EarningsperShareTables 64 false false All Reports Book All Reports vnda-20240630.htm vnda-20240630.xsd vnda-20240630_cal.xml vnda-20240630_def.xml vnda-20240630_lab.xml vnda-20240630_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 82 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vnda-20240630.htm": { "nsprefix": "vnda", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "dts": { "inline": { "local": { "vnda-20240630.htm" } }, "schema": { "local": { "vnda-20240630.xsd" } }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/irrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/irrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/irrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" } }, "calculationLink": { "local": { "vnda-20240630_cal.xml" } }, "definitionLink": { "local": { "vnda-20240630_def.xml" } }, "labelLink": { "local": { "vnda-20240630_lab.xml" } }, "presentationLink": { "local": { "vnda-20240630_pre.xml" } } }, "keyStandard": 214, "keyCustom": 30, "axisStandard": 18, "axisCustom": 0, "memberStandard": 23, "memberCustom": 20, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 1, "segmentCount": 144, "entityCount": 44, "elementCount": 480, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 549, "http://xbrl.sec.gov/dei/2023": 33, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.vandapharmaceuticals.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "",

body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "unique": true } }, "R3": { "role": "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "unique": true } }, "R4": { "role": "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "unique": true } }, "R5": { "role": "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "unique": true } }, "R6": { "role": "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUnaudited", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-32", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-37", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "unique": true } }, "R7": { "role": "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCAASHFLOWSUnaudited", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "unique": true } }, "R8": { "role": "http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation", "longName": "0000008 - Disclosure - Business Organization and Presentation", "shortName": "Business Organization and Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.vandapharmaceuticals.com/role/PONVORYu00aeAcquisition", "longName": "0000010 - Disclosure - PONVORYu00ae Acquisition", "shortName": "PONVORYu00ae Acquisition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.vandapharmaceuticals.com/role/MarketableSecurities", "longName": "0000011 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.vandapharmaceuticals.com/role/FairValueMeasurements", "longName": "0000012 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang":

```

Tables (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "R26": { "role": "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables", "longName": "9954473 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "R27": { "role": "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables", "longName": "9954474 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "R28": { "role": "http://www.vandapharmaceuticals.com/role/InventoryTables", "longName": "9954475 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "vnda:ScheduleOfInventoriesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "vnda:ScheduleOfInventoriesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "R29": { "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables", "longName": "9954476 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "R30": { "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables", "longName": "9954477 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "R31": { "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveLossTables", "longName": "9954478 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "R32": { "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables", "longName": "9954479 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "R33": { "role": "http://www.vandapharmaceuticals.com/role/EarningsPerShareTables", "longName": "9954480 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "R34": { "role": "http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetails", "longName": "9954481 - Disclosure - Business Organization and Presentation (Details)", "shortName": "Business Organization and Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "vnda:DescriptionOfBusinessPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "vnda:DescriptionOfBusinessPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "R35": { "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfReconciliationofCashCashEquivalentsandRestrictedCashDetails", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-55", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "unique": true }, "R36": { "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetProductSalesDetails", "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Schedule of Net Product Sales (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Net Product Sales (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-56", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vnda-2
```

```

"role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleOfFutureIntangibleAssetsAmortizationDetails", "longName": "9954493 - Disclosure - Intangible Assets - Schedule of Future Intangible Asset Amortization (Details)", "shortName": "Intangible Assets - Schedule of Future Intangible Asset Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "unique": true } }, "R47": { "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "longName": "9954494 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-5", "name": "vnda:AccruedResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "vnda:AccruedResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanapNarrativeDetails", "longName": "9954495 - Disclosure - Commitments and Contingencies - Fanap - Narrative (Details)", "shortName": "Commitments and Contingencies - Fanap - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-105", "name": "vnda:RoyaltyPayableOnNetSalesPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-105", "name": "vnda:RoyaltyPayableOnNetSalesPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails", "longName": "9954496 - Disclosure - Commitments and Contingencies - HETLIOZ - Narrative (Details)", "shortName": "Commitments and Contingencies - HETLIOZ - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-99", "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-106", "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "unique": true } }, "R50": { "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipantNarrativeDetails", "longName": "9954497 - Disclosure - Commitments and Contingencies - Tradipant - Narrative (Details)", "shortName": "Commitments and Contingencies - Tradipant - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-110", "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-110", "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails", "longName": "9954498 - Disclosure - Commitments and Contingencies - CFTR Activators and Inhibitors - Narrative (Details)", "shortName": "Commitments and Contingencies - CFTR Activators and Inhibitors - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-116", "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-116", "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765NarrativeDetails", "longName": "9954499 - Disclosure - Commitments and Contingencies - VQW-765 - Narrative (Details)", "shortName": "Commitments and Contingencies - VQW-765 - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-122", "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails", "longName": "9954500 - Disclosure - Commitments and Contingencies - Other Agreements - Narrative (Details)", "shortName": "Commitments and Contingencies - Other Agreements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-124", "name": "vnda:DividendDistributionNumberOfRightsPerCommonShare", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-124", "name": "vnda:DividendDistributionNumberOfRightsPerCommonShare", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsNarrativeDetails", "longName": "9954501 - Disclosure - Commitments and Contingencies - Purchase Commitments - Narrative (Details)", "shortName": "Commitments and Contingencies - Purchase Commitments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveLossDetails", "longName": "9954502 - Disclosure - Accumulated Other Comprehensive Loss (Details)", "shortName": "Accumulated Other Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails", "longName": "9954503 - Disclosure - Stock-Based Compensation - Narrative (Details)", "shortName": "Stock-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-126", "name": "vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US",
```

"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "firstAnchor": "64", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [{ "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "vnda-20240630.htm", "first": true }, { "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [{ "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "vnda-20240630.htm", "unique": true }] }, "tag": { "us-gaap AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r17"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r16"] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } } }, "presentation": ["http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and other accrued liabilities", "label": "Accounts Payable and Other Accrued Liabilities, Current", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r541"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r194", "r195"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } } }, "presentation": ["http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consulting and other professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r19"] }, "vnda_AccruedResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "AccruedResearchAndDevelopmentExpense", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Accrued Research And Development Expense", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties payable", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r19", "r558"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss on marketable securities", "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax", "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r689"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses." } } }, "auth_ref": ["r122", "r125", "r126", "r127", "r363"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 }, "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r24", "r25", "r67", "r119", "r422", "r445", "r446"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r10", "r25", "r348", "r351", "r375", "r441", "r442", "r690", "r691", "r692", "r696", "r697", "r698"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r633"] }, "us-gaap_AdditionalFundingAgreementTermsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalFundingAgreementTermsMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional Funding Agreement Terms", "label": "Additional Funding Agreement Terms [Member]", "documentation": "Terms of commitments to provide additional funding under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": ["r323", "r757"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r61"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r318", "r319", "r320", "r455", "r696", "r697", "r698", "r763", "r780"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r639"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r639"] }, "ecd_AdjToNonPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r639"] }, "ecd_AdjToPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to PEO Compensation, Footnote", "label": "Adjustment to PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r639"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r48", "r49", "r284"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r604", "r615", "r625", "r650"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r607", "r618", "r628", "r653"] }, "vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesPurchaseCommitmentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Agreements for clinical and marketing services, termination notice period", "label": "Agreements For Clinical And Marketing Services, Termination Notice Period", "documentation": "Agreements For Clinical And Marketing Services, Termination Notice Period" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r639"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive

Categories [Member]] } } }, "auth_ref": ["r646"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PyvDisclosure", "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } } }, "auth_ref": ["r611", "r619", "r629", "r646", "r654", "r658", "r666"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } } }, "auth_ref": ["r664"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails", "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } } }, "auth_ref": ["r313", "r321"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 }, "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWSUnaudited", "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Intangible asset amortization", "verboseLabel": "Intangible asset amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } } }, "auth_ref": ["r77", "r40", "r43"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.vandapharmaceuticals.com/role/EarningsPerShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from calculations of diluted net income (loss) per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } }, "auth_ref": ["r171"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipantNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765NarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } } }, "auth_ref": ["r342"] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/PONVORYAcquisitionDetails", "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } } }, "auth_ref": ["r759"] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": ["http://www.vandapharmaceuticals.com/role/PONVORYAcquisitionDetails", "lang": { "en-us": { "role": { "terseLabel": "Total consideration", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } } }, "auth_ref": ["r582", "r760", "r761", "r762"] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/PONVORYAcquisitionDetails", "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } } }, "auth_ref": ["r759"] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/PONVORYAcquisition", "lang": { "en-us": { "role": { "terseLabel": "PONVORYu00ae Acquisition", "label": "Asset Acquisition [Text Block]", "documentation": "The entire disclosure for asset acquisition." } } } }, "auth_ref": ["r759"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } } }, "auth_ref": ["r94", "r115", "r145", "r178", "r184", "r188", "r229", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r343", "r345", "r364", "r417", "r492", "r583", "r595", "r724", "r725", "r767"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } } }, "auth_ref": ["r111", "r121", "r145", "r229", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r343", "r345", "r364", "r583", "r724", "r725", "r767"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "lang": { "en-us": { "role": { "terseLabel": "Assets measured at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } } }, "auth_ref": ["r52"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } } }, "auth_ref": ["r203"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails", "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } } }, "auth_ref": ["r204"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } } }, "auth_ref": ["r661"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } } }, "auth_ref": ["r662"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } } }, "auth_ref": ["r657"] }, "ecd_AwardTmgHowMnpiCnsrdrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsrdrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } } }, "auth_ref": ["r657"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } } }, "auth_ref": ["r657"] }, "ecd_AwardTmgMnpiCnsrdrFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsrdrFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } } }, "auth_ref": ["r657"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } } }, "auth_ref": ["r657"] }, "ecd_AwardTmgPredtrmdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } } }, "auth_ref": ["r657"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } } }, "auth_ref": ["r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } } }, "auth_ref": ["r660"] }, "ecd_AwardsCloseToMnpiDiscName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } } }, "auth_ref": ["r659"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } } }, "auth_ref": ["r658"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } } }, "auth_ref": ["r658"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } } }, "auth_ref": ["r50", "r51"] }, "us-gaap_BasisOfAccountingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies", "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationSegmentAllocationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationSegmentAllocationLineItems", "presentation": ["http://www.vandapharmaceuticals.com/role/PONVORYAcquisitionDetails", "lang": { "en-us": { "role": { "terseLabel": "Business Combination Segment Allocation [Line Items]", "label": "Business Combination Segment Allocation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": [] }, "us-

gaap_BusinessCombinationSegmentAllocationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationSegmentAllocationTable", "presentation": ["http://www.vandapharmaceuticals.com/role/PONVORYAcquisitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Segment Allocation [Table]", "label": "Business Combination, Segment Allocation [Table]", "documentation": "Disclosure of information about goodwill in a business combination." } } }, "auth_ref": ["r9"] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentation"], "lang": { "en-us": { "role": { "terseLabel": "Business Organization and Presentation", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r58", "r77", "r78"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r28", "r113", "r556"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r29"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of period", "periodEndLabel": "End of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r28", "r74", "r143"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r74"] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsMember", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r113"] }, "vnda_CftrActivatorsAndInhibitorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "CftrActivatorsAndInhibitorsMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCftrActivatorsandInhibitorsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "CFTR Activators and Inhibitors", "label": "CFTR activators and inhibitors [Member]", "documentation": "CFTR activators and inhibitors [Member]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r637"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r107", "r116", "r117", "r118", "r145", "r165", "r166", "r168", "r170", "r176", "r177", "r229", "r251", "r253", "r254", "r255", "r258", "r259", "r263", "r264", "r266", "r267", "r269", "r364", "r449", "r450", "r451", "r452", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r480", "r501", "r520", "r535", "r536", "r537", "r538", "r539", "r672", "r693", "r699"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r270"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, number of securities called by each warrant or right (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r638"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r638"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Notes 9 and 14)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r22", "r55", "r418", "r479"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r84", "r245", "r246", "r542", "r721"] }, "vnda_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "CommitmentsAndContingenciesLineItems", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCftrActivatorsandInhibitorsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipantNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765NarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies [Line Items]", "label": "Commitments and Contingencies [Line Items]", "documentation": "Commitments and contingencies." } } }, "auth_ref": [] }, "vnda_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "CommitmentsAndContingenciesTable", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCftrActivatorsandInhibitorsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipantNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765NarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies [Table]", "label": "Commitments and Contingencies [Table]", "documentation": "Commitments and contingencies." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUnaudited", "http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock, par value \$0.001 per share", "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r586", "r587", "r588", "r590", "r591", "r592", "r593", "r696", "r697", "r763", "r779", "r780"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r60"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r60", "r480"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders

and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r60"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r11", "r60", "r480", "r498", "r780", "r781"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, \$0.001 par value; 150,000,000 shares authorized; 58,287,308 and 57,534,499 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r60", "r421", "r583"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r643"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r642"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r644"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r641"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r26", "r130", "r132", "r138", "r412", "r430"] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveLoss", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": ["r66", "r137", "r411", "r428"] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r33", "r35", "r53", "r54", "r193", "r541"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r33", "r35", "r53", "r54", "r193", "r447", "r541"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r33", "r35", "r53", "r54", "r193", "r541", "r674"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r33", "r35", "r53", "r54", "r193"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r33", "r35", "r53", "r54", "r193", "r541"] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "crdr": "credit", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amount of net product sales recognized related to a change in estimate", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained." } } }, "auth_ref": ["r572"] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Corporate debt", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r576", "r578", "r778"] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold excluding amortization", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": ["r676", "r677"] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r70"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r147", "r148", "r260", "r265", "r376", "r561", "r563"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditConcentrationRiskMember", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Concentration Risk", "label": "Credit Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement." } } }, "auth_ref": ["r91"] }, "vnda_CumulativeNetSalesToAchieveMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "CumulativeNetSalesToAchieveMilestone", "crdr": "credit", "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cumulative worldwide sales milestone", "label": "Cumulative Net Sales To Achieve Milestone", "documentation": "Net cumulative worldwide sales to achieve milestone and trigger payment of milestone obligation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r34", "r193"] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails", "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current", "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale, classified as current." } } }, "auth_ref": ["r719"] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails", "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities", "terseLabel": "Fair Market Value", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current", "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale, classified as current." } } }, "auth_ref": ["r719"] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on sale of marketable securities", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale." } } }, "auth_ref": ["r714"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": ["http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale." } } }, "auth_ref": ["r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-Sale Marketable Securities",

"label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value measured at fair value recognized in other comprehensive income (available-for-sale.)" }, { "auth_ref": ["r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714"] }, "us-gaap DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r325", "r326"] }, "us-gaap DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r7", "r89", "r105", "r335", "r336", "r695"] }, "us-gaap Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Depreciation of property and equipment", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r7", "r44"] }, "vnda_DescriptionOfBusinessPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "DescriptionOfBusinessPolicyTextBlock", "presentation": { "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Business Organization", "label": "Description of Business [Policy Text Block]", "documentation": "Description of Business" } } }, "auth_ref": [] }, "vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "DevelopmentAndMilestoneObligationsPaidToThirdParty", "crdr": "debit", "presentation": { "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFRActivatorsandInhibitorsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFRActivatorsandInhibitorsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Development and milestone obligations paid to third party", "label": "Development And Milestone Obligations Paid To Third Party", "documentation": "Development And Milestone Obligations Paid To Third Party" } } }, "auth_ref": [] }, "vnda_DevelopmentAndMilestonePaymentConclusionOfClinicalStudiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "DevelopmentAndMilestonePaymentConclusionOfClinicalStudiesMember", "presentation": { "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFRActivatorsandInhibitorsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Development and Milestone Payment, Conclusion of Clinical Studies", "label": "Development And Milestone Payment, Conclusion Of Clinical Studies [Member]", "documentation": "Development And Milestone Payment, Conclusion Of Clinical Studies [Member]" } } }, "auth_ref": [] }, "vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty", "crdr": "debit", "presentation": { "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFRActivatorsandInhibitorsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFRActivatorsandInhibitorsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Possible future milestone payment", "label": "Development And Milestone Payments Potentially Due To Third Party", "documentation": "Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones." } } }, "auth_ref": [] }, "vnda_DevelopmentMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "DevelopmentMilestonesMember", "presentation": { "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFRActivatorsandInhibitorsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Developmental Milestone", "label": "Development Milestones [Member]", "documentation": "Development Milestones" } } }, "auth_ref": [] }, "us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://www.vandapharmaceuticals.com/role/StockBasedCompensation": { "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r282", "r286", "r314", "r315", "r317", "r580"] }, "us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]", "documentation": "Dividend Distribution Number Of Rights Per Common Share" } } }, "auth_ref": [] }, "vnda_DividendDistributionNumberOfRightsPerCommonShare": { "xbrltype": "sharesItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "DividendDistributionNumberOfRightsPerCommonShare", "presentation": { "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of rights (in shares)", "label": "Dividend Distribution, Number Of Rights Per Common Share", "documentation": "Dividend Distribution, Number Of Rights Per Common Share" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.vandapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.vandapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": { "http://www.vandapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": { "http://www.vandapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.vandapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A: the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.vandapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r599"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": { "http://www.vandapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r632"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": { "http://www.vandapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": [] }, "us-gaap EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share", "label": "Earnings Per Share [Abstract]", "documentation": "Earnings Per Share, Basic And Diluted EPS" } } }, "auth_ref": [] }, "us-gaap EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r139", "r154", "r155", "r156", "r157", "r158", "r163", "r165", "r168", "r169", "r170", "r174", "r355", "r356", "r413", "r431", "r564"] }, "vnda_EarningsPerShareBasicAndDilutedEPSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "presentation": { "http://

fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r316"] } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "cldr": "debit", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expenses related to unvested RSUs", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r755"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "cldr": "debit", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expenses", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not Yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r755"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r597"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/inter by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r597"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r597"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r671"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r597"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r597"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r597"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r597"] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofNetProductSalesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r11", "r109", "r133", "r134", "r135", "r149", "r150", "r151", "r153", "r159", "r161", "r175", "r230", "r231", "r271", "r318", "r319", "r320", "r331", "r332", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r366", "r368", "r369", "r370", "r371", "r372", "r375", "r441", "r442", "r443", "r455", "r520"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "auth_ref": ["r640"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r604", "r615", "r625", "r650"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]", "auth_ref": ["r601", "r612", "r622", "r647"] }, "rt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "E.U.", "label": "Europe [Member]" } } }, "auth_ref": ["r782", "r783", "r784", "r785"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r646"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r358", "r359", "r360"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r358", "r359", "r360"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r52", "r90"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r261", "r275", "r276", "r277", "r278", "r279", "r280", "r359", "r380", "r381", "r382", "r569", "r570", "r576", "r577", "r578"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurements"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of

fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r357"] } }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r261", "r275", "r280", "r359", "r380", "r357", "r577", "r578"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r261", "r275", "r280", "r359", "r381", "r569", "r570", "r576", "r577", "r578"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r261", "r275", "r276", "r277", "r278", "r279", "r280", "r359", "r382", "r569", "r570", "r576", "r577", "r578"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r261", "r275", "r276", "r277", "r278", "r279", "r280", "r381", "r382", "r569", "r570", "r576", "r577", "r578"] }, "vnda_FanaptMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "FanaptMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/InventoryNarrativeDetails", "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofNetProductSalesDetails"] }, "lang": { "en-us": { "role": { "verboseLabel": "Fanaptu00ae net product sales", "terseLabel": "Fanaptu00ae", "label": "Fanapt [Member]", "documentation": "Fanapt." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r262", "r268", "r353", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r429", "r568", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r714", "r715", "r716", "r717"] }, "vnda_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r114", "r242"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r83"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r83"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r83"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r83"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"] }, "lang": { "en-us": { "role": { "verboseLabel": "Fully amortized intangible assets", "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r82", "r410"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r409"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r82", "r409"] }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Intangible assets capitalized", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "vnda_FiveMajorCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "FiveMajorCustomersMember", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Five Major Customers", "label": "Five Major Customers [Member]", "documentation": "Five Major Customers" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r608", "r619", "r629", "r654"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r608", "r619", "r629", "r654"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r608", "r619", "r629", "r654"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r608", "r619", "r629", "r654"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r608", "r619", "r629", "r654"] }, "vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "FuturePercentageOfRoyaltyPaymentsBasedOnNetSales", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765NarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Future percentage of royalty payments based net sales", "label": "Future Percentage Of Royalty Payments Based On Net Sales", "documentation": "Future Percentage Of Royalty Payments Based On Net Sales." } } }, "auth_ref": [] }, "vnda_FutureRegulatoryApprovalAndSalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "FutureRegulatoryApprovalAndSalesMilestonesMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Future Regulatory

Approval and Sales Milestones", "label": "Future Regulatory Approval And Sales Milestones [Member]", "documentation": "Future Regulatory Approval And Sales Milestones [Member]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "vnda_HetliozMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "HetliozMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "http://www.vandapharmaceuticals.com/role/InventoryNarrativeDetails", "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofNetProductSalesDetails"], "lang": { "en-us": { "role": { "terseLabel": "HETLIOZu000ae net product sales", "verboseLabel": "HETLIOZu000ae", "label": "Hetlioz [Member]", "documentation": "Hetlioz [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r0", "r68", "r96", "r178", "r183", "r187", "r189", "r414", "r426", "r566"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": ["r243", "r244", "r505"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": ["r244", "r505"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": ["r146", "r324", "r328", "r329", "r330", "r333", "r337", "r340", "r341", "r454"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Provision (benefit) for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r100", "r106", "r160", "r161", "r181", "r327", "r334", "r433"] }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherReconcilingItems", "crdr": "debit", "presentation": ["http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discrete income tax expense", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments." } } }, "auth_ref": ["r758"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "vnda_IncreaseDecreaseProductRevenueAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "IncreaseDecreaseProductRevenueAllowances", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Product revenue allowances", "label": "Increase (Decrease) Product Revenue Allowances", "documentation": "The increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual [Axis]" } } }, "auth_ref": ["r611", "r619", "r629", "r646", "r654", "r658", "r666"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r664"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r600", "r670"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r600", "r670"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r600", "r670"] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssets", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsDisclosureTextBlock"], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r241"] }, "vnda_Inventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "Inventory", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryNarrativeDetails", "http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total inventory", "terseLabel": "Inventory", "label": "Inventory", "documentation": "Inventory" } } }, "auth_ref": [] }, "vnda_InventoryAndOtherNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "InventoryAndOtherNonCurrent", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Non-current inventory and other", "label": "Inventory and Other Non Current", "documentation": "Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/Inventory", "http://www.vandapharmaceuticals.com/role/Inventory", "http://www.vandapharmaceuticals.com/role/Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r240"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r81", "r559"] }, "vnda_InventoryFinishedGoodsNetOfReservesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "InventoryFinishedGoodsNetOfReservesNonCurrent", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNonCurrent", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves, Non Current", "documentation": "Finished goods inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLineItems", "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Line Items]", "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "vnda_Inventory", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"]

"http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Total inventory, current", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r120", "r557", "r583"] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNetAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Inventory, Net [Abstract]" } }, "auth_ref": [] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "vnda_Inventory", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total inventory, non-current", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": ["r685"] } }, "us-gaap_InventoryNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNoncurrentAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-Current assets", "label": "Inventory, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "vnda_InventoryRawMaterialsNetOfReservesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "InventoryRawMaterialsNetOfReservesNonCurrent", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves, Non Current", "documentation": "Raw materials inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [] }, "vnda_InventoryTable": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "InventoryTable", "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventory Table", "label": "Inventory [Table]", "documentation": "Inventory [Table]" } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": ["r81", "r560"] }, "vnda_InventoryWorkInProcessNetOfReservesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "InventoryWorkInProcessNetOfReservesNonCurrent", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves, Non Current", "documentation": "Work in process inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of premiums and accretion of discounts on marketable securities", "label": "Investment Income, Net, Amortization of Discount and Premium", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } }, "auth_ref": ["r72"] } }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/MarketableSecurities"], "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/MarketableSecurities"], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r92", "r98", "r99", "r108", "r196", "r198", "r361", "r362"] } }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalMattersAndContingenciesTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/LegalMatters"], "lang": { "en-us": { "role": { "terseLabel": "Legal Matters", "label": "Legal Matters and Contingencies [Text Block]", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies." } } }, "auth_ref": ["r85"] } }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": ["r18", "r145", "r229", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r344", "r345", "r346", "r364", "r478", "r565", "r595", "r724", "r767", "r768"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u0020equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r65", "r95", "r424", "r583", "r694", "r718", "r764"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u0020EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r20", "r112", "r145", "r229", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r344", "r345", "r346", "r364", "r583", "r724", "r767", "r768"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": ["r193", "r575", "r728", "r776", "r777"] }, "us-gaap_MajorCustomersPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MajorCustomersPolicyTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Major Customers", "label": "Major Customers, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity." } } }, "auth_ref": ["r32", "r33", "r35", "r79"] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": ["r56"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFRActivatorsandInhibitorsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r247", "r248", "r249", "r250", "r281", "r407", "r440", "r470", "r471", "r523", "r525", "r527", "r528", "r530", "r552", "r553", "r567", "r571", "r579", "r585", "r726", "r769", "r770", "r771", "r772", "r773", "r774"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure", "label": "Measure [Axis]" } } }, "auth_ref": ["r638"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r638"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r657"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r665"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": ["r193", "r575", "r728", "r776", "r777"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r639"] } }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r142"] } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r74", "r75", "r76"] } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited", "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.vandapharmaceuticals.com/role/EarningsperShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r69", "r76",

"r97", "r110", "r128", "r131", "r135", "r145", "r152", "r154", "r155", "r156", "r157", "r160", "r161", "r167", "r178", "r183", "r187", "r189", "r229", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r356", "r364", "r427", "r500", "r518", "r519", "r566", "r594", "r724"] }, "us-gaap NetIncomeLossAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/EarningsperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Numerator":, "label": "Net Income (Loss) Attributable to Parent [Abstract]" } }, "auth_ref": [] }, "us-gaap NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei NoTradingSymbolFlag": { "xbrltype": "trueItem", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "No Trading Symbol Flag", "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } } }, "auth_ref": ["r638"] }, "ecd NonNeosMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } } }, "auth_ref": ["r608", "r619", "r629", "r646", "r654"] }, "ecd NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r636"] }, "ecd NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r635"] }, "ecd NonPeoNeoMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } } }, "auth_ref": ["r646"] }, "ecd NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r665"] }, "ecd NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r665"] }, "us-gaap NonUsMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-US", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": ["r782", "r783", "r784", "r785"] }, "us-gaap NumberOfOperatingSegments": { "xbrltype": "integerItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r701"] }, "vnda NumberOfProductsInPortfolio": { "xbrltype": "integerItem", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "NumberOfProductsInPortfolio", "presentation": ["http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of products in portfolio", "label": "Number Of Products In Portfolio", "documentation": "Number Of Products In Portfolio" } } }, "auth_ref": [] }, "us-gaap NumberOfReportableSegments": { "xbrltype": "integerItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": ["http://www.vandapharmaceuticals.com/role/BusinessOrganizationandPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r701"] }, "vnda OliPassCorporationMember": { "xbrltype": "domainItem", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "OliPassCorporationMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "OliPass Corporation", "label": "OliPass Corporation [Member]", "documentation": "OliPass Corporation" } } }, "auth_ref": [] }, "us-gaap OperatingIncomeLoss": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r178", "r183", "r187", "r189", "r566"] }, "us-gaap OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap AccountsPayableandAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/AccountsPayableandAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "netLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r374"] }, "us-gaap OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "verboselabel": "Operating lease non-current liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r374"] }, "us-gaap OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "verboselabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r373"] }, "us-gaap OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "parentTag": "us-gaap OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Change in net unrealized gain (loss) on marketable securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax", "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r123", "r124", "r125"] }, "us-gaap OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), before Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "parentTag": "us-gaap OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net foreign currency translation gain (loss)", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r3", "r67"] }, "us-gaap OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "parentTag": "us-gaap ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUnaudited", "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), net of tax", "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r11", "r15", "r129", "r132", "r137", "r366", "r367", "r372", "r411", "r428", "r690", "r691"] }, "us-gaap OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited": { "parentTag": "us-gaap OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax benefit (provision) on other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": ["r4", "r133", "r137", "r327", "r338", "r339", "r366", "r370", "r372", "r411", "r428"] }, "us-gaap OtherIncome": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": ["r432", "r502", "r531", "r532", "r533"] }, "us-gaap OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r21"] }, "us-gaap OtherNoncashIncomeExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Other non-cash adjustments, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": ["r76"] }, "ecd OtherPerfMeasureAmt": { "xbrltype": "decimalItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r638"] }, "ecd OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r606", "r617", "r627", "r652"] }, "ecd OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r609", "r620", "r630", "r655"] }, "ecd OutstandingRecoveryIndName": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r609", "r620",

"r630", "r655"] } , "vnda_PONVORYAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "PONVORYAcquisitionMember", "presentation": ["http://www.vandapharmaceuticals.com/role/PONVORYAcquisitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "PONVORY Acquisition", "label": "PONVORY Acquisition [Member]", "documentation": "PONVORY Acquisition" } } }, "auth_ref": [] }, "vnda_PONVORYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "PONVORYMember", "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofNetProductSalesDetails"], "lang": { "en-us": { "role": { "terseLabel": "PONVORYu00ae net product sales", "verboselabel": "PONVORYu00ae", "label": "PONVORY [Member]", "documentation": "PONVORY" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": ["r634"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "vnda_PaymentsForAssetAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "PaymentsForAssetAcquisitions", "crdr": "credit", "calculation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Asset acquisition", "label": "Payments For Asset Acquisitions", "documentation": "Payments For Asset Acquisitions" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r27", "r140", "r197"] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Acquisition of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": ["r73"] } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r73"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": ["r637"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r637"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r636"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r646"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r639"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r635"] }, "vnda_PercentageOfFutureSublicenseFeesPayable": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "PercentageOfFutureSublicenseFeesPayable", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of future sublicense fees payable to third-party", "label": "Percentage Of Future Sublicense Fees Payable", "documentation": "Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754"] }, "vnda_PreNDAApprovalMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "PreNDAApprovalMilestonesMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesNDAApprovalNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pre-NDA Approval Milestones", "label": "Pre-NDA Approval Milestones [Member]", "documentation": "Pre-NDA Approval Milestones [Member]" } } }, "auth_ref": [] }, "us-gaap_PREFERREDStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r59", "r263"] }, "us-gaap_PREFERREDStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r59", "r480"] }, "us-gaap_PREFERREDStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": ["r59", "r263"] }, "us-gaap_PREFERREDStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r59", "r480", "r498", "r780", "r781"] }, "us-gaap_PREFERREDStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, \$0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at June 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r59", "r420", "r583"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r688"] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Sales and maturities of marketable securities", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r140", "r141", "r702"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r5", "r14"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails", "http://www.vandapharmaceuticals.com/role/InventoryNarrativeDetails", "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofNetProductSalesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": ["r190", "r408", "r434", "r435", "r436", "r437", "r438", "r439", "r554", "r573", "r584", "r675", "r722", "r723", "r728", "r776"] }, "vnda_ProductRevenueAllowancesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ProductRevenueAllowancesCurrent", "crdr": "credit", "calculation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Product revenue allowances", "label": "Product Revenue Allowances, Current", "documentation": "Product Revenue Allowances, Current" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesFanaptNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleofFutureIntangibleAssetAmortizationDetails", "http://www.vandapharmaceuticals.com/role/InventoryNarrativeDetails", "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofNetProductSalesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": ["r190", "r408", "r434", "r435", "r436", "r437", "r438", "r439", "r554", "r573", "r584", "r675", "r722", "r723", "r728", "r776"] } }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and

```
{ "en-us": { "role": { "terseLabel": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth ref": [ "r634" ] }, "ecd PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth ref": [ "r634" ] }, "srt RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth ref": [ "r247", "r248", "r249", "r250", "r274", "r281", "r309", "r310", "r311", "r383", "r407", "r440", "r470", "r471", "r523", "r527", "r528", "r530", "r552", "r553", "r567", "r571", "r579", "r585", "r588", "r720", "r726", "r770", "r771", "r772", "r773", "r774" ] }, "srt RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth ref": [ "r247", "r248", "r249", "r250", "r274", "r281", "r309", "r310", "r311", "r383", "r407", "r440", "r470", "r471", "r523", "r525", "r527", "r528", "r530", "r552", "r553", "r567", "r571", "r579", "r585", "r588", "r720", "r726", "r770", "r771", "r772", "r773", "r774" ] }, "ecd RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth ref": [ "r601", "r612", "r622", "r647" ] }, "vnda RegulatoryApprovalMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "RegulatoryApprovalMilestoneMember", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipantNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory Approval Milestone", "label": "Regulatory Approval Milestone [Member]", "documentation": "Regulatory Approval Milestone [Member]" } } }, "auth ref": [ ] }, "srt RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth ref": [ "r147", "r148", "r260", "r265", "r376", "r562", "r563" ] }, "us-gaap ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipantNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth ref": [ "r323", "r757" ] }, "us-gaap ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesCFTRActivatorsandInhibitorsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipantNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth ref": [ "r323", "r757" ] }, "us-gaap ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap CostsAndExpenses", "weight": 1.0, "order": 2.0 }, "presentation": [ "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth ref": [ "r57", "r322", "r775" ] }, "us-gaap ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "presentation": [ "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration for entering into the arrangement", "label": "Research and Development Expense (Excluding Acquired In Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth ref": [ "r756" ] }, "us-gaap ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth ref": [ ] }, "ecd RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Axis]" } } }, "auth ref": [ "r602", "r613", "r623", "r648" ] }, "ecd RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth ref": [ "r603", "r614", "r624", "r649" ] }, "ecd RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth ref": [ "r610", "r621", "r631", "r656" ] }, "us-gaap RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "presentation": [ "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in non-current inventory and other", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth ref": [ "r28", "r93", "r113", "r143", "r419" ] }, "us-gaap RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth ref": [ ] }, "us-gaap RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 5.0 }, "presentation": [ "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth ref": [ "r62", "r86", "r423", "r444", "r446", "r453", "r481", "r583" ] }, "us-gaap RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth ref": [ "r109", "r149", "r150", "r151", "r153", "r159", "r161", "r230
```

"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveLossTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Balances Related to Each Component of Other Comprehensive Loss", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth ref": ["r25", "r765", "r766"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210"] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/EarningsperShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Net Income Per Share of Common Stock", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth ref": ["r700"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth ref": ["r47"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth ref": ["r47"] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfNetProductSalesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Revenue from External Customers by Products and Services [Table]", "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information." } } }, "auth ref": ["r39"] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Product Sales", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth ref": ["r39"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleOfFutureIntangibleAssetAmortizationDetails", "http://www.vandapharmaceuticals.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth ref": ["r41", "r42", "r409"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth ref": ["r41", "r42"] }, "vnda_ScheduleOfInventoriesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ScheduleOfInventoriesTableTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/InventoryTables"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Schedule Of Inventories [Table Text Block]", "documentation": "Schedule of inventories." } } }, "auth ref": [] }, "vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfRSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]", "label": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]", "documentation": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]" } } }, "auth ref": [] }, "vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfRSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]", "label": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]", "documentation": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]" } } }, "auth ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth ref": ["r283", "r285", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of RSU Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth ref": ["r46"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth ref": ["r12", "r13", "r46"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth ref": ["r88"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Intangible Asset Amortization", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth ref": ["r42"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth ref": ["r596"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth ref": ["r598"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipantNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth ref": ["r191", "r192", "r467", "r468", "r469", "r524", "r526", "r529", "r534", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r551", "r555", "r574", "r588", "r728", "r776"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth ref": ["r71"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth ref": [] }, "vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "SeriesAJuniorParticipatingPreferredStockPurchaseRightMember", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Series A Junior Participating Preferred Stock Purchase Right, par value \$0.001 per share", "label": "Series A Junior Participating Preferred Stock Purchase Right [Member]", "documentation": "Series A Junior Participating Preferred Stock Purchase Right" } } }, "auth ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A Junior Participating Preferred Stock Purchase Right, par value \$0.001 per share", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth ref": ["r686", "r687", "r727"] }, "vnda_ServiceOptionAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ServiceOptionAwardsMember", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails", "http://xbrl.sec.gov/edc/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Service option awards", "label": "Service Option Awards [Member]", "documentation": "Service Option Awards [Member]" } } }, "auth ref": [] }, "us-

gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCSHFLOWUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCSHFLOWUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth ref": ["r6"] }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAnnualAwardVestingPeriodEmployeesAndNewDirectors": { "xbrltype": "durationItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAnnualAwardVestingPeriodEmployeesAndNewDirectors", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting period for subsequent stock options granted to employees and new directors", "label": "Share Based Compensation Arrangement By Share Based Payment Annual Award Vesting Period Employees And New Directors", "documentation": "Period which an employee and new director's right to exercise an annual option award is no longer contingent on satisfaction of either a service, market or a performance condition." } } }, "auth ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth ref": ["r303"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth ref": ["r303"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth ref": ["r301"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth ref": ["r301"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth ref": ["r298", "r299"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth ref": ["r298", "r299"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant\00aDate Fair\00aValue", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Grant date fair value of common stock granted (in shares)", "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth ref": ["r302"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value of common stock vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth ref": ["r305"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofRSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth ref": ["r310"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofBlackScholesMertonOptionPricingModelforEmployeeandDirectorStockOptionsGrantedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth ref": ["r311"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofBlackScholesMertonOptionPricingModelforEmployeeandDirectorStockOptionsGrantedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth ref": ["r309"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofOptionActivityDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r283", "r285", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares of common stock authorized for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth ref": ["r581"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares of common stock available for future grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth ref": ["r45"] }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueRollForward", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleofOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward]", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]" } } }, "auth ref": [] }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares subject to outstanding options and

RSUs (in shares)", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options and Restricted Stock Units Outstanding Number", "documentation": "Number of options outstanding, including vested and non-vested options, as of the balance sheet, plus the number of non-vested restricted stock units outstanding as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r292"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r292"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r297"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r294"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options granted, weighted average fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r304"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r45"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r290", "r291"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number/u00a0of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding (Roll Forward)", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r290", "r291"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted/u00a0Average Exercise/u00a0Price/u00a0at Grant Date", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted/u00a0Average Remaining/u00a0Term (Years)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r306"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r306"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r306"] }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards": { "xbrltype": "percentItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Portion of initial stock options granted to employees and new directors that vests on first anniversary of grant date", "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards", "documentation": "Percentage of new hire stock option award that vests after one year of service." } } }, "auth_ref": [] }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards": { "xbrltype": "percentItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Portion of initial stock options granted to employees and new directors that vests ratably over three years after completion of first year of service", "label": "Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards", "documentation": "Percentage of new hire stock option award that vests monthly after one year of service." } } }, "auth_ref": [] }, "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl": { "xbrltype": "durationItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceOptionAwardsFullAccelerationOfVestingInvoluntaryTerminationPeriodPostChangeOfControl", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Full acceleration of vesting, employee or executive officer subject to involuntary termination, period post change of control of the Company", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Service Option Awards, Full Acceleration Of Vesting, Involuntary Termination, Period Post Change Of Control", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Full Acceleration Of Vesting, Involuntary Termination, Period Post Change Of Control" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfRSUActivityDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r297"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r294"] }, "vnda_ShareBasedCompensationOptionAwardsContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationOptionAwardsContractualTerm", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation option awards contractual term", "label": "Share Based Compensation Option Awards Contractual Term", "documentation": "Contractual term of stock option awards." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfBlackScholesMertonOptionPricingModelForEmployeeandDirectorStockOptionsGrantedDetails"], "lang": { "en-

us": { "role": { "terseLabel": "Weighted average expected term (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMNdTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r308"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r45"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMNdTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r87"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMNdTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r306"] }, "vnda_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationRestrictedStockUnitsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of vesting equal installments", "label": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments", "documentation": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r77", "r144"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails", "http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r107", "r116", "r117", "r118", "r145", "r165", "r166", "r168", "r170", "r176", "r177", "r229", "r251", "r253", "r254", "r255", "r258", "r259", "r263", "r264", "r266", "r267", "r269", "r364", "r449", "r450", "r451", "r452", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r480", "r501", "r520", "r535", "r536", "r537", "r538", "r539", "r672", "r693", "r699"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r11", "r23", "r109", "r133", "r134", "r135", "r149", "r150", "r151", "r153", "r159", "r161", "r175", "r230", "r231", "r271", "r318", "r319", "r320", "r331", "r332", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r366", "r368", "r369", "r370", "r371", "r372", "r375", "r441", "r442", "r443", "r455", "r520"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r149", "r150", "r151", "r175", "r408", "r448", "r466", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r499", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r589"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": ["r149", "r150", "r151", "r175", "r408", "r448", "r466", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r495", "r496", "r497", "r499", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r589"] }, "ecd_StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompdisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r605", "r616", "r626", "r651"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock from the exercise of stock options and settlement of restricted stock units (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r111", "r59", "r60", "r86"] }, "vnda_StockOptionsAndRestrictedStockUnitsRSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "StockOptionsAndRestrictedStockUnitsRSUsMember", "presentation": ["http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Options and RSUs", "label": "Stock Options and Restricted Stock Units (RSUs) [Member]", "documentation": "Stock Options and Restricted Stock Units (RSUs) [Member]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r60", "r63", "r64", "r80", "r482", "r498", "r521", "r522", "r583", "r595", "r694", "r718", "r764", "r780"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParententical"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "vnda_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "vnda_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": ["http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "documentation": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r645"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r637"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r644"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r664"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r666"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": ["http://www.vandapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "vnda_TradipitantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "TradipitantMember", "presentation": ["http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipitantNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tradipitant", "label": "Tradipitant [Member]", "documentation": "Tradipitant [Member]" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": ["http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleOfAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } },

"auth_ref": ["r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r262", "r268", "r353", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r429", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r714", "r715", "r716", "r717"] }, "ecd TrdArrAdoptionDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r667"] } }, "ecd TrdArrDuration": { "xbrltype": "durationItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r668"] } }, "ecd TrdArrIndName": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r666"] } }, "ecd TrdArrIndTitle": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r666"] } }, "ecd TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r669"] } }, "ecd TrdArrTerminationDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r667"] } }, "vnda TwoThousandSixPlanAndTwoThousandSixteenPlanMember": { "xbrltype": "domainItem", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "TwoThousandSixPlanAndTwoThousandSixteenPlanMember", "presentation": { "http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails", "http://www.vandapharmaceuticals.com/role/StockBasedCompensationScheduleOfOptionActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "2006 Plan and 2016 Plan", "label": "Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]", "documentation": "Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]" } } }, "auth_ref": [] } }, "vnda TwoThousandSixteenPlanMember": { "xbrltype": "domainItem", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "TwoThousandSixteenPlanMember", "presentation": { "http://www.vandapharmaceuticals.com/role/StockBasedCompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "2016 Plan", "label": "Two Thousand Sixteen Plan [Member]", "documentation": "Two Thousand Sixteen Plan [Member]" } } }, "auth_ref": [] } }, "us-gaap TypeOfArrangementAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": { "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipantNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765NarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r342"] } }, "country US": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": { "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesHETLIOZNarrativeDetails", "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesTradipantNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "UNITED STATES" } } }, "auth_ref": [] } }, "us-gaap USTreasuryAndGovernmentMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryAndGovernmentMember", "presentation": { "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury and government agencies", "label": "US Treasury and Government [Member]", "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": ["r415", "r576", "r778"] } }, "ecd UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r663"] } }, "us-gaap UseOfEstimates": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": { "http://www.vandapharmaceuticals.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r36", "r37", "r38", "r101", "r102", "r103", "r104"] } }, "vnda VQW765Member": { "xbrltype": "domainItem", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "VQW765Member", "presentation": { "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesVQW765NarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "VQW-765", "label": "VQW-765 [Member]", "documentation": "VQW-765 [Member]" } } }, "auth_ref": [] } }, "vnda WarrantsOrRightsOutstandingTermsOfAgreementOwnershipPercentageThreshold": { "xbrltype": "percentItem", "nsuri": "http://www.vandapharmaceuticals.com/20240630", "localname": "WarrantsOrRightsOutstandingTermsOfAgreementOwnershipPercentageThreshold", "presentation": { "http://www.vandapharmaceuticals.com/role/CommitmentsandContingenciesOtherAgreementsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Ownership acquired percentage", "label": "Warrants Or Rights Outstanding, Terms Of Agreement, Ownership Percentage Threshold", "documentation": "Warrants Or Rights Outstanding, Terms Of Agreement, Ownership Percentage Threshold" } } }, "auth_ref": [] } }, "us-gaap WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.vandapharmaceuticals.com/role/EarningsperShareDetails": { "parentTag": "us-gaap WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.vandapharmaceuticals.com/role/EarningsperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": ["r700"] } }, "us-gaap WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.vandapharmaceuticals.com/role/EarningsperShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.vandapharmaceuticals.com/role/EarningsperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r164", "r170"] } }, "us-gaap WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] } }, "us-gaap WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.vandapharmaceuticals.com/role/EarningsperShareDetails": { "parentTag": "us-gaap WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.vandapharmaceuticals.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.vandapharmaceuticals.com/role/EarningsperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r163", "r170"] } }, "us-gaap WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": { "http://www.vandapharmaceuticals.com/role/EarningsperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] } }, "std ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481913/940-20-25-1", "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481877/830-230-45-1", "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1", "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14A", "Subparagraph": "(c).3", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748112/505-10-50-2", "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A", "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15", "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A", "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5", "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13", "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4", "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1", "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1", "r31": { "role": "http://fasb.org/us-

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Y[N]1FX]I.G\$SQ4WB;3B=3L3SYWU1D*% MCA%51/E1,53"%X]8>363?IWH(IGA,9KA(=IY]5]CJF^H#=#=Q9VXJ]J4>E7?Q27 MRY96J] !7%?M#9]J, Z OKJ]&U6?FQ9U2T2[5FJ]J[64= QWU#* ZJS>R M3M16^WI >=QXXCY7GE". B%ZL]I)HGDMDZ3ERVY77G'06W'DN4=O%)Y& 3UKNM8 M]?: 2.9^BKK1031.T]DVE-.GL]LT3 ONQV+ M6EAT:D7UT52]6.^V/W@V] "9Y-PJLH-EYV'GD=5?MH'V UO. BS:1~]5 MM@<M+K8P^CT^0&U7&N8iB3 *>]j65K3 B*TW(W)*[KICE=+A]I J]G/6WK6]?: M5WNZ5~]:HK-BF@TK-Y>+&6-K8I8^K W]V:EE?> ULQNMD]4D0S%ND [^_M/@9%G&CS M75XZ' /SY%G[G]Z83->A#E+GSU2N. Y'XZ>4<=CX=B'2WFY+<M^%E.M%O' MQJ;Q^+U#+3M5DB]5~]:HKB2A'2902.PL.BX;9]J#>U^]AIF=M,9F#HB>L06I@'D]P]ND[1^JT M;_YJ@WTU=>OEPOLF.904MZ]4^J+>GQ'G\$S'7EZ9J;]>C]P^?>T1U]1^N, L, %*%#Tz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~2;U^R*61>V^FFDDW505D]EVL(4~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~2;U^R*61>V^FFDDW505D]EVL(4~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~2;U^R*61>V^FFDDW505D]EVL(4~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~2;U^R*61>V^FFDDW505D]EVL(4~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~2;U^R*61>V^FFDDW505D]EVL(4~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~2;U^R*61>V^FFDDW505D]EVL(4~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~2;U^R*61>V^FFDDW505D]EVL(4~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~2;U^R*61>V^FFDDW505D]EVL(4~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~2;U^R*61>V^FFDDW505D]EVL(4~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~2;U^R*61>V^FFDDW505D]EVL(4~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

[illegible]

!74-4-0:BWUQ0-5-1-3Y) MHSK!>DfK+4 QP6G&4-EK+4-4H) USJX3 (3W-0)F1M=-K:K3LRN%MGCBT MO>H<-+6K17-FO 1Y-1N8>+>016 *Q&4-LL80) JPS= M? ==8,B0Y)APK.7-7Z1>0<21UWVWS@K#5Y0B!UJ, #/4.(2)UW%2R%K UJ&C-PD-MWJ?<-;3OH#JY?EJ)GE#KB>-TS.B3.W-2R%M\$R-86F);9/A,9ADU(XND MJ4/<000J82UJEU0<915NVS3J/9803?>:S1?9.R-U-B?T%5K#?14VS3J?Y&G?>N-7H-BQE-L4-M0\$HGZRT=>G5N<3V10>H-K2=1992ZYXZK1)H0?LOH.CVP?KXL,E%WY^43 M(OGB&B#2VX1,^4/4-9MHIKZ-BMBU-UPGMM-A=^L-66KMU24OMXR77ZG6TQ74G)>+?%MU^OW2H(G5NW<4J)MKFBXU^8VJ7J54*6 MP&+<+GE%#K8M10%OW2ESJQ>B2(G)Y-U-2-1=I7N18%N5;@.ZJ4K.N05&S MDM7,B4:~UNJ9HRL4/3SP-BSIX18L^09S&0%-T10D^JTFC.X<-<4SU-^?&O(YPI92=7?1\$0.%(GJ)DYV&K&8MPH12<~K!~RYQ.<Q^XEXI^7UK=VXJRJ&U+D&G5FEN^W021EN.N04W01>+>1-M-8CMZ4&T5Z\$>O^L^%652M4;7#07121MSYVE-U^E^@NHX918T7C=1&)(FE MJ5^NC60V^4^Z9:75#J4Z5>3SZ2+N9+^?+^FJ5M&^00A^U)>+>8)G#%1R M)HKEW\$S;-[RIG>#>11R%4JLR4^43^IR-G)/F2J^1H@1%UOXH0CPVF@H M+^B5C@S^B^0B>+IAY@JRH^OH#G2R0F@<2LJ56^2\$2J) VDI47JBH73CQ,Q&Q2-M-RP-Q-CE/34SV0&+<4J^M^9F92^1^&35;Y3Y (SNV;#>BZXPRQ>YRJ>J)X15Q24.Y44&KR<045-M4O7VJ87J>#E#W;G;X9M5J^I^S/H.O9;SU/GB(C-U=9UOVHXDVN5Z)U1-MM56\$QJK /f321<~M.NMMH5YHYPP3AFQZJFJPMQ/G2^K@1K@<FLN13%2ZWV M4)>+BB^IWEVG12=IR.SX.8QK<#1\$3%+<1098N6.Y^#EDG8(DX4E(B-MI&TC)>+1\$(<H>6RLQ^MH)? 510T2<~.7#PN\$<K4Z+KW^9>A?>+6GJF=I-M.X^>FNHQI:B^U^Y)>+4/6(M^QUQ3.XR.7.Z0B4^5&A.O\$<G6>+<H9N>MMJMU^KJ.GMXIY;+50E1A^6\$)>MM#1C1&F^3\$(YK;<J2S7/WS:3Y-BZ/9645^M;JZZ+ZBJJ=74@54.0@>+X;2=1^I1^K576IP8MW;7V3@:L8;A/M^\$L&T-2-M.JPGUL4+JYUB&JX12UE80,T5M>XQN JY(PA+R(F,B0^H^UJ2P)B+4?M^JL^TRB5J+100V>.6H>@>1%6KLTQJ85)>5%Q.X<E.B8RK8PUJH4-DR-M3K^~RC1VMSG?76M^L@V-MLK&C<?>D+H.G51 M5)M1F^B124P^VWL=J)HLE7J2297.TBMK\$Y1+<+JLSQ.N.JO^9S9W&W+CRT-M>NRN9,OM\$J^NZE^H^WB4Z5YEK\$Y1^ZV^#5E1ED>LOA-ZR^DMYJ- <N=RSVIG^H+VHCH^912M9J>K#K7P^TK\$D).<G+G6.8+K4578XW;KJ,DUHJX60;6^U^XJ12>PQJ59-1^>D)E\$+<MJU@1>-10/>E=14V8F8. M44-<2>+<5\$5K~B8^BX8UPT&15@RR67#>94B9V=ZT+G1M^XKX9KQ?J=U-MTMN^W06N3KVZ5J3^IHZ35BH^5=5^55/>UJXUJQV64(B-R#K)>7C-MUT5(K? WT:PS^HDPH^DG((1<19^0\$QF^DB^UJ^WZFYF:CRBFLC%8&XNHAY2^MM^<K6?>#<D4:X8W#8=CH2)S#BU(596)?%OR4M&T9:ASUZ&TCJJ|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~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~LU^SY^HK3-M2JES:801&60H?T=>_OR<^L>+V^F^D1^F5W5)2J1-2-4J4,0^M908^RSR. (GQUH)5Y8J^B90J;BTC30;7N5J>CI95+X>~^J^1?\$(QC<-M2KL\$08H-S1?%G+V^UJ7>>8-O1Q^N6G1T@<+>Y=(7JFW^<4&HJ&07B-M8J3:09HEH9)J/3(<? >85ANJ<N<J1+4:4M5EYB+7M^V2>=P1+U+K1E=3B3PT>H71=>@<@M1N^YRHH^S1>WTF2<7>+>M^<87QZ<4-N-PP-7RFN6W8;X>BPB4&8+9)T M2M9QR19J^T1R,5\$0YX<A;U9X&M0<3^A;Z0&1T@<JXS;2JDF^#E@DD)71M=1-7=12Q)BS2^RJDJ<@>~INS^FPN183G3NHD^GFOK;29+5F>ZJ2A>ZGFMELJO4A,^3U.U.C1SIR- K4%N)J&Q45GK0Z<D7%TWM;M-6D<K&^#TH\$A^RR<@<7&2-79B&J/MJL(PNFFJ^E&S-TKX5HJ^20^XIE8K0)BF5T2RJIB>BP2J,^&AAD^M@<L>WJW-MDSK4-D5 <1BXKN7(6HG<0,B1J03W=HJYH8SH7@9UD;GWTF7&M02Q^M^Q2;L+J^JW^J.J(GQ/75-PEJ-7JG1V7Z)DU7JH~KZ>QH<8^S<?JZY98-MJ@<LHHW?%

[illegible]

[illegible]

[illegible]

4(FJGP4)*RJ+Y+;KL*A5Z1PL8JTBW~M&EAC;OV17((3%18&HS&&3*L UW2;JC'SI#MT+33)2@2E4H!7SP^&00>P9LSB-O!&=IO F0D=82:2]@-I>X%{0QE MMN)UN-R<0G6&E
-1.0>4P07Q~IRBN@&L~^~^\$GUBVD53'D06'MD=+21LU* M+BjHW5JQH+;DP2=^J@].~#YMj5K2Z..M6==>OC1SD1YK725JPH7FPE[K0~^M1H;T#TN6&Y(-I.N'DRP-0L6&
D8..46DG6P+*SB=HX7UYTWGZ@KZL~B-MV@FPGU;R:M3X4JNF^NSN~Y&A!^Z9!~#JDMJ11B5~*51~#F~&S2Q]@<1.M/H\$HB)+03V@<(^ZL-M;LJZZ0T%6N!>B;/'K M?P
GNYDS'Q?~5.A9IAN(LAK%418CG6)-0G&0J'V7.BV.3TX)5A;?AL~MFR#17B7~1LVK;#&YQF5?1.V7BHMJTN-M9N*1)7P7.5)%=J\$-OK&..5X6AGOV^&M-9)Y@S21\$~DTA!F"
OH>8&7\$2_#86!45F@+2.MML9J?;WK=YL>O2>&~27105T7^Q^X~K[Y^Y-14?>7(AL-M-G^~^Y(5=G8G]7LN>%FJVYA*L[C#]/JXD57%?>^,K+O)Z(1+DHS0,81QZ!~+B
M89@&&88>\$1F)XAA3G)@

/>&-5K\$FG(QTY!FU6Y:5)^J%6T7W-25W1+BR)8~.=KC,1/OSD);S- B@GY! 7G(945TQ?;AB2@.,\$\$(O,0G.C\$"
<6X0W^=H(6I?Z"J,%H;/RM: M=,Q,I7\$VZIW;3IEC)MKI?&F,^Y;8 O>WW_HN6 MKK5:60I*V=R(UD1HYNA
<1J9#=-UBLD48AC9* TR1*\$&9& ML0Q#^!;KBRTV2C^<~.;L47W@A,^:~J;IN&?H"G+!~//C!WYKEPHAM#G1778 ML>;
(*6&YC*4RH@^E!KA!Q-1J-M.LY,W"J&Y|B(-/<@EYGE11QB#~?4I59<'Q1 MU7_5LGMDOLIK_ED:G>S3JH8?2RY531?
XI+&HZ_R~T578?/CLL14ND221 M1X?@~(TD:2?O/CP1_51J\$A)X!&=\$Q8'1/"A+/"96)+C2@PI~UKR4THS, E
M,XW2@<0;C..I5:2M.85;~(*>MA= 848:~!SYV"O.M:XZJUH8<6V1008I51 MQ0+EWNCZ6NH!>%B.5MEW@9%\$F,((K1)
(L)I#**W#H\$O%&\$5ZL^+WJ7Z9Y MW9T/>RWASUKA|!~@F8QF-9HSLW4O.B^L0WZ:~2210ME_D*Y8L=|5=)"~.MA
M_KI7UM?QELR>VG4"!~B; DFET_NFF|~JCR/_R=#JC@WFF1\MGU^7^XR1: M52,/++M~?~(X?~UJ9(VG+~J>?
EHJRXTKRI=O^,\O\F@O<|RLFI4J@2A?~;5 MUV*U6!XF,8^9P@2X7L0D8! P@B&U-L#>;D+HSC4GTAD GGB6YS\$
#QN4#!~H MO6G\$O&.%IGI0EI@+>87\$%%&.VB&P'XVZ0N5+M\D<|0A>RS:~!IZ53LL^M-
~;"Z^=0\$(5S..GGG9_5NU4:P'5;%D4HIED-1!~5@&-LSK M!VDIR<~(+E\$^XF6OOR)H40N:CB2#2.'YX:~+3A?
MU...OLTLY"6S.5I0MNRFC@2&&~!88R|""(48)BEE, @D|N(!&L&C^~^>&COG>XW+ M>N(+!~B^~)D|B+6V|/I&
/_/52@D6P7(1+P?;N~;"CV2>D10>? &F=RL3,"4 MAI0FL4~4Q6&2T+3;K ^KJ7T-
|K=J@|V1G1UHN^*~L5;V(7@DN^S.PRV+H\$> M^E=@2"/J2/39?K>P)&~?QKW/MUV>WLEJ~T#;%LZ#_~E15~\
|>K|78G|93 MT,X%/XWT@LG+5!)A~?W\$%Q!%~..4JH!%&41\CR\$B5'.S~*B6!~"AFEJ|A:
M*C7YT,JR/9LKW@2C*U!7RVW*HP0D=ZPQHJM^UZNKB|P,EOLF:~JGW8G+~)1X
M!5ITKEI=75V=UMGI7"~@LY(|WJH)=H1:I~I=96JDY!C.GEEJSZ#B|U^XAXJU M#ZLZKU^^^28~:9;NNZJ_X435U0)&O-
%T;V7&B@AF849AQ&,6!2R)><1T*|5. M 9A8C;4@P0XF4\$#URD\AF18DIB@U\$Q~&)I5^LV1(E5S=G)!6>K-1LBIUC M-
OB<>>S@2UTN|WCY6-V(NY)!77W"?~!;2:3^I=O~!P*\$TO0QEL^&NCJ.#1 M3!~OZ3K-B?\$HBAFF F7%OW@A(\$-
*~X"J>,TVH53AE8=K9PRCA1_7"~QM/V MW;J~J\JA8;2>;UB45QKW=W"~J@V?T9BL>ES@&Q9B)W@LX)!&R\$K(L:~E!~N
M.7N+1C~\$G6I2?N|1V);0~RP6F&Q~*~(QH0SB&B2P31(5>LPE/F^B|B&XVU
MM<~)B^@S4>/(.5,E+O7ONY!PR\$~E+LD~+~%XUIW3^EM?+~)4XO/6\TOV;^&2= M|A:S./LW.S\YB?TWYGZE~\?~
#F<|W)E!\$!ACU2-D|Z22L/C_2R13J,196\$FM8H(L~&?\$HBY3R+8X'3-(CC1\$O)G(4PL8+9=@!K@8/(JHFX!&O>M^&R?
+^,NYHNI~-,NQH1:=3@|2R~.6;B MJ.V7"1QG)H1;&=Q: &8SQ\$W(|10H1N^9"WKK"|Hf;=)%5\3DXL,3\$DJ;.@@P8TZ&"K
LVB7A4F@C3\$@G&)7/IW'7Z~1.5*#~+~#X>,2<&Q&P(@U%;R>CWW +WDA^OR|6?ZEL?~.M<~)W|;PK>
MIGS:C&KISIQ^>+>N:GE3*S_GF.3+O^YYMWY<+R7:S_P=KNG#^T^|~.9=\\8T~
M|6:OVOJ/S^M/E1QBI*5<82EL12141W-D6O)ZHW=(H1ARCT,20X2"~U\$ E# M|L1:M> V>RH*M:0TJO.05*+<1%>5?
EI@KNA6@+;15 M^4IXA|9437'3NL=4VH_TRI4-U43?7P#~;H7X\$M~H-X88\$T-I46_'P#N MZ)"~;C=U0TN7;~FAQO7Y-
~"O'9U-B(A*4IK90-60A3WT~2H4~*B@ M @G6M"~CD"~CX~*~J373C:~\$6A1EG"~F@JH.PQ5G+LLX0H!Q7<~;Y!^W,OJZ)
M,V>GK=0N|VSA1G!|(4>2_2UJ~.^~.ZO\$C&~'AH4FT%EM-S~&'!HO MAF^~!Q:~^~JMOZR7W/1+YJBJE?
%S5|~.2W^N&%&*72*KAP?M790@NCA/4#"^~/ M.RY^~;TLJFJ1ADHDJ,B@EV8(HB"
(8.9+TSD.A8A1&JH&YXMG7I+~"07U)~!+D MZ^~T#UOZ/(ZY5O@=NT^~;7JW;D@F;J0BC+ SBD C!\$(R\$ZIO\$LPIF-AA% =,
M(#!6A&F5@4_10 L5V, |W!9OC0!?(~T>FV6Z=DW+AEAI@<~2VZJ*!~" GZ6R
M9H_0Z8MH6G!OI5YFCWB#TIC|H^PTY|FIVG&\$2Q+Z4|DI>8C|J\$8.DP2B)) P\$RD'DR#A-4)9Y1282*H
MO;5GN(3\\=U, /J4ZXF<)3WF%XH_OH_7VAA+U@GL^4E3?~59)>@>28=2<^H1 MV^~.M~_JJCMIJ@~/?
BX+M=WU5AFW"~!8@G@D#5NN.AV#4I8"AL/4T~J~E1 M-PIS8LG:~W"K+I 3?..=W#SBD?3
^~^;6/L+3<~;^\$>=L5T>@~|H\$S.L2QR~. M?~QJL^~#XJ-1~U4X9;.8Y?FOS"~#~1OIOOQ_ZAR(N#~!00!V\$J%0!)88H)@|%/
M4Q8'A*=TICJR<@|A\$|G#ALJAW\$.ZJD&IWPQ4PP;T"~33=(# M/L'(1&U*~6F\$<7BSZ@~M@^~U@?Z+EAY#G)=~
Z|CW>4671;66G|PN)3|Q1.+~' M~(D#~2,L%C(O_~\$XC#D7'~#&?>X;^~J&H\$UM#\$C8;~FV(5C!;H9_V+HZAIID MEZ:?
RQ43#)U<~_H@!U7\$!C1Z,J_0AK7N>6#ME'GBYMERSZ6;SG%2WS)FWT M1ORVKO(5KZK;8IG3E|TW&_~(@YBC%D
3F(D41T7)G:T.< M6.PW4.%>8I77<,<@Z8/6DP;%O1)6&\$F|~#WHRL?~N5'BP'0\$7I+WA@TOW#~
M(|M&G&=XY:A9A@F~@XTSM!~:KXF&~5U|~#36,7K3T"ZZR8^1&W&QWGLUA MOV"(4YYY/@QI\$4-YS<\$0H!3/9R#~.*
~("9I@H>'<6TM0~PP.N^EQWXY2J#K2A M)~\$LKS3|BBXX8.AEW!*~!0J^~CQ%OI G(<AR5_(LG'G=D6/D^CDG1U^P+(U4
MY0Y=70%77G=..|C 6\$6+~*~XFI\$~*~AHNZAE\$X22Y&~(DR8WAB_02@3"VT#Y(R>F%Y,KYF(=I#
~.WO%'OYQ^~\!)8@~*#)+FJ@~#L)8|YZM2\$RCZK+ M|A^V:~WO:<6;~O|&736ZEZ8^~+5G&~R3.RPY%U%B)BTGNF>HZ5(L?~\
|9&B^= MS3_X2| %O3,V*~W<~N. @...&8%??YBKU7;6+E&\$<\$8XAHK&R~B2'R,H< TS@+?"ZF?Z~^D#~:/9F^6#7#S
M>45V/-6Y:\$(~*~+~X<)Z*~BS_F6=S<"M.BHOG&@1.BM6)^2@2~W0D9:7DS M=U0PZN|)4.&K~&FBYXI;~D=|Z;
|N(A8K^OGZ4MN7+C?B>WZ|RD5~JH1 M51FL:D*4BGDO+I3M?~(EL8^YE\$~" WG7AR@+!~"0H"R\$E5%X>J* ATLH;~@4
M|9VBO40)0P!7L\$&;+~!|QI3/Q|DOS5T-03<4'3+0 M3!U;~<~%0\$YNL_Y2MJ|R3_~.O&^910)?
ZIQ^N2954SNNE~PIH*\$Z0T~!~!C M~FAW^~_K^|~>AO'D?7|~@H^~.#, N9_%^JV#PNDD_0@~|U)T.F;I~K
MV\$&~00I3AL\$~^H/|H9S=%1#87WAK/Y5)\$,1X862|EHL.7V8+~>K-A3-8U8 MB*,">3#U2081|2*8\$E3 (@BD*)
@20JM9~PMZB,2Y%RMKT%+Q^Y\$7D.TRB*(~\H~*~HS9-FZN-M/3YS/OL~&EV DOE:A-E%T2#_~WW\$KU,~2!)N7M?
3\554,^~S#(

A5M60-0IC1V|W~GL;7X34-5TPLA0Z:F*IKY22.G!L5YN&Y9 RY,H*~+2G M1.Y Q))N,>' J9CZ2BE1|RN/ MK"LYM(
@IMHO<%?ZX3U^EDQZFUA1*VNAKVL&W4SW%W)61?#7@&ZWG00F'S#U MWW?|@?3YJ5D>)HP0OD6(G~'~@B+^4U'
PB=^BM+&IXE6XJ|S=&|~^T~^~I> M-6G05)U|H~H^OAI*~+CP|97EM>;RGZ;HV/-7AN P~*~#~4|CZ;<~&~XE-B MKN~*%~.
|V+576Q:GM&5 QSAJ|(|C1PBT/E%+1@H3F/HXBZC~PMA+ M|5K|68?0J)^<4Q#5~*QU8#3=E|81~4~'@XF8GK-I'2>YL-
B27D=H6TWEE6BZ M;0NO~\!8W>M#IN:(MRM?K"EO8&|W+O&N0+D(8/1#91~L!~LEJv&+~8"<MQ"H&Y;
<4INBG|8X1BD&AAX,3PQ|UL|KVA&U*9|7L_FZ|3Q=W:U7%;?~1%1U
MEJ9)A(H80Q:D.41>B"~WQ|A#QOPP0*4A+E609 M&OB0RC+^@~#)NB\$75@ M JAKS-6,MO&1U%;~\VNM4=-1?
@K@MGPZ|@X0\$~NFG2YUIT>~(33|YH M,OJ&WV=I~!U&/?6CC> (IN-9D!@9DF84G9F59P'2-3+/
M6|C,Y!29G|MLP/TP6\,SV5 @~P;/%%~*%~!9P\$~).~2,S8/9-
M(\-5S!13,QVK>BPOR%_KV9+=+T6;GM7;_5Q4XRRH~,8|BT>F?N8S|K)E\$~N, M0!2&~!((OS
~.C^~.H2SQ&N5DIH^4B=NH(OTU~|_T/7 E'K1|)B)~*~NOH MRX.>\$M(5DT!60;+2/FT|(@)L T7H&5C
B0C\$PG;|4G0M+6.OOR6-(X&8?~. M1A^0?4UCL0)X^TOO>CB;~4>93 ~K(0>F|FFZXH~RjX3,SQ-9/SYN(JUF
M%/RX2(8A|YX%~<~.WCXNS&P>>~.YPZ"FE,^&HX+F(CML+O'S;(7G38"~.0|F
MFOHL+M(HAF\$0)1#%20(Q(A^D+D)\$~*~\$D8%AKX.E)DF/GX&T8_,^<~\@-6E+S
MH#G@~|~1V:~>Q743T|FL#~'F)Q<%HR\$V;44\$|Q8'FRI+VNHZ6F"~;@>~*~@P M,~Q4_9-6U4'3;8|XW"06^~8RA~WUY,
YBCPH)=32KPD8UD<6M_~\$30H1|IGWO MX29|T4);/4GM;#65N_~\$~(#0N59|QWPH| T,EL16WN95A2/UCD#O~|ZH/
M;|MG&GO^XB=>TCO9MKBZ?GV>+>6~HO%~5O.2KIWI7+|RI9D5G~;?T;8E\$64
M!;ZXDJ5\$S%/"~*4..@5&6&YG_I%JJ4T7 LPLAZ2W#07M|2|PG;|~?7VD=^8GL~L3H'?303J" /R~|I+FY(-
&-3/|I)5*6%YU7!~P M~&~%~!R@D)B=JLWAZ^\$/?Q@~5% M|~#|H.NLFH9!@A\$~
^A*~84H21.81@F!61*%7I21*\$~.QSBETC~#(IT5#%DBZ MH"4,~A"D;~OB'(5*3;G;

[illegible]

[illegible]

```


```

<!--#include virtual="/includes/A0%#@+<!--#include virtual="/includes/A0%#@+
XBRRL DOCUMENT 0001347178 2024-01-01 2024-06-30 0001347178 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001347178
vnda:SeriesAJuniorParticipatingPreferredStockPurchaseRightMember 2024-01-01 2024-06-30 0001347178 2024-07-25 0001347178 2024-06-30 0001347178 2023-12-31
0001347178 2024-04-01 2024-06-30 0001347178 2023-04-01 2023-06-30 0001347178 2023-01-01 2023-06-30 0001347178 us-gaap:CommonStockMember 2023-12-31
0001347178 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001347178 us-
gaap:RetainedEarningsMember 2023-12-31 0001347178 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2024-
01-01 2024-03-31 0001347178 2024-01-01 2024-03-31 0001347178 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001347178 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001347178 us-gaap:CommonStockMember 2024-03-31 0001347178 us-
gaap:AdditionalPaidInCapitalMember 2024-03-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001347178 us-
gaap:RetainedEarningsMember 2024-03-31 0001347178 2024-03-31 0001347178 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001347178 us-
gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001347178 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001347178 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001347178 us-gaap:CommonStockMember 2024-06-30 0001347178 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001347178 us-
gaap:RetainedEarningsMember 2024-06-30 0001347178 us-gaap:CommonStockMember 2022-12-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2022-12-31
0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001347178 us-gaap:RetainedEarningsMember 2022-12-31 0001347178 2022-12-31
0001347178 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001347178 2023-01-01
2023-03-31 0001347178 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-
03-31 0001347178 us-gaap:CommonStockMember 2023-03-31 0001347178 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001347178 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001347178 us-gaap:RetainedEarningsMember 2023-03-31 0001347178 2023-03-31 0001347178 us-
gaap:CommonStockMember 2023-04-01 2023-06-30 0001347178 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001347178 us-
gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001347178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001347178 us-
gaap:CommonStockMember 2023-06-30 0001347178 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001347178 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001347178 us-gaap:RetainedEarningsMember 2023-06-30 0001347178 2023-06-30 0001347178
vnda:FanapMember 2024-04-01 2024-06-30 0001347178 vnda:FanapMember 2023-04-01 2023-06-30 0001347178 vnda:FanapMember 2024-01-01 2024-06-30 0001347178
vnda:FanapMember 2023-01-01 2023-06-30 0001347178 vnda:HetliozMember 2024-04-01 2024-06-30 0001347178 vnda:HetliozMember 2023-04-01 2023-06-30 0001347178
vnda:HetliozMember 2024-01-01 2024-06-30 0001347178 vnda:HetliozMember 2023-01-01 2023-06-30 0001347178 vnda:PONVORYMember 2024-04-01 2024-06-30
0001347178 vnda:PONVORYMember 2023-04-01 2023-06-30 0001347178 vnda:PONVORYMember 2024-01-01 2024-06-30 0001347178 vnda:PONVORYMember 2023-01-01
2023-06-30 0001347178 vnda:FiveMajorCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30
0001347178 vnda:FiveMajorCustomersMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-06-30 0001347178
vnda:PONVORYAcquisitionMember 2023-12-07 2023-12-07 0001347178 us-gaap:USTreasuryAndGovernmentMember 2024-06-30 0001347178 us-
gaap:CorporateDebtSecuritiesMember 2024-06-30 0001347178 us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0001347178 us-
gaap:CorporateDebtSecuritiesMember 2023-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2024-06-30 0001347178
us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2024-06-30 0001347178 us-gaap:FairValueInputsLevel3Member us-
gaap:USTreasuryAndGovernmentMember 2024-06-30 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001347178
us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001347178 us-gaap:FairValueInputsLevel3Member us-
gaap:CorporateDebtSecuritiesMember 2024-06-30 0001347178 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001347178 us-gaap:FairValueInputsLevel2Member 2024-
06-30 0001347178 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2023-
12-31 0001347178 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-
gaap:USTreasuryAndGovernmentMember 2023-12-31 0001347178 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001347178
us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001347178 us-gaap:FairValueInputsLevel3Member us-
gaap:CorporateDebtSecuritiesMember 2023-12-31 0001347178 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001347178 us-gaap:FairValueInputsLevel2Member 2023-
12-31 0001347178 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001347178 us-gaap:CashEquivalentsMember 2024-06-30 0001347178 us-
gaap:CashEquivalentsMember 2023-12-31 0001347178 vnda:FanapMember 2024-06-30 0001347178 vnda:FanapMember 2023-12-31 0001347178 vnda:HetliozMember 2024-
06-30 0001347178 vnda:HetliozMember 2023-12-31 0001347178 vnda:HetliozMember 2014-01-01 2014-01-01 0001347178 vnda:HetliozMember 2018-04-01 2018-04-01
0001347178 vnda:HetliozMember 2018-01-01 2018-12-31 0001347178 vnda:PONVORYMember 2024-06-30 0001347178 vnda:PONVORYMember 2023-12-31 0001347178
vnda:FanapMember 2014-12-31 2019-12-31 0001347178 vnda:FanapMember 2014-12-31 2014-12-31 0001347178 vnda:HetliozMember 2004-02-01 2024-06-30 0001347178
vnda:HetliozMember us-gaap:NonUSMember 2024-01-01 2024-06-30 0001347178 vnda:HetliozMember country:US 2022-01-01 2022-11-30 0001347178 vnda:HetliozMember
country:US 2022-12-01 2022-12-31 0001347178
```


```

height:120%;">HETLIOZ@(tasmilteon) for the treatment of jet lag disorder, insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24; </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*PONVORY@(ponesimod) for the treatment of psoriasis and ulcerative colitis;</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*Tradipitant (VLY-686), a small molecule neurokinin-1 (NK-1) receptor antagonist, for the treatment of gastroparesis, motion sickness and atopic dermatitis; </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">**Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors, including VSJ-110 for the treatment of dry eye and ocular inflammation and VPO-227 for the treatment of secretory diarrhea disorders, including cholera; </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of onychomycosis and hematologic malignancies and with potential use as a treatment for several oncology indications; </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, for the treatment of social/performance anxiety and psychiatric disorders; and </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*Antisense oligonucleotide (ASO) molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease, Type 2S (CMT2S), caused by cryptic splice site variants within the IGHMBP2 gene.</div><div style="margin-top:12pt">Basis of Presentation</div><div>The accompanying unaudited condensed consolidated financial statements include the accounts of Vanda Pharmaceuticals Inc. and its wholly-owned subsidiaries and have been prepared in accordance with United States generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company's consolidated financial statements and accompanying notes included in the Company's annual report on Form 10-K (Annual Report) for the fiscal year ended December 31, 2023. The financial information as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023 is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheet data as of December 31, 2023 was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Company's operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period.</div><div style="margin-top:6pt">Vanda Pharmaceuticals Inc. (the Company) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in one reporting segment. </div><div style="margin-bottom:6pt;margin-top:12pt">The Company's commercial portfolio is currently comprised of three products, Fanapt@for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ@for the treatment of Non-24 Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), and PONVORY@for the treatment of relapsing forms of multiple sclerosis (MS) to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, in adults. HETLIOZ@is the first product approved by the United States Food and Drug Administration (FDA) for patients with Non-24 and for patients with SMS. In addition, the Company has a number of drugs in development, including: </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*Milasaperidone (VIX-896), the active metabolite of Fanapt@for the treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia; </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*Fanapt@for the treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia; </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*HETLIOZ@for the treatment of jet lag disorder, insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24; </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*PONVORY@for the treatment of psoriasis and ulcerative colitis;</div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*Tradipitant (VLY-686), a small molecule neurokinin-1 (NK-1) receptor antagonist, for the treatment of gastroparesis, motion sickness and atopic dermatitis; </div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt">*<span style="color:#000000;font-family:'Times

[illegible]

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">\$(/span></td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom;">50,474 </td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom;"></td><td colspan="3" style="background-color:#fffff;padding:0 1pt"></td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom;">\$(/span></td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom;">46,056 </td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom;"></td><td colspan="3" style="background-color:#fffff;padding:0 1pt"></td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom;">\$(/span></td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom;">97,936 </td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom;"></td><td colspan="3" style="background-color:#fffff;padding:0 1pt"></td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom;">\$(/span></td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom;">108,554 </td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom;"></td></tr></table></div><div style="margin-top:7pt">The Company's HETLIOZ@ net product sales as reported for the three months ended March 31, 2023 reflected higher unit sales as compared to recent prior periods. The higher unit sales during the three months ended March 31, 2023 resulted in a significant increase of inventory stocking at specialty pharmacy customers at March 31, 2023. During the remainder of 2023, although there was continued destocking at specialty pharmacy customers, inventory levels remained elevated relative to inventory levels prior to the entrance of generic competition and remained elevated at March 31, 2024 and June 30, 2024. Going forward, HETLIOZ@ net product sales may reflect lower unit sales as a result of reduction of the elevated inventory levels at specialty pharmacy customers or may be variable depending upon when specialty pharmacy customers need to purchase again. Further, HETLIOZ@ net product sales will likely decline in future periods, potentially significantly, related to continued generic competition in the U.S. The Company constrained HETLIOZ@ net product sales for the three and six months ended June 30, 2024 and 2023 to an amount not probable of significant revenue reversal. The amount of revenue recognized during the three months ended June 30, 2024 and 2023 related to changes in estimates on revenue constrained during the first quarter of 2024 and 2023 was \$0.7 million and \$4.8 million, respectively. The amount of revenue recognized during the six months ended June 30, 2024 related to changes in estimates on revenue constrained during the year ended December 31, 2023 was \$1.6 million. HETLIOZ@ net product sales could experience variability in future periods as the remaining uncertainties associated with variable consideration related to inventory stocking by specialty pharmacy customers are resolved.</div><div style="margin-top:12pt">Major Customers</div><div style="margin-top:6pt">Fanapt@ is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. HETLIOZ@ is available in the United States (U.S.) for distribution through a limited number of specialty pharmacies and is not available in retail pharmacies. PONVORY@ is available in the U.S. for distribution primarily through specialty distributors. The Company invoices and records revenue when its customers, wholesalers, specialty pharmacies and specialty distributors,</div><div style="margin-top:6pt">receive product from the third-party logistics warehouse, which is the point at which control is transferred to the customer. Outside the U.S., the Company has a distribution agreement for the commercialization of Fanapt@ in Israel and sells HETLIOZ@ in Germany. There were five major customers that each accounted for more than 10% of total revenues and, as a group, represented 73% of total revenues for the six months ended June 30, 2024. There were five major customers that each accounted for more than 10% of accounts receivable and, as a group, represented 73% of total accounts receivable at June 30, 2024. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.</div><div style="margin-top:12pt">Recent Accounting Pronouncements</div><div style="margin-top:6pt">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision-Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements.</div><div style="margin-top:12pt">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company's consolidated financial statements.</div><div style="margin-top:6pt">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management's evaluation could change. Actual results could differ from those estimates.</div><div>For purposes of the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows, cash equivalents represent highly liquid investments with a maturity date of three months or less at the date of purchase. Cash and cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers. Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company's Washington, D.C. headquarters.</div><div style="margin-top:12pt">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Condensed Consolidated Statements of Cash Flows.</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom;">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2023</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$(/span></td><td style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">\$(/span></td><td style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">102,953</td><td style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">469</td><td style="background-color:#fffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">469</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">Total cash, cash equivalents and restricted cash</td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$(/span></td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150,031</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">Total cash, cash equivalents and restricted cash</td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$(/span></td><td style="background-color:#ceefff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150,031</td></tr></table></div></div>

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
<table><tr><td colspan=
```

[illegible]

[illegible]

[illegible]

text-align:right;vertical-align:bottom"></td></tr></table></div>

-1000 21000 -329000 -51000 -330000 -30000 Stock-Based Compensation

As of June 30, 2024, there were 7,677,419 shares subject to outstanding options and restricted stock units (RSUs) under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan), and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms in April 2016, and the Company adopted the 2016 Plan. Outstanding options under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company's stockholders approved the 2016 Plan. The 2016 Plan has been amended a number of times since to increase the number of shares reserved for issuance, among other administrative changes. Each of the amendments to the 2016 Plan was approved by the Company's stockholders. There is a total of 15,690,000 shares of common stock authorized for issuance under the 2016 Plan, 4,673,878 shares of which remained available for future grant as of June 30, 2024.

The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have 10-year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over four years, with the first 25% of the shares subject to service option awards vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the service option awards in 36 equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Service option awards granted to executive officers and certain other employees provide for partial acceleration of vesting if the executive officer or employee is subject to an involuntary termination, and full acceleration of vesting if the executive officer or employee is subject to an involuntary termination within 24 months after a change in control of the Company. Service option awards granted to directors provide for accelerated vesting if there is a change in control of the Company or if the director's service terminates as a result of the director's death or total and permanent disability.

As of June 30, 2024, \$4.6 million of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of 1.0 years. No option awards are classified as a liability as of June 30, 2024.

A summary of option activity under the Plans for the six months ended June 30, 2024 follows:

| | Weighted Average Grant Date Fair Value | Exercise Price | Grant Date |
|----------------------------------|--|----------------|------------|
| Outstanding at December 31, 2023 | \$4.792,506 | | |
| Granted | | | |
| Expired | | | |
| Vested | | | |
| Expected to Vest | | | |
| Forfeited | | | |
| Balance at June 30, 2024 | \$4.848,508 | | |

The weighted average grant date fair value of options granted was \$2.95 and \$3.53 per share for the six months ended June 30, 2024 and 2023. There were no proceeds from the exercise of stock options for the six months ended June 30, 2024 and 2023.

Restricted Stock Units

An RSU is a stock award that entitles the holder to receive shares of the Company's common stock as the award vests. The fair value of each RSU is based on the closing price of the Company's stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that are subject to terms and conditions established by the compensation committee of the board of directors. Service RSUs granted to employees and new directors upon their

election vest in four equal annual installments. Subsequent annual service RSUs granted to directors vest on the first anniversary of the date of grant. Service RSUs granted to executive officers and certain other employees provide for accelerated vesting if the executive officer or employee is subject to an involuntary termination within 24 months after a change in control. Service RSUs granted to directors provide for accelerated vesting if there is a change in control of the Company.

As of June 30, 2024, \$16.0 million of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of 1.7 years. No RSUs are classified as a liability as of June 30, 2024.

A summary of RSU activity for the Plans for the six months ended June 30, 2024 is as follows:

| | Number of Shares | Unvested at December 31, 2023 |
|--|------------------|-------------------------------|
| Weighted Average Grant Date Fair Value | 1,610,903 | \$8.7 million |
| Vested | 2,725,399 | |
| Forfeited | 10,310 | |
| Stock-Based Compensation Expense | | \$8.7 million |

The grant date fair value for the 752,809 shares underlying RSUs that vested during the six months ended June 30, 2024 was \$8.7 million.

Stock-Based Compensation Expense

| | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|--|----------------------------------|--------------------------------|
| Research and development | 1,799 | 674 |
| Total stock-based compensation expense | 1,799 | 674 |

Total stock-based compensation expense

| | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|--|----------------------------------|--------------------------------|
| Research and development | 1,799 | 674 |
| Total stock-based compensation expense | 1,799 | 674 |

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

</div><div style="margin-top:12pt">In September 2023, the Company filed a lawsuit in the DC District Court against the FDA challenging the FDA's approval of MSN's ANDA for its generic version of HETLIOZ@ capsules under the APA, the FDCA, and FDA regulations. The Company believes that MSN's underlying approval data, particularly its bioequivalence studies, are faulty. On this basis, the Company has asked the DC District Court to, among other things, vacate the FDA's approval of MSN's ANDA, declare that the approval of the ANDA was unlawful, arbitrary, and capricious and compel the FDA to order MSN to recall its generic HETLIOZ@@ product. In December 2023, the Company filed a motion for summary judgment. In January 2024, the FDA opposed the Company's motion and moved to waive the administrative record, following which the court held an oral argument on the cross-motions. The DC District Court issued an order compelling the FDA to serve the administrative record and has set deadlines for further proceedings. In April 2024, the Company filed a motion for summary judgment. In July 2024, the DC District Court held an oral argument on the motion to dismiss that the FDA filed in January 2024, which the Company opposed in February 2024. The Company's lawsuit remains pending.</div><div style="margin-top:12pt">In April 2024, the Company filed a lawsuit in the Delaware District Court against MSN, Amneal, and Impax alleging claims for false advertising in violation of the Lanham Act and unfair competition under several state laws as well as claims for breach of express representation and fraudulent inducement of a license agreement. The Company's lawsuit remains pending.</div><div style="margin-top:12pt">HETLIOZ LQ@@ before the expiration of each of the Asserted Patents, enter judgment that the use of MSN's generic version of HETLIOZ LQ@ in the U.S. before the expiration of each of the Asserted Patents will directly infringe at least one claim of each of the Asserted Patents, order that the effective date of any approval by the FDA of MSN's generic version of HETLIOZ LQ@@ until the expiration of each of the Asserted Patents or such later date as the Court may determine, and award monetary damages, to the extent applicable. The Company's lawsuit remains pending.</div><div style="margin-top:12pt">Other Matters From April 2022 to July 2024, the Company filed eighteen lawsuits in the DC District Court against the FDA to compel the FDA to produce records under the Freedom of Information Act (FOIA) regarding, among other matters: the FDA's denial of the Company's supplemental New Drug Application (sNDA) for HETLIOZ@ in the treatment of jet lag disorder; cases in which the FDA waived its putative requirement of a 9-month non-rodent toxicity study before drugs can be tested on human patients for extended durations; communications external to and within the FDA relating to traditipant, HETLIOZ@ and Fanapt@ a warning letter that the FDA sent to the Company concerning its webpages for HETLIOZ@ and Fanapt@ the FDA's removal of a clinical trials design presentation from its website; discipline reviews relating to the FDA's evaluations of the Company's sNDA for HETLIOZ@ and a third-party sNDA for jet lag; internal standard operating procedures or guidance relating to the FDA's processing of incoming FOIA requests; and bioequivalence and other study reports submitted relating to the FDA's consideration of tasimelteon ANDAs. Four of these lawsuits have since been resolved in the Company's favor, one is pending resolution and the other thirteen remain outstanding. The FDA has failed to respond and provide the requested documents within the statutory timeframe with respect to each of these fourteen outstanding requests. The Company has asked the DC District Court to, among other things, compel the FDA to comply with its obligations and declare that its lack of compliance violates FOIA.</div><div style="margin-top:12pt">In April 2022, the Company filed a lawsuit in the U.S. District Court for the District of Maryland (MD District Court) against the Centers for Medicare & Medicaid Services (CMS) and the Administrator of CMS challenging CMS' rule broadly interpreting the defined terms "line extension" and "new formulation" under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (ACA), which went into effect in January 2022 (the Rule). The Company believes that the Rule is unlawful and contrary to the intent of Congress when it passed the ACA. Under the Rule, certain of the Company's products would be treated as line extensions and new formulations subject to enhanced rebates, despite the statutory text and CMS' own long-standing practice, under which such products would not constitute line extensions or new formulations. In March 2023, the MD District Court ruled that CMS' interpretation of the terms was reasonable and consistent with Congress' intent. In April 2023, the Company appealed the ruling to the U.S. Court of Appeals for the Fourth Circuit (Fourth Circuit). In January 2024, the Fourth Circuit held an oral argument. In April 2024, the Fourth Circuit ruled against the Company. On June 7, 2024, the Company filed an application for an extension of time to file a petition for a writ of certiorari with the U.S. Supreme Court to review the Fourth Circuit's decision. Chief Justice Roberts granted the application, extending the time to file to September 6, 2024.</div><div style="margin-top:12pt">In May 2022, the Company filed a lawsuit in the DC District Court against the FDA challenging the FDA's denial of Fast Track designation for traditipant. In October 2021, the Company submitted to the FDA a request for Fast Track designation for traditipant under the Food and Drug Administration Modernization Act of 1997 (FDAMA). The FDAMA provides for expedited development and review of drugs that receive Fast Track designation from the FDA. Under the FDAMA, the FDA must designate a drug as a Fast Track product if it both (1) is intended to treat a serious or life-threatening disease or condition and (2) demonstrates the potential to address unmet medical needs for such disease or condition. Although Fast Track designation is non-discretionary when the criteria are satisfied, the FDA denied the Company's request for Fast Track designation. The Company does not believe that the FDA based its decision on the relevant criteria. Therefore, among other reasons, the Company maintains that the FDA's denial is unlawful. The Company has asked the DC District Court to, among other things, set aside and vacate the FDA's denial. An oral argument was held in January 2023. In August 2023, the DC District Court ruled against the Company. In September 2023, the Company appealed the ruling to the U.S. Court of Appeals for the District of Columbia Circuit. The Court of Appeals has scheduled an oral argument for September 25, 2024.</div><div style="margin-top:12pt">In September 2022, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with two separate non-discretionary obligations under the FDCA and its implementing regulations: an obligation to publish a notice of an opportunity for a hearing on the Company's sNDA for HETLIOZ@ in the treatment of jet lag disorder in the Federal Register within 180 days of the filing of the sNDA, and a separate obligation to publish the same notice within 60 days of the request for a hearing. The FDA published the notice of an opportunity for a hearing on October 11, 2022. The Company has asked the DC District Court to, among other things, compel the FDA to comply with its obligations and declare that its lack of compliance violates the FDCA and the FDA regulations. In January 2024, the DC District Court held an oral argument on dispositive cross-motions, following which the DC District Court granted in part the Company's motion for summary judgment. The DC District Court ruled that the FDA violated the statute and ordered the FDA to either finally resolve the Company's application or commence a hearing on or before March 5, 2024. In March 2024, the Company and the FDA filed a consent motion for entry of final judgment in the Company's favor on its Administrative Procedure Act claim for the FDA's unreasonable delay in resolving the hearing request.</div><div style="margin-top:12pt">In May 2023, the Company filed a lawsuit in the U.S. Court of Federal Claims (Federal Claims Court) against the federal government for the uncompensated taking and misuse of the Company's trade secrets and confidential information. The Company believes that the FDA violated the Fifth Amendment's due process clause by improperly providing confidential details from the Company's drug master files for HETLIOZ@ and Fanapt@ to generic drug manufacturers during the FDA's</div><div style="margin-top:12pt"> review of the manufacturers' ANDAs. The Company has asked the Federal Claims Court to, among other things, declare that the FDA's disclosure of the Company's confidential commercial information constitutes a taking for purposes of the Fifth Amendment and award just compensation. The federal government filed a motion to dismiss the complaint, which the Company opposed. In January 2024, the Federal Claims Court held an oral argument on the motion to dismiss, following which the Federal Claims Court issued a decision denying in part the government's motion, allowing the Company's takings claim to proceed. The Company's lawsuit remains pending.</div><div style="margin-top:12pt">In February 2024, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with its statutory obligations under the FDCA and its implementing regulations, and to challenge the FDA's complete response letter and 60-day filing regulations, which the Company believes do not absolve the FDA of its statutory responsibilities. Under the FDCA, the FDA has an obligation to either approve the Company's sNDA for HETLIOZ@ in the treatment of insomnia characterized by difficulties with sleep initiation within 180 days of the filing of the sNDA or give the Company a notice of an opportunity for a hearing. The Company submitted the sNDA on May 4, 2023. The Company has asked the DC District Court to, among other things, compel the FDA to comply with its obligations, declare that its lack of compliance violates the FDCA and the FDA regulations and declare the FDA's complete response letter and 60-day filing regulations unlawful. In June 2024, the Company filed a motion for summary judgment and the FDA published a notice of opportunity for a hearing. In July 2024, the FDA opposed the Company's motion for summary judgment. The DC District Court has scheduled an oral argument for September 17, 2024.</div><div style="margin-top:12pt">In March 2024, the

Company filed a petition for review in the U.S. Court of Appeals for the District of Columbia Circuit seeking review of the FDA’s final order refusing to hold a hearing or to approve the Company’s sNDA for HETLIOZ® in the treatment of jet lag disorder. Under the FDCA, the FDA has an obligation to either approve an sNDA or to hold a hearing on the application’s approvability. The Company’s petition asks the DC Circuit to set aside the FDA’s order refusing to hold a hearing and refusing approval. The Company’s petition remains pending.</div><div style="margin-top:12pt">On April 22, 2024, a purported stockholder of the Company filed a lawsuit in the Court of Chancery of the State of Delaware against the members of the Company’s board of directors and the Rights Agent, along with the Company as nominal defendant (collectively, the Defendants), captioned Steamfitters Local 449 Pension Fund v. Mihael H. Polymeropoulos, et al., CA No. 2024-0416-KSJM. The lawsuit contends, among other things, that the members of the Company’s board of directors breached their fiduciary duties in adopting the Rights Agreement. The lawsuit seeks relief declaring, in part, that provisions of the Rights Agreement be deemed unenforceable and seeks to enjoin the use of such provisions as well as damages, costs, and other remedies, and also sought to enjoin for 30 days the Company’s 2024 Annual Meeting of Stockholders (the Annual Meeting) that was held on May 17, 2024. At a hearing on May 7, 2024, the Delaware Chancery Court denied the plaintiff’s request to enjoin the Annual Meeting. A three-day trial in the case is scheduled to begin on November 4, 2024. The Defendants believe the claims are without merit and intend to vigorously defend the lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.</div> false false false false